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Angiotensin-II (Ang-II), a peptide hormone, is a potent vasoconstrictor and cell mitogen. It has 
been implicated in the development of hypertension as well as atherosclerosis. Recent work has 
shown that sclerotic aortic valves possess expression of angiotensin type I receptor (AT-1R) and 
angiotensin converting enzyme (ACE), suggesting altered angiotensin signaling during disease. 
The role of altered angiotensin signaling on aortic valve mechanics, however, is not clearly 
understood. We seek to understand the direct effects of the renin angiotensin signaling (RAS) 
system on the biological and biomechanical properties of aortic valve tissue and develop a finite 
constitutive model that mimics the effects of RAS on aortic valves. Our results showed that the 
mechanical properties such as stiffness were altered by RAS mediators. Three phenomenological 
constitutive models were utilize to characterize the biomechanical changes that occur due to 
RAS mediators on aortic valves, and the Fung-type model was shown to be the best fit model for 
the experimental data. Tissue maintained in anisotropy behavior, but the cross-coupling of the 
fibers was affected. Immunohistochemistry (IHC) showed that RAS affects the phenotypic 
properties of the cells in the aortic valve tissues. Picrosirius red (PSR) staining suggests that RAS 
mediators affect the production of collagen fibers, and quantitative polarized light imaging 
(QPLI) demonstrated that RAS mediators affect the orientation of collagen fibers. We concluded 
that RAS mediators affected the biological and mechanical functions of the aortic valve leaflet. 
The activation of VICS and increased production and disorganization of collagen fibers 
correlated to the stiffness of the tissue. These are all hallmarks of early disease progression, and 
in the future, we will further investigate the effects of RAS mediators in mechanics of the valve 
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CHAPTER 1 INTRODUCTION 
Cardiovascular disease (CVD) is one of the most prevalent diseases worldwide and 
accounts for almost one third of deaths globally (1). Heart valve disease is the most common 
cardiovascular disease on the left side of the heart due to the higher pressure the valves 
experience (2). Aortic stenosis (AS) is the second most prevalent adult valve disease in the 
United States, accounting for approximately 4% of patient 45 years or older (3). If left untreated, 
AS can become fatal. Calcific aortic valve disease (CAVD) is the most common form of stenotic 
aortic valve disease. CAVD accounts for the majority of severe aortic stenosis in cases in which 
the patient is 70 years or older (4). Valve leaflets become thicker, fibrosed, and calcified as the 
disease progresses making them stiffer and narrowing the orifice of the valve. The number of 
valve replacements has doubled in the United States in the past decade, and surgery is the only 
option as there is currently no effective medical treatments for CAVD (5). There is a need to 
understand the pathophysiology of AS, and research is needed to understand the mechanisms of 
valve disease in order to develop new treatments/therapeutic strategies for CAVD. Angiotensin 
converting enzyme (ACE), angiotensin II (ang-II), and type 1 ang-II receptor (AT-1R) are 
present in stenotic aortic valves, strongly implying that the renin angiotensin system (RAS) 
signaling pathway is a factor in the disease progression (6). The fibrotic process is thought to be 
modified by RAS. Ang-II increases the amount of collagen present in the leaflet and in turn 
affects its mechanical properties. Ang-II has also shown to increase the stiffness of aortic valve 
leaflets and decreases their extensibility (7).  
Biaxial testing has been shown to be the ideal method to mechanically-characterize soft 
incompressible materials such as biological tissues. Biaxial testing is where a material is 
subjected to load in both the x and y direction in contrast to uniaxial testing which only subjects 
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the material to load in one direction. In biaxial testing, Green strain (E) is calculated taking into 
account the deformation the tissue experiences in contrast to the engineering strain which only 
calculates the change in length the tissue undergoes. There are three stresses that take into 
account the orientations, force and area, that arise due to the tensorial nature of stress: Cauchy 
stress, 1st Piola-Kirchoff (P-K) stress, and 2nd P-K stress. Stress and strain information can be 
used to develop phenomenological constitutive models. These constitutive models can provide 
additional information on the mechanical responses of material. There are various constitutive 
forms that exist for soft biological tissues, and these are explored in this thesis.  
To evaluate the potential for targeting RAS as a therapeutic strategy against valve 
disease, the objective of this thesis is thus to investigate how the renin-angiotensin signaling 
pathway affects the acute biological and biomechanical function of the aortic valve by 
investigating the role of angiotensin receptors (AT-1R and AT-2R) to which ang-II binds to, and 
the enzymes (ACE and chymase) that convert ang-I to ang-II. The first aim focuses on 
quantifying the biomechanical effects of RAS via biaxial mechanical testing of porcine aortic 
valve tissues pretreated with mediators of RAS signaling. Tissue tangent modulus, extensibility, 
areal strain, and anisotropy index are quantified to assess if RAS inhibition altered tissue 
mechanical properties. In the second aim, three non-linear phenomenological constitutive 
models were used to characterize the mechanical behavior of aortic valve tissues pretreated with 
RAS mediators. The third aim focuses on investigating the acute biological effects that RAS 
inhibition had on aortic valve tissue. The phenotypic changes the cells undergo on the tissue due 
to RAS were investigated via immunohistochemistry. The changes in collagen fibers undergo 




CHAPTER 2 BACKGROUND AND SIGNIFICANCE 
2.1 The Heart  
2.1.1 Anatomy  
The heart is an important organ that acts as a pump and provides blood to the body. In a 
human, it is located in the center of the chest between the lungs and behind the sternum (Figure 
2-1), but in other animals, location can vary slightly. The apex is the conical tip at the bottom of 
the heart that lies on the diaphragm that points to the left side of the body (8). The heart is 
separated into two sides by the intraventricular septum. The right side of the heart pumps 
deoxygenated blood from the body to the lungs and the left side pumps oxygenated blood from 
the lungs to the rest of the body. The heart is comprised of four chambers: the right and left 
ventricles and the right and left atria. The atria collects the blood, similar to a reservoir, and the 
ventricles pump the blood either to the lungs or the rest of the body (9). There are two coronary 
arteries, the left and the right, that provide blood to the heart itself (Figure 2-1). The superior and 
inferior vena cava are venous blood vessels that bring deoxygenated blood from the body to the 
right atrium. The superior vena cava carries the deoxygenated blood from the upper half of the 
body, and the inferior vena cava carries deoxygenated blood from the lower half of the body. The 
pulmonary artery carries the deoxygenated blood from the right ventricle to the lung to become 
oxygenated. The pulmonary veins then carry the oxygenated blood from the lungs into the left 
atrium. The aorta then delivers the oxygenated blood from the left ventricle to the rest of the 





Figure 2-1. A view of the heart location in the thoracic cavity, anterior external view, and 
anterior cross-sectional view (8) 
 
The heart contains four valves (Figure 2-2) which open and close to allow blood to flow 
in one direction. There are the atrioventricular valves (AV-valves) located between the atria and 
ventricles: the tricuspid valve (right side) and the mitral valve (left side). Then there are two 
semilunar valves that will allow the blood to leave the heart: the pulmonary valve (right side) and 
the aortic valve (left side) (10).   
 
Figure 2-2. The four valves of the heart (8) 
2.1.2 Physiology 
Deoxygenated blood from the body is received by the right atria. Blood from the lower 
body enters the right atrium through the inferior vena cava and blood from the upper body enters 
through the superior vena cava. The deoxygenated blood then flows from the right atrium into 
the right ventricle through the tricuspid valve. Once the right ventricle has been filled, the 
tricuspid valve closes and the pulmonary valve opens to allow the right ventricle to pump blood 
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through the pulmonary valve into the pulmonary artery to the lungs. The lung then oxygenates 
the blood. The oxygenated blood then flows from the lungs to the right atrium by the four 
pulmonary veins. Similar to the right side, the blood flows from the left atrium into the left 
ventricle. The blood flows through the mitral valve, also known as the tricuspid valve, into the 
ventricle, and closes once the left ventricle has been filled with oxygenated blood. The left 
ventricle, the strongest chamber, then pumps the blood into the aorta when the aortic valve 
opens. The aorta then disperses the oxygenated blood to the rest of the body (11). When the 
aortic valve closes, oxygenated blood also flows through the coronary arteries. The left coronary 
artery provides oxygenated blood to the posterior area of the heart, and the right coronary artery 
provides oxygenated blood to the anterior area of the heart (Figure 2-3) (12). 
 
Figure 2-3. The physiology of the heart (8) and the cardiovascular system and organ blood 
supply (11) 
 
The circulation of blood through the heart is due to the contraction and relaxation of the 
heart, also known as the cardiac cycle (Figure 2-4). The relaxation state is also known as the 
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diastolic state where the ventricles fill with blood, and the contraction state is also known as the 
systolic state in which the blood is pumped either to the lungs or rest of the body. When the 
cardiac cycle begins, both the atria and ventricles are relaxed. Blood fills into the atrium and then 
the AV valve opens and the atrium contracts slightly to allow the blood to flow from the atrium 
to the ventricle. Once the ventricle is filled, the AV valve closes and the atrium returns to its 
relaxed state. The ventricle then starts to contract and the aortic valve opens to allow the blood to 
be pumped into the aorta. The left ventricle experiences a high amount of pressure during this 
time. Once all the blood is ejected from the ventricle, the aortic valve closes and the left ventricle 
returns to its relaxed state. The atrium starts to fill once more with blood and the cycle starts 
again (11).  
 
Figure 2-4. The cardiac cycle and Wiggers diagram (11) 
2.2 The Aortic Valve 
2.2.1 Anatomy  
The aortic valve allows oxygenated blood to flow from the left ventricle to the aorta and 
in turn to the rest of the body. The valve opens and closes with each heartbeat. It consists of 3 
cusps or leaflets: the right coronary leaflet, non-coronary leaflet, and left coronary leaflet. The 
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right and left leaflets correspond to the left and right coronary arteries which are arteries that 
specifically provide blood to the heart (13). In the normal condition, each leaflet is less than 1 
mm thick, smooth, flexible, and a mobile structure (14). During the systolic state, the aortic valve 
opens from 3 to 5 cm2 (15) 
The aortic valve predominately contains two cell types: valve endothelial cells (VECs) 
and valve interstitial cells (VICs). The VECs regulate valve anti-thrombogenicity, permeability, 
inflammatory cell adhesion, and paracrine signaling. The VICs maintain valve homeostasis and 
provide the strength and elasticity of the valve by secreting extracellular matrix (ECM) (Figure 
2-5) (16). VECs line the surface of the leaflet and can undergo endothelial-mesenchymal 
transformation (EndoMT). On the inflow surface, they are oriented circumferential to the leaflet 
and have an anisotropic alignment. On the outflow surface, they exhibit no preferred orientation 
and have an isotropic alignment. This is due to the fact that they typically orient perpendicular to 
the flow, and in the outflow surface, the blood flow has an oscillatory blood flow (17). VICs are 
fibroblast-like cells but are phenotypically different from dermal fibroblast and have unique 
characteristics. Hence they are considered myofibroblast as they have characteristics of both 
fibroblast and smooth muscle-like cells (18). They adapt to their microenvironment, modulating 
their phenotype as a function mechanical force and soluble factors. VICs synthesize ECM 
components such as collagen, elastin, proteoglycans, and glycoproteins (19).  
To meet the demands of the mechanical loading during each cardiac cycle, the valve is 
comprised of three different ECM fibrous layers with distinct matrices and mechanical 
properties: the fibrosa, spongiosa, and ventricularis (Figure 2-5) (5). The fibrosa is the layer 
closest to the aorta, contains type I and III collagen, and serves a load-bearing function. The 
spongiosa is the middle layer, contains glycosaminoglycan, and lubricates the other layers as 
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they shear and deform during each cardiac cycle. The ventricularis is the layer closest to the left 
ventricle, contains elastin fibers, and function to assure effective coaptation during diastolic 
closure (16). The leaflets are attached to the aortic root at the annulus which is a dense 
collagenous network. The annulus also dissipates the mechanical force the valve leaflets 
experience (5).  
 
Figure 2-5. The architecture of the aortic valve (16) 
2.2.2 Mechanical forces experienced by the aortic valve 
The aortic valve experiences normal, shear and bending stresses. Normal stress is the 
stress perpendicular to the surface, and shear stress is the stress parallel to the valve surface. 
During systole, the ventricular side of the aortic valve is exposed to laminar shear stress (Figure 
2-6a). During the diastole, the aortic side of the aortic valve mostly experiences oscillatory shear 
stress (Figure 2-6b). The left and right coronary cusps partially experience laminar shear stress 
while the non-coronary cusp only experiences oscillatory shear stress during diastole (Figure 
2-6c) (13). The shear stress is highest on the left and right coronary arteries in comparison to the 
non-coronary, because they experience the blood flow to the coronary arteries (5). The 
circumferential and radial length is also longer during diastolic state in comparison to the systolic 
state. The strain the valve experiences during the cardiac cycle is due to the axial blood pressure, 




Figure 2-6. Shear stress (dotted arrows) and strain (solid arrows) that the aortic valve 
experiences during (A) systole and (B and C) diastole (13) 
The fibrosa and ventricularis layers of the leaflet contain collagen and thus these layers 
bear the load on the valve during each cycle. The ventricularis contributes to the low strain/stress 
behavior, and the fibrosa contributes to the high strain/stress behavior. The mechanical response 
of the valve also differs in the circumferential (fiber orientation) and radial (cross-fiber 
orientation) direction. The radial direction undergoes higher strain than in the circumferential 
direction (20). Stella et.al showed that the fibrosa layer alone showed similar mechanical 
responses as an intact leaflet in the circumferential direction and only slightly less extensibility in 
the radial direction. The ventricularis layer however showed different mechanical responses to 
the intact leaflet. It had a longer toe region in both the circumferential and radial direction 
implying a compliant equibiaxial behavior (21).  
2.3 Cardiovascular Disease  
Cardiovascular disease (CVD) is one of the most prevalent diseases in the United States 
and the number one cause of death (1). CVD is any abnormal condition characterized by 
dysfunction of the heart and/or blood vessels. The severity of heart disease can vary from 
minor/unnoticeable to life threatening. There are two types of heart disease: congenital and 
acquired. Congenital heart disease is a genetic condition that comes from birth. There are certain 
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congenital diseases that can be unnoticed by the person their whole life and there are others so 
severe that if not treated immediately could cause death days or even hours after birth (22). 
Acquired heart disease is developed with time during a person’s lifetime. Some risk factors for 
acquired CVD include: smoking, alcohol, physical inactivity, diabetes, overweight/obesity, high 
blood pressure, high cholesterol, and old age (23).  
2.3.1 Heart valve disease 
Heart valve disease is most common on the left side of the heart due to the higher 
pressures the left-sided valves experience. There are two types of valve diseases: valvular 
stenosis and valvular insufficiency/regurgitation (2). Both types may either be an acquired 
disease or a congenital disease. Valvular stenosis is when the leaflets thicken and in turn cannot 
open properly. Valvular regurgitation is when the valve cannot close properly thus causing back 
flow (2). This is most common in the mitral valve. However, the combination of aortic stenosis 
and regurgitation is much higher than each individually (2).  
Aortic stenosis (AS) is the second most prevalent adult valve disease in the United States, 
accounting for approximately 4% of patient 45 years or older (3). If left untreated, AS can 
become fatal with an average survival of 2 to 3 years and an annual mortality of 25% (24). 
As AS manifests and the leaflet thickens, the aortic valve area (AVA) begins to decrease to 
approximately 2 cm2 in contrast to a healthy valve’s AVA of 3 to 5 cm2. The average decline in 
the AVA as AS progresses is 0.1cm2 and an increase of 5 to 8mmHg in the mean gradient across 
the valve (15). The narrowing of the aortic valve prevents blood to flow from the left ventricle to 
the aorta properly. In elderly patients, aortic stenosis can be due to atherosclerosis and 
calcification (25). In contrast to a healthy valve in which leaflets are smooth, flexible, and 
mobile, the leaflets in valves that experience aortic stenosis become thickened, fibrosed, and 
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calcified. This reduces the mobility in the leaflet and can lead to valvular obstruction (14). It also 
increases the valve stiffness and narrows the valve orifice (5).  
AS is similar to atherosclerosis which commonly affects the elderly (26). AS is very 
similar to the early stages in atherosclerosis in which the valve experiences an increase in 
mechanical stress and altered fluid shear stress due to endothelial damage (5). At the cellular 
level, VICs transition to osteoblast-like bone forming cells due to their activation, VECs undergo 
endothelial-to-mesenchymal transformation (EndoMT) due to their dysfunction or denudation, 
and the ECM forms calcific nodules. Inflammatory and immune cells infiltrate the valve and 
inhibitors of calcification are downregulated (16).  
The mechanisms for AS are still largely unknown, but the importance of determining the 
pathological changes is important for the development of therapeutic treatments that might block 
or reverse the disease process (27). As of now, there are no drug-based therapies. Current 
treatments include balloon valvuloplasty, surgical aortic valve replacement, and transcatheter 
aortic valve replacement (24). Balloon valvuloplasty is used in patients who cannot undergo 
surgical or transcatheter aortic valve replacement due to the high surgical risks. Long-term 
survival however is not changed. There is an approximate 50% survival at 1 year, 35% at 2 
years, and 20% at 3 years. Each year in the United States, approximately 67,500 surgical aortic 
valve replacements are performed (24). They are performed with either mechanical or 
bioprosthetic valves. Though bioprosthetic valves do not require anticoagulants like mechanical 
valves, a study showed that there was no significant difference in 15-year survival or stroke in 
patients between the ages of 50-69 years old (24). In inoperable and high-risk patients, 
transcatheter aortic valve replacement has shown to be beneficial and reduce the mortality by 
21.8%. There are several approaches including transfemoral, transapical, transaxillary, 
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transcarotid, transcaval, and transaortic.  In high risk but operable patients, the 5-year mortality 
was similar in patients who underwent transcatheter or surgical aortic valve replacements (24).  
2.3.2 Calcific aortic valve disease  
Calcific aortic valve disease (CAVD) is the most common form of stenotic aortic valve 
disease. CAVD accounts for the majority of severe aortic stenosis in cases in which the patient is 
70 years or older (4). In cases involving younger patients, aortic stenosis is due to an abnormal 
valve such as a bicuspid valve (4). The degree of the calcification is determined by the severity 
of the valve lesions, the progression of the disease, and the development of symptoms and 
adverse events (5). Risk factors of CAVD include hypertension, smoking, diabetes, elevated 
cholesterol, and male gender. The biological processes involved in CAVD include endothelial 
dysfunction and inflammatory responses which lead to the remodeling of the valves (28). As 
alluded to earlier, the only treatment for CAVD is aortic valve replacement. Medical therapies to 
prevent or decrease the progression of CAVD have not been possible as there is still a need to 
better understand the mechanical and biological process that cause CAVD, and to identify 
interventions to prevent the initiation and progression of CAVD (6). 
The aortic valve of patients with CAVD become progressively thickened, fibrosed, and 
calcified. Throughout history, this has been thought to be a result of “wear and tear” and age-
associated valvular degeneration. However, recent studies have shown that due to biochemical, 
humoral, and genetic factors, the CAVD occurs via an active disease process that includes 
inflammation which then leads to fibrosis and calcification. In areas of inflammation in the 
valve, endothelial injury or distribution has been observed. Lipoproteins are able to stimulate 
intense inflammatory activation, and are present in early aortic valve lesions. An increase in 
mechanical stress and reduced shear stress is believed to be due to endothelial damage. A 
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combination of these two events triggers inflammation in the valve. Inflammatory cells penetrate 
the valve and may then stimulate the valve to induce a fibrotic and calcific process (Figure 2-7). 
The inflammatory activity activates the fibroblast-like cells in the valve, and they differentiate 
into a more myofibroblast-like cell. This activity then increases the synthesis and degradation of 
fibrous tissue. Fibrous tissue and the remodeling of the ECM thickens the valve. The valve 
progressively stiffens affecting the mechanics of the valve. The disease then progresses as the 
myofibroblasts differentiate into osteoblast-like cells making the valve stenotic. Osteoblasts 
drive the calcification process. Calcific nodules form on the valve and contain a bonelike matrix 
of collagen, osteopontin, and other bone matrix proteins. Calcification is known to narrow the 
opening of the valve. CAVD develops which can be fatal to patients (5). 
 
Figure 2-7. The process of the progression of healthy valves to CAVD diseased valves (5) 
The trilayer structure of the valve is important in both the biological and mechanical 
function of the valve. As CAVD develops, the trilayer structure becomes disturbed and 
consequently its function is impaired. Type I collagen has features that regulate cellular 
behaviors. The length, thickness, alignment, and density of the collagen fibers can modulate cells 
proliferation and differentiation, and affect their cell polarity and motility (29). CAVD has been 
associated with the remodeling of the collagen fibers, which in turn affects the biological and 
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mechanical factors of the valve. In the fibrosa layer, fibers in a diseased valve are shorter than 
that of those in a healthy valve (30). As far as fiber number, width, density, and alignment, the 
diseased valve seems to have similar properties of that in a healthy valve (30). However, in the 
diseased spongiosa layer, the collagen fibers appear to become wider and denser thought with 
unchanged length (30). It can be speculated that the crosslinking of the fibers is affected in the 
fibrosa layer while the collagen production is affected in the spongiosa layer (30). In the 
spongiosa layer, there are more immature fibers while in the fibrosa layer there are more mature 
fibers (30). The increased production of collagen and the disorganization of the fibers are an 
indication of CAVD, and will be explored in this thesis. 
2.3.3 Mechanical alterations in diseased valves 
The velocity of blood flow through a diseased aortic valve is higher as the pressure 
gradient is higher (mean pressure gradient >40mmHg) between the aorta and left ventricle during 
cardiac systole due to the narrowing of the valve. A healthy valve experiences a peak velocity of 
1.35 ± 0.35 m/s while the velocity in a valve that has developed AS can exceed 4 m/s (13). The 
increase in pressure, increase in forces, and changes in length of the valve increases the stiffness 
and hence decreases the strain. The stiffness reduces the opening of the valve which increases the 
axial pressure on the ventricular said and in turn changes the direction of the blood flow during 
the systolic state (13). The systolic pressure may then exceed the diastolic pressure, and the 
pressure gradient can be four to six times higher than normal. During calcification, the cusp loses 
its stretch and can also result in regurgitation, that is, blood flowing back from the aorta into the 
left ventricle (13). Echocardiography is a useful tool in diagnosing AS by providing clinical 
information such as peak velocity of blood flow through the valve, mean pressure gradient, and 
aortic valve area. It is essential to know the aortic valve area to determine AS because velocity 
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and pressure gradients are only flow-dependent variables. Changes in velocity and pressure 
gradients can also be attributed to other cardiovascular diseases such as impaired left ventricular 
contractility. In patients with severe AS, the aortic valve area is estimated to be ≤ 1 cm2 (4). 
The mechanical functions of the valve are affected by the collagen alterations in the 
trilayer structure (30). In a healthy valve, the collagen fibers in the fibrosa and 
spongiosa/ventricularis layers are oppositely aligned (30). In a diseased valve, the alterations to 
the fiber alignments seen in the fibrosa and the increased production of fibers in the spongiosa 
affect the mechanical load being applied by the mechanical stress the valve experiences. The 
stress that the fibrosa and ventricularis layers cause can apply friction between the layers, and 
when the density of the fibers increases in the spongiosa, the role of the spongiosa to minimize 
that friction is affected (30).  
The VECs and VICs are able to actively respond to the biomechanical factors the valves 
experience. VECs are the first to experience the shear stress as they line the valve. The changes 
in shear stress alter VEC gene expression patterns (31). Unlike laminar shear stress, oscillatory 
shear stress does not induce the protective genes suggesting that the change in shear stress could 
be responsible for the changes in the VECs function (32). The different biomechanical forces the 
VECs experience in the aortic and ventricular side also contribute to the differential gene 
expression of the VECs located on either side of the valve. In the aortic side, the VECs have 
higher expression of genes associated with calcification, and in the ventricular side, VECs have 
higher expression of genes associated with inflammation (33). VICs are protected from shear 
stress by the endothelial layer, but they experience the changes in the stress and strain during the 
cardiac cycle. In in vitro studies were cells were grown in statistic state, cells became 
hypersynthetic, and when exposed to flow, synthesis is maintained at normal levels suggesting 
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the importance of strain on VICs (34). The cell physiology is regulated by the mechanical forces 
and can affect the biosynthetic activity of the cells. Cyclic stretch can upregulate the expression 
of smooth-muscle markers such as α-SMA suggesting that VICs are becoming more 
myofibroblast-like or smooth muscle cell-like (35). Increase in VIC stiffness correlates with the 
biosynthesis of collagen proteins (18). The stiffness of the environment in conjunction with the 
differentiation of VICs can cause calcification (36). The cellular response to environmental 
mechanical forces needs to be further studied to have a deeper understanding of valve 
mechanobiology for the potential of therapeutic treatments (37).  
2.3.4 Mechanisms of CAVD 
The development and progression of CAVD is determined by active biological processes 
(38).  VICs undergo cell differentiation and display osteoblast-like phenotypes. There are various 
signaling pathways including the Runx-2/NOTCH-1 signaling, Wnt-2/Lrp5-β catenin signaling 
pathway, and the renin angiotensin signaling (RAS) pathways that are thought to modulate the 
CAVD process (5).  During disease progression, VICs become more bone-like and express 
osteoblast markers such as osteopontin, osteocalcin, bone morphogenetic proteins 2 (BMP-2) 
and 4 (BMP-4), and osteoblast-specific transcription factors (19). TGF-β1, a cytokine, is present 
in the extracellular matrix (ECM) in calcified aortic cusps. The accumulation of TGF-β1 could 
be due to the endothelial injury and inflammatory cell infiltration that VICs undergo which 
initiates apoptosis of the cells leading to calcification (39). In the presence of cyclic strain, the 
upregulation of TGF-β can alter ECM architecture and compromise the valve function (40). 
When strain is increased above the normal physiological state, VICs respond by increasing pro-
inflammatory proteins such as VCAM-1, ICAM-1, and E-selection (41). Elevated cyclic pressure 
also upregulates the expression of VCAM-1 and down regulates the expression of OPN (42). The 
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renin-angiotensin system (RAS) plays a key role in promoting and maintaining inflammation, 
and it has shown to upregulate the expression in pro-inflammatory cell adhesion molecules such 
as VCAM-1 and ICAM-1 in vascular disease (43). Thus in this thesis, we seek to explore the 
how RAS affects the biomechanical functions of valve leaflets. 
2.4 Renin-Angiotensin System 
2.4.1 Renin-angiotensin signaling pathway 
The renin-angiotensin system (RAS) plays a role in the regulation of blood pressure and 
is a regulatory system for renal and cardiovascular function (44-46). The RAS is a very complex 
signaling pathway (Figure 2-8).  
 
Figure 2-8. The multiple pathways in the renin-angiotensin signaling system (47)   
The central pathway in the activation of RAS occurs when angiotensinogen is cleaved by 
renin, a proteinase enzyme released by the kidney, to form angiotensin I (1-10) (ang-I). Ang-I is 
then converted rapidly to angiotensin II (1-8) (ang-II) by the angiotensin-converting enzyme 
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(ACE) or ACE independent pathways such as chymase (47). The concentration of 
angiotensinogen, ang-I, and ang-II was measured in the plasma and kidney of rat models. This 
study showed that the plasma concentration of angiotensinogen was much greater than the 
concentration of ang-I and ang-II implying that the active concentration of ang-II is a small 
fraction of what could be produced via the conversion of angiotensinogen to ang-I and ultimately 
ang-II (48).  
Ang-II then binds to two different receptor subtypes, type 1 ang-II receptor (AT-1R) or 
type 2 ang-II receptor (AT-2R), to induce the downstream signaling effects (49). AT-1R is 
present in the kidney, heart, brain, adrenal cortex and vessel walls. It mediates the effects of ang-
II in most cardiovascular function. AT-2R is mostly expressed in regions of the brain and adrenal 
medulla. Little is known over the role of AT-2R in cardiovascular function, however it is 
expressed in the vascular wall, cardiac ventricles, and valve (50, 51). AT-1R causes 
vasoconstriction, cell-proliferation, endothelial dysfunction, and hypertrophy whereas AT-2R 
causes vasodilation, anti-proliferation, and apoptosis which counterbalances the effects of AT-1R 
(Figure 2-9) (52-54).  
 
Figure 2-9. The local renin-angiotensin signaling pathway  
There are also non-angiotensin converting enzymes such as chymase and cathepsins also 
play a role in the conversion of ang-I to ang-II. The ability for chymase to generate ang-II in the 
heart tissue is not well known, however it is present in diseased tissue (55). RAS regulates 
intravascular volume, blood pressure, and tissue repair, and though can be protective, when 
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highly stimulated it can cause vasoconstriction, vascular smooth muscle proliferation, endothelial 
dysfunction, inflammation, fibrosis, and thrombosis (50, 56). 
2.4.2 Renin angiotensin system inhibitors 
Extensive research has been conducted on inhibiting RAS to treat hypertension, renal 
failure, cardiac failure, atherosclerosis, and myocardial infarction such as renin inhibitors, ACE 
inhibitors (ACEIs), ang-II receptor blocking agents (ARBs), and chymase inhibitors. By 
blocking RAS, the formation or binding of ang-II can be prevented and in turn reducing its 
downstream effects (57, 58).  
ACEIs were discovered in the late 1970s and have been an effective treatment in various 
cardiovascular diseases such as hypertension and left ventricular dysfunction. ACEIs prevent 
ang-I from converting into ang-II (59, 60). They have been shown to improve endothelial 
function and have anti-atherosclerotic, anti-inflammatory, anti-proliferative, and antioxidant 
properties (61, 62). Not all ACEIs can be used to treat both hypertension and heart failure but 
drugs such as lisinopril, captopril, and quinapril have shown to help greatly with both (44). 
However, by targeting ACE there can be an upregulation of ang-I, and ang-I could still be 
converted into ang-II through an ACE independent pathway such as chymase (55). Chymase 
inhibitors such as chymostatin alone or in combination with ACEIs have been used to treat 
atherosclerotic human coronary arteries but further research needs to be conducted on other 
effects of ang-II on cardiovascular disease (63).  
Due to the ability for ang-I to convert to ang-II even with ACEIs, ARBs are also used to 
treat RAS-induced disease. ARBs block ang-II from binding to angiotensin receptors such as 
AT-1R. Losartan is an ARB that inhibits ang-II from binding to AT-1R. By blocking AT-1R, the 
harmful effects of ang-II such as vasoconstriction and cell proliferation are eliminated (55). An 
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ELITE study of over 3,000 patients compared losartan to captopril by randomizing the patients 
and assigning them to either treatment (64). Mortality, cardiac death, and hospital admission did 
not differ significantly between both treatments, however, there were many more patients that 
withdrew from the captopril treatment due to adverse side effects. This study showed that 
losartan was a more tolerable treatment that captopril, and that ARBs can be an effective 
treatment for those patients that are not able to be treated with ACEIs (64).  
2.4.3 Renin angiotensin system and valve disease 
Studies have shown that ACE is not present in normal aortic valves but is present in 
stenotic valves (65). ACE is carried by low-density lipoprotein (LDL) particles and enters the 
lesions in the stenotic valve from circulation bound to it (66). In addition to ACE, ang-II and AT-
1R are also present in stenotic aortic valves (28). Though ang-II is present and produced in other 
parts of the body, the presence of ACE in stenotic valves suggests that ang-II is being converted 
locally. This observation implied that the RAS signaling pathway is a factor in the valve disease 
process (6). The fibrotic process is thought to be modified by RAS. Stenotic valves have an 
upregulation of ACE and ang-II, and AT-1R is present on valve myofibroblasts. The binding of 
ang-II to AT-1R can lead to an increase in inflammatory responses, inducing the cells within the 




Figure 2-10. Potential role of RAS in calcific aortic disease and its interaction with lipoprotein 
retention and signaling and oxidative stress (67) 
Myles et al. demonstrated that ang-II increased the elastic modulus in the radial direction 
of the aortic valve via biaxial mechanical testing. They also showed that ang-II decreased the 
extensibility of the leaflets which correlates with an increase in stiffness. In addition, ang-II 
increased the amount of collagen present in the leaflet. It can be implied that the increase in 
collagen synthesis affects the mechanical properties of the tissue as it correlates with the 
increased stiffness and inversely correlates with decreased extensibility (7). 
Even though ACE inhibitors and angiotensin receptor blockers are well known to reduce 
hypertension, the impact they may have in the context AS is not well studied (5). It has been 
suggested as a potential therapeutic for CAVD, and studies are currently trying to find the 
correlation between the inhibitors and AS (27, 67).  
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To evaluate the potential for targeting RAS as a therapeutic strategy against valve 
disease, the objective of this thesis is thus to investigate how the renin-angiotensin signaling 
pathway affects the biological and biomechanical function of the aortic valve by investigating 
the receptors (AT-1R and AT-2R) in which ang-II binds to and the enzymes (ACE and chymase) 
that convert ang-I to ang-II.   
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CHAPTER 3 MOTIVATION AND SPECIFIC AIMS 
3.1 Motivation of Study 
In a previous study conducted by us, the interaction between serotonin (5HT) and 
angiotensin II (ang-II) were investigated to understand their effects on aortic valve mechanics 
and remodeling (68). In this previous study, there were four treatment groups: control, 5HT, ang-
II, and 5HT/ang-II. VICs were assayed for cellular contractility, cytoskeletal organization, and 
collagen remodeling, and in an in vivo mouse model, blood pressure was monitored and 
echocardiography were performed in addition to histology and immunohistochemistry. Results 
suggested that the interaction of 5HT and ang-II altered the function and remodeling of the valve, 
but our results also showed that ang-II alone had detrimental effects on the aortic valve. In vitro, 
VICs treated with ang-II had a higher actin orientation parameter and COL1A1 mRNA 
expression. In-vivo, ang-II treated mice had a higher blood pressure, ejection fraction, end-
diastolic volume, and end-systolic volume after 3 weeks of treatment. Picrosirius red staining 
showed that ang-II had a higher percentage of thick fibers in the leaflet attachment region to the 
aortic root indicating collagen remodeling (Figure 3-1).  
 
Figure 3-1. (A) H&E staining and (B) Picrosirius red (PSR) staining (scale bar = 200µm). 
Arrows point to the valve free edge.  Valve attachment zone labeled “a”. (C) Quantification of 




Immunohistochemistry showed an increase of expression of Ki-67, α-SMA, TFGβ1, 
collagen III, and AT-1R indicating ECM remodeling (68). This prior work is the primary 
motivation for us to further investigation the renin angiotensin system (RAS) signaling 
pathways, and its effects in both the cellular and tissue level on the aortic valve (Figure 3-2).  
 
Figure 3-2. Representative micrographs of samples immunohistochemically labeled with Ki-67, 
α-SMA, TGFβ1, AT-1 receptor, and collagen type III. Arrows indicate the aortic valve leaflets.  
The aortic root is indicated by the letter “a”. (scale bar=100µm) (68) 
There has been research conducted by others on the influence of ang-II on the 
biomechanical properties of aortic valves. Biaxial testing showed that ang-II increased the 
stiffness of aortic valve leaflets, and it was believed that an increase in collagen content altered 
valve mechanical properties (7).  Studies have also shown that stenotic aortic valves have an 
25 
 
increase in expression of angiotensin converting enzyme (ACE) and type 1 angiotensin II 
receptor (AT-1R) in comparison to healthy valves (28). These results suggest that RAS may 
participate in the progression of aortic stenosis and that blocking RAS can serve as a therapeutic 
strategy (65). Towards this end, further studies need to be conducted to investigate the role of 
ang-I and ang-II signaling on the biomechanical properties of the aortic valve. Our collaborators 
in Imperial College have studied the role of RAS in cardiac fibroblasts, calcific aortic valves, 
blood vessels, radial arteries, and internal thoracic arteries, and have shown that RAS mediators 
can be inhibited using ACE inhibitors (ACEIs) quinaprilat, receptor antagonists losartan and 
PD123319, and the chymase inhibitor chymostatin (Figure 3-3) (63, 69-71). 
 
 
Figure 3-3. Inhibitors of the renin angiotensin system receptors and converting enzymes 
To evaluate the potential for targeting RAS as a therapeutic strategy against valve 
disease, the objective of this thesis is thus to investigate how the renin-angiotensin signaling 
pathway affects the biological and biomechanical function of the aortic valve by investigating 
the receptors (AT-1R and AT-2R) in which ang-II binds to and the enzymes (ACE and chymase) 
that convert ang-I to ang-II. It is hypothesized that a local renin-angiotensin signaling exists 
within the valve milieu and affects the biological and mechanical function of the aortic valve.  
The first aim focuses on quantifying the biomechanical effects of RAS via biaxial 
mechanical testing of porcine aortic valve tissues pretreated with the aforementioned mediators 
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of RAS signaling (Figure 22). Tissue tangent modulus, extensibility, areal strain, and anisotropy 
index are quantified to assess if RAS inhibition altered tissue mechanical properties. 
In the second aim, three non-linear phenomenological constitutive models were used to 
characterize the mechanical behavior of aortic valve tissues pretreated with RAS mediators.  
The third aim focuses on investigating the biological effects that RAS inhibition had on aortic 
valve tissue. The phenotypic changes the cells undergo on the tissue due to RAS were 
investigated via immunohistochemistry. The changes in collagen fibers undergo were 
investigated with quantitative polarized light microscopy and picrosirius red staining. 
The next three sections of this chapter will give a more detailed overview of each aim. 
 
3.2 Specific Aims 1: Quantify the biomechanical effects of mediators of the renin angiotensin 
signaling (RAS) system on aortic valves. 
In this aim, we sought to quantify the biomechanical effects of RAS on aortic valve 
tissues through biaxial mechanical testing. There are two commonly utilized methods for the 
tensile testing of soft biological tissues – uniaxial and biaxial mechanical testing. Uniaxial testing 
tests the sample in one direction, and is commonly used for failure testing of isotropic or 
transversely isotopic materials. However, biaxial mechanical testing is a more effective way of 
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testing anisotropic material, directionally dependent material, and for developing 
phenomenological constitutive models to characterize their material behavior.  
We sought to understand the effects of RAS on valve tissues by testing the ability of ang-
II to bind to the AT-1R and AT-2R sub-types, and the ability for ang-I to convert to ang-II via 
ACE and chymase activity. To do so, tissue was treated for 48 hours with either ang-I or ang-II 
alone to understand their direct effect. 24 hours prior to being treated with ang-I or ang-II valve 
leaflets were treated with only RAS mediator inhibitors, and tissue was the co-treated with ang-I 
or ang-II and the inhibitors for 48 hours. To understand the binding to the AT-1R and AT-2R 
receptor subtypes, tissue was treated with ang-I or ang-II in combination with AT-1R or AT-2R 
inhibitors, losartan and PD123,319 respectively. To understand the conversion of ang-I to ang-II, 
tissue was treated with ang-I in combination with the ACE and chymase inhibitors, quinaprilat 
and chymostatin, respectively. After appropriate treatment, the tissue was tested via  biaxial 
tensile testing at five different tension ratio protocols at a maximum membrane tension of 90 
N/m: Tcirc:Trad – 1:1, 1:0.75, 1:0.5, 0.75:1, 0.5:1. 
The Green strain and the 2nd Piola-Kirchhoff (2nd P-K) stress were calculated for each 
individual sample. Mechanical characteristics of the individual samples and the average model 
were first calculated using the equibiaxial protocol. The stiffness of a sample was characterized 
with the low and high tangent modulus for both the circumferential (fiber direction) and radial 
(cross fiber direction) direction. From the gradient of the high tangent modulus, the extensibility 
of the tissue was calculated. The higher the extensibility, the more strain the sample underwent 
for the given maximum tension. With the maximum Green strain in the radial and 
circumferential direction, the areal strain and the strain anisotropy index was calculated. An 
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anisotropy index close to one indicated that the sample was more isotropic, whereas an 
anisotropy index greater than or less that one indicated that the sample was more anisotropic. 
3.3 Specific Aims 2: Utilize phenomenological constitutive models to characterize the 
biomechanical changes that occur due to RAS mediators on aortic valves. 
In this aim, three finite constitutive models were used to characterize changes in the 
mechanical properties of the aortic valve samples due to RAS mediators: modified Mooney-
Rivlin (M-R) isotropic model, modified M-R anisotropic model, and Fung-type model. The 
Fung-type constitutive model is typically used to characterize the multiaxial behavior of a soft 
anisotropic material, while the Mooney-Rivlin constitutive model is usually used to characterize 
isotropic materials. We fit our biaxial mechanical data to these phenomenological models to 
better characterize the mechanical changes that occurred due to the RAS mediators. 
3.4 Specific Aims 3: Investigate the biological effects of mediators of the RAS system on aortic 
valves. 
In this aim, we sought to understand the biological effects that mediators of the RAS 
system had on aortic valve tissues. Tissue received similar treatment as in specific aim 1. The 
changes in valve cell phenotype was analyzed through immunohistochemistry (IHC) by 
qualitatively analyzing the expression of certain proteins known to be correlated with the 
valvular interstitial cells (VICs) during valve disease progression. The alterations of collagen 
fiber due to RAS mediators was quantitatively analyzed with quantitative polarized microscopy 




CHAPTER 4 SPECIFIC AIM 1 
Quantify the biomechanical effects of mediators of the renin angiotensin signaling (RAS) 
system on aortic valves 
4.1 Introduction 
Aortic stenosis (AS) is one of the most common valve diseases in the western hemisphere 
(3).  Mechanical stress is thought to be one of the factors central to its progression (13). The 
renin angiotensin signaling (RAS) system has been implicated in the progression of aortic valve 
disease as activated RAS can induce fibrosis within the valve (5), altering the mechanical stress 
that the valve experiences, accelerating the progression of the disease (14). In addition, the 
endothelial damage observed in the early stages of AS increases the mechanical stress and alters 
the fluid shear stress on the valve (5). Calcific aortic valve disease (CAVD) is induced by the 
long-lasting mechanical stress and is a degenerative and currently irreversible process (6). The 
mobility of the leaflet becomes restricted as the calcification progresses (3).  
The aortic valve is comprised of three different layers: the fibrosa, spongiosa, and 
ventricularis. This structure is important in the biological and mechanical function the valve (30). 
The calcific nodules and lesions that occur due to CAVD are primarily in the fibrosa layer (16). 
The progression of this disease can compromise the integrity of the trilayer surface and 
consequently its biological and mechanical function. In a healthy valve, the collagen fibers in the 
fibrosa and spongiosa/ventricularis layers are oppositely aligned, and the alterations to the fiber 
alignments and production seen in the diseased fibrosa and spongiosa layer affect its mechanical 
function (30).  
Planar biaxial mechanical testing is the ideal method to assess changes in mechanical 
properties for incompressible materials such as aortic valve tissue as it allows for the 
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quantification of a two-dimensional stress-strain relationship. Biaxial testing is where a material 
is subjected to load in both the x and y directions in contrast to uniaxial testing which only 
subjects the material to load in one direction (72). In anisotropic materials, uniaxial testing is not 
recommended. Mechanical responses in aortic valve leaflets are dependent on the direction of the 
load. In a leaflet, the collagen fibers are oriented in the circumferential direction, and thus has a 
larger stiffness in the circumferential direction in comparison to the radial direction (73). When 
stretched in the circumferential direction, the tension in the fibers prevent the collagen fibers 
from further stretching as the fibers are aligned. In the radial direction, the collagen fibers 
provide less resistance and hence have a lower stiffness in that direction (7). In biaxial testing, an 
equibiaxial loading and proportional loading protocols are used to for mechanical 
characterizations. Equibiaxial loading is where the same load is applied in both direction, and 
proportional loading is where the load is kept at a constant proportion between both directions 
(73). Using equibiaxial loading experimental data, mechanical properties of the leaflets can be 
calculated such as extensibility, tangent modulus, and degree of anisotropy. (74).   
This aim focuses on quantifying the biomechanical effects of RAS signaling on the aortic 
valve via equibiaxial mechanical testing. Tissue tangent modulus, extensibility, areal strain, and 
anisotropy index will be calculated using equibiaxial experimental data from biaxial tests. The 
average 2nd Piola-Kirchoff stress and Green strain data was used to determine changes in 





4.2 Materials and Methods 
Protocols can be found in Appendix A. MATLAB codes and instructions can be found in 
Appendix B.  
4.2.1 Tissue treatment 
Fresh porcine hearts (3-6 months old) were provided by Cockrum’s Custom Meat 
Processing and Taxidermy (Rudy, AR) or Braunschweig Processing (Neosho, MO), both FDA-
approved abattoirs. They were transported in cold sterile dPBS. The hearts were then dissected 
aseptically, and the left, right, and non-coronary aortic valve leaflets were pooled and washed in 
dPBS. They were then incubated with 150 U/ml penicillin/streptomycin in PBS for 10 mins.  
The leaflets were then cultured in DMEM supplemented with 2% FBS, 150 U/ml P/S, 
and HEPES. The binding of ang-I and ang-II to the receptors was investigated by inhibiting AT-
1R or AT-2R. The samples were treated with either AT-1R inhibitor losartan (1μM) or AT-2R 
inhibitor PD123-319 (1μM) for 24 hour before being treated in combination with ang-I (10 μM) 
or ang-II (10 μM) for an additional 48 hrs (69). The local conversion of ang-I to ang-II was 
investigated by inhibiting ACE or chymase. Samples were treated and tested as outlined before 
but with ACE inhibitor quinaprilat (1 μM) or chymase inhibitor chymostatin (10 μM) and only 
ang-I and not ang-II. Tissue for biaxial mechanical testing was immediately tested following the 
treatment period (69).  
4.2.2 Biaxial mechanical testing 
Samples were cut into 1cm2 square specimens aligned in the radial-circumferential 
directions.  A four-marker array was then placed in form of beads on the tissue to track the 
displacement of the tissue. Tissue was mounted onto a TestResources biaxial testing device 
(Figure 4-1) with zinc-plated steel wires with the radial direction aligned with the y-axis and 
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circumferential direction aligned with the x-axis. The specimen was then immersed into a saline 
bath at 37C (Figure 4-2). 
 
Figure 4-1. Biaxial mechanical testing device. 
 
Figure 4-2. Sample mounted on biaxial testing device.  
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The specimen was brought to a tare load of 0.05 N along each axis. The system was 
operated in the position-based settings at a data acquisition (DAQ) rate of 100 Hz and cycle rate 
(frequency) of 1 Hz. Specimen was then preconditioned by cycling 20 times to a membrane 
tension of 90 N/m.  Mechanical testing in the circumferential and radial axes consisted of the 
following tension ratios with a maximum tension of 90 N/m:  Tcirc:Trad – 1:1, 1:0.75, 1:0.5, 
0.75:1, 0.5:1. Tissue was then stretched three times, and data acquired. Only the 1:1 tension data 
was used in this aim, while the entire data set was used in aim 2 for constitutive modeling. 
A camera placed above the sample captured images at 100 Hz while the tissue was being 
stretched. These images were later used to detect the displacement of the beads in the four 
marker array to calculate deformation.   
4.2.3 Stress and strain calculations 
The MATLAB code Biaxial_1 was used to determine which stretch cycle had the closest 
desired maximum load (0.9N) for analysis. The code works in the following way. Before running 
the code, make sure that columns 2-5 in the csv file output by the system correspond to force x1, 
y1, x2, and y2, and then delete all words in the file as it won’t be read correctly otherwise. The 
user then runs the code and is then asked to select the csv file. Note: If the system being used 
exports an excel file, the code needs to be changed to read an .xls files instead. Next the code 
plots the force in all axis and the average of the x and y axis. By doing this, the user can see how 
many stretches were completed during the test being analyzed. Usually, only three stretches are 
done. However, there were times that the system would falter and export fewer data sets. To 
overcome this, sometimes the sample would have to be stretched more than 3 times to get the 
data of at least the first 2 to 3 stretches. The user is then asked to input how many stretches were 
done. The code then finds the peaks of the x2, and then sorts them in a descending order to find 
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the n number of stretches. It indexes the row in which they were found and sorts them in 
ascending order. This is done because the max force for each peak varies, and if you use the 
order in which they are found, the stretches would be in order of max force and not in order that 
they were done.  
A cycle is done at a DAQ of 100 Hz and frequency of 1 Hz so 100 data points are 
acquired for each cycle. The first 50 data points are the loading curve and the last 50 data points 
are the unloading curve. The maximum force reached is point 50 in the cycle. To zero the force, 
force at point 50 is subtracted by force at point 1 in the cycle. To do so, the maximum force in 
the row indexed for the stretch is subtracted by the force indexed 49 data points before it. The 
force from each stretch of the x and y axis is displayed in the command window so the user can 
choose the stretch to analyze. Note: The x1 loading cell was not working properly so the force 
showed is not an average of x1 and x2 but just x2. 
Prior to running MATLAB code Biaxial_2, the images acquired from the camera were 
separated into individual folders from each stretch. This is done so by going through the images 
and separating the 100 images that correspond to each stretch. Before running the code, the user 
must change lines 51-53. Line 51 is the path to the folder containing the images (path1=), line 52 
is the file name of the first image excluding the last 3 numbers (name1=), and line 53 is the 
pathname for the folder containing the MATLAB code in which the information will be 
outputted to (out1). Add “\point” to the end of the path name in line 53 (out1). Lines 51 and 52 
will change for every run, but line 53 will stay the same if the MATLAB code run is in the same 
folder/path.  
The user can then run the program. The user is first asked to input the number of the first 
image in the command window. 100 images will be analyzed so to calculate the number of the 
35 
 
last image, so 99 is added to the number of the first image to index the numbers of the 100 
images being analyzed. The first image is then opened. The code is written to track 4 points so 
the user clicks the 4 points that will be tracked. The user must choose the area in the center and 
must be chosen in the following order: 
3---------4 
                     /             / 
                  /             / 
      2---------1 
  
After clicking the 4th point, the code opens the second file and used the function 
automarkertrack to track the distance the points have moved to from the previous image by 
analyzing a set distance of pixels from the point chosen. The optimal pixel number was 50. The 
code then writes the x and y position of every point chosen into a text file (point1.txt, point2.txt, 
point3.txt, and point4.txt) which is exported in the MATLAB folder. The code then reads the 
files and makes a 100x8 array containing the x and y positions of each point for all 100 images. 
The distance the point has moved is calculated by subtracting the initial coordinates of the points 
in the first image. An isoperimetric equation is used to compute the strain at the center of the 
element and the element of the Jacobian. The elements of the deformation gradient (F) were 
computed using the Jacobian factor and isoperimetric strain-differentials. Green strain (E) is 
calculated using F with the following equation: E= 0.5(FTF-1). It then creates an excel file 
(deformresults.xlsx) containing the Exx, Eyy, Exy, Ezz, E1, E2, dir1, and dir2. It also saves the 
deformation gradient as defg.mat and the lambda z as lamz.mat. Lastly, the code plots the Exx 
and Eyy. By doing this, the user can see if the tracking of the points was smooth. If the lines are 




MATLAB code Biaxial_3 then creates the excel file rawdata.xlsx that contains the x and 
y force values from the csv file acquired from the system and the deformation calculated from 
MATLAB code Biaxial_2 for the stretch being analyzed. The user runs the program and is asked 
to input the number stretches done and the stretch that will be analyzed. Like in MATLAB code 
Biaxial_1, the code sorts and indexes the force according to each stretch from the csv file. It then 
creates matrices of the x and y force of the loading curve of the analyzed stretch and their 
averages. It then reads the excel sheet deformresults.xlsx and creates matrices of the deformation 
gradient in the x and y deformation of the loading curve. It then creates an excel file 
(rawdata.xlsx) containing the force and deformation gradients.  
The last MATLAB code (Biaxial_4) calculates the x and y tension as well as the 1st and 
2nd Piola-Kirchhoff (P-K) stress. The excel file rawdata.xlsx is read and the x and y force and the 
green strain in the circumferential and radial direction are loaded. The user is then prompted to 
input the thickness of the sample. This can be measured by placing a portion of the sample tested 
into OCT, sectioning samples, and then measuring the thickness in ImageJ. The width is 
assumed to be 1 cm. The 1st P-K stress is calculated by dividing the force by the area of the 
sample. Defg.mat and lamz.mat is loaded, the deformation gradient at F11 and F22 is extracted 
from defg.mat. The 2nd P-K stress is calculated by multiplying the inverse of F by 1st P-K stress. 
Areal strain is calculated by multiplied the E in the circumferential direction by E in the radial 
direction. The anisotropy index is calculated by dividing the max E in the circumferential 
direction by E in the radial direction. In the command window, the maximum areal strain and the 
anisotropy index will be shown. It then creates an excel file (plotdata.xlsx) containing E, S, and P 
in both the circumferential and radial direction and the areal strain. 
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4.2.4 Quantifying mechanical properties  
Using the equibiaxial data, various mechanical properties can be quantified. As biological 
soft tissues have non-linear mechanical properties, we quantified the low and high tangent 
moduli as follows. The low tangent modulus is the stiffness in the toe region that represents the 
uncrimping of the collagen fibers in the tissue. The high tangent modulus is the stiffness in the 
linear region that represents the stretching of tissue collagen fibers. The best fit line (y=mx+b) 
was calculated these two tangent moduli in the circumferential and radial directions, where the 
slope (m) of each line was the tangent modulus (74). Extensibility was calculated by the x-
intercept of the high tangent modules. The intersection on the x-axis was calculated by using the 
high tangent modulus best fit line (x= (y-b) ÷ m) (Figure 4-3) (74). 
 
Figure 4-3. 2nd P-K stress vs Green strain graph indicating (A) high and low tangent modulus 
and (B) extensibility. 
 
Areal strain was calculated by multiplying the maximum Green strain in the 
circumferential and radial direction (ECIRC,MAX * ERAD,MAX). Strain anisotropy index was 
calculated by dividing the maximum Green strain in the circumferential and radial direction 
(ECIRC,MAX ÷ ERAD,MAX) (Figure 4-4). A strain anisotropy index close to 1 indicated a more 




Figure 4-4. 2nd P-K stress vs Green strain graph indicating maximum Green strain used to 
calculate areal strain and strain anisotropy.  
 
4.2.5 Statistical methods 
Results are reported as mean with standard error. Data was first analyzed for normality 
using the Shapiro-Wilk normality test. For the enzyme inhibition, a one way ANOVA was run 
using multiple comparisons versus the diseased (ang-II) state using the Dunnett’s Method. For 
the receptor inhibition, a two way ANOVA was run using all pairwise multiple comparison 
followed by the Tukey post hoc test for normally distributed data. Analyses were performed 
using Sigma Plot. A p value of less than 0.05 was used to indicate statistical significance.  
4.3 Results 
A total of 6-8 samples were tested for each treatment group. After testing, some samples 
were excluded from the analysis (Table 4-1). See Appendix C for images of samples during 
testing (Figure 0-1). Reasons to exclude samples: 
 Steel wires ripped off during testing 
 Steel wires were not placed properly causing the sample to be loaded unevenly  
 Sample believed to be mounted backwards (circumferential in y axis and radial in x axis) 




Table 4-1. Number of samples tested and number of samples excluded and included in analysis 






Control 8 3 5 
Ang-I 8 3 5 
Ang-II 8 2 6 
Ang-I+Quinaprilat 7 3 4 
Ang-I+Chymostatin 6 1 5 
Ang-I+Losartan 7 2 5 
Ang-II+Losartan 8 4 4 
Ang-I+PD123,319 7 2 5 
Ang-II+PD123,319 8 3 5 
 
Equibiaxial stress-strain data allows the quantification of the mechanical properties of the 
aortic valve leaflets. The max areal strain (ASmax), anisotropy index (AI), low (TML) and high 
(TMH) tangent modulus for the circumferential and radial direction, and extensibility for the 
circumferential and radial direction was calculated for each individual sample and were then 













Table 4-2. Max areal strain (ASmax), anisotropy index (AI), low (TML) and high (TMH) tangent 
modulus for the circumferential and radial direction, and extensibility for the circumferential and 
radial direction for the average (ave) of each individual specimens and standard error (SEM).   












Control Ave 0.097 0.525 54.8 3107.0 22.5 1102.8 0.176 0.338 
SEM 0.014 0.084 10.1 523.5 5.9 71.0 0.024 0.029 
          
Ang-I Ave 0.115 0.581 41.8 2522.0 20.6 1275.5 0.201 0.379 
SEM 0.017 0.084 8.1 276.3 5.5 169.4 0.018 0.057 
          
Ang-II Ave 0.083 0.463 56.3 3604.2 19.1 1344.7 0.138 0.337 
SEM 0.018 0.083 17.2 750.0 3.1 228.2 0.036 0.035 
          
Ang-I+ 
Quinaprilat 
Ave 0.098 0.513 56.0 2986.4 21.5 1146.2 0.168 0.375 
SEM 0.011 0.119 7.8 778.3 4.3 192.0 0.013 0.054 
          
Ang-I+ 
Chymostatin 
Ave 0.083 0.507 53.8 3268.5 33.9 1295.8 0.163 0.325 
SEM 0.013 0.084 10.7 277.3 4.4 193.5 0.025 0.032 
          
Ang-I+ 
Losartan 
Ave 0.110 0.385 37.7 2690.7 12.6 1101.0 0.158 0.440 
SEM 0.025 0.055 6.5 643.6 1.9 283.1 0.022 0.044 
          
Ang-II+ 
Losartan 
Ave 0.076 0.321 42.1 5147.7 16.7 1079.2 0.126 0.395 
SEM 0.011 0.054 8.4 1145.7 5.0 78.0 0.016 0.044 
          
Ang-I+ 
PD123,319 
Ave 0.094 0.361 64.6 5214.7 19.7 1198.4 0.154 0.433 
SEM 0.012 0.062 11.0 496.6 4.8 116.9 0.019 0.048 
          
Ang-II+ 
PD123,319 
Ave 0.094 0.455 60.9 3388.1 17.3 1415.0 0.158 0.398 
SEM 0.012 0.072 6.4 463.9 2.0 319.9 0.014 0.035 
 
 
4.3.1 Areal strain and strain anisotropy index 
The max areal strain (ASmax) and strain anisotropy (AI) were calculated from the 
maximum Green strain (E) in the equibiaxial loading condition. The ang-I treated group had a 
higher ASmax than the control while the ang-II treated group had a lower ASmax than the control 
(Figure 4-5a,b). When ang-I was supplemented with an ACE inhibitor, it had a similar ASmax to 
the control and lower ASmax than the ang-I treated group. When ang-I was supplemented with a 
chymase inhibitor, it had a lower ASmax than the control and ang-I treated group (Figure 4-5a). 
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Ang-I supplemented with an AT-1R antagonist had similar ASmax than the ang-I treated group 
and higher ASmax than the control. When ang-II was supplemented with an AT-1R antagonist, it 
had a lower ASmax than the control and ang-II treated group. Ang-I supplemented with an AT-2R 
antagonist had a similar ASmax than the control and lower ASmax than the ang-I treated group. 
Ang-II supplemented with an AT-2R antagonist had a higher ASmax than the ang-II treated group 
and a lower ASmax than the control (Figure 4-5b). Ang-I treated group had a higher AI than the 
control while the ang-II treated group had a lower AI than the control (Figure 4-5c,d). Ang-I 
supplemented with an ACE and chymase inhibitor had a lower AI than the control and ang-I 
treated group (Figure 4-5c). When ang-I and ang-II were supplemented with an AT-1R 
antagonist, it had a lower AI than the control, ang-I, and ang-II treated groups. When ang-I was 
supplemented with an AT-2R antagonist, it had a lower AI than the control and ang-I treated 
group. When ang-II was supplemented with an AT-2R antagonist, it had a lower AI than the 




Figure 4-5. The areal strain for (A) enzyme and (B) receptor inhibitors and the strain anisotropy 
for (C) enzyme and (D) receptor inhibitors. Red dotted line is the untreated, native leaflets. 
4.3.2 Tangent modulus 
The low tangent modulus (TML) is the stiffness in the toe region where the fibers are “un-
crimping”. In the circumferential region, the control and ang-II had a similar TML whereas the 
TML for samples treated with ang-I was slightly less (Figure 4-6a,b).  When treated with ang-I 
supplemented with the ACE or chymase inhibitors, the TML was similar to that of the control 
(Figure 4-6a).  When treated with ang-I or ang-II supplemented with the AT-1R inhibitor, the 
samples had a lower TML than when treated with ang-I or ang-II alone implying that by 
inhibiting binding of ang-II to AT-1R the samples are less stiff.  When treated with ang-I or ang-
II supplemented with the AT-2R inhibitor, the samples had a higher TML than when treated with 
ang-I or ang-II alone. This implies that by inhibiting AT-2R and allowing more ang-II to bind to 
AT-1R, the leaflets are stiffer (Figure 4-6b). In the radial direction, the control, ang-I, and ang-II 
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had a similar TML (Figure 4-6c,d). When treated with ang-I supplemented with the ACE 
inhibitor, the TML was similar to that of the control. However, ang-I supplemented with the 
chymase inhibitor had a higher TML (Figure 4-6c). When treated with ang-I or ang-II 
supplemented with the AT-1R inhibitor, the samples had a lower TML than when treated with 
ang-I or ang-II alone. When treated with ang-I or ang-II supplemented with the AT-2R inhibitor, 
the samples had a similar TML than when treated with ang-I or ang-II alone (Figure 4-6d).  
The high tangent modulus (TMH) is the stiffness in the linear region where the fibers have 
been “uncrimpled” and are now being stretched. In the circumferential direction, ang-I had a 
lower tangent modulus than the control, and ang-II had a higher TMH than the control (Figure 
4-6e,f). The TMH of samples treated with ang-I supplemented with ACE and chymase inhibitor 
was similar to that of the control (Figure 4-6e). Tissue treated with ang-I supplemented with the 
AT-1R inhibitor had a lower TMH, and tissue treated with ang-I supplemented with AT-2R 
inhibitor had a higher TMH. On the contrary, tissue treated with ang-I supplemented with the AT-
1R inhibitor had a higher TMH, and tissue treated with ang-I supplemented with AT-2R inhibitor 
had a lower TMH (Figure 4-6f). In the radial direction, ang-I treated tissue had a higher TMH 
than the control, and ang-II treated tissue had a higher TMH than both the control and ang-I 
(Figure 4-6g,h). When treated with ang-I supplemented with the ACE inhibitor, the TMH was 
similar to that of the control. However, tissue treated with ang-I supplemented with chymase 
inhibitor had a similar TMH than when treated with ang-I alone (Figure 4-6g). When treated with 
ang-I or ang-II supplemented with the AT-2R inhibitor, the TMH was similar to that of the 
control. When treated with ang-I or ang-II supplemented with the AT-2R inhibitor, the TMH was 




Figure 4-6. The low tangent modulus (TM) for (A) enzyme and (B) receptor inhibitors in the 
circumferential direction and for (C) enzyme and (E) receptor inhibitors in the radial direction. 
The high tangent modulus (TM) for (E) enzyme and (F) receptor inhibitors in the circumferential 
direction and for (G) enzyme and (H) receptor inhibitors in the radial direction. Red dotted line 
is the untreated, native leaflets. 
4.3.3 Extensibility 
In the circumferential direction, ang-I had a higher extensibility than the control, and ang-
II had a lower extensibility than the control (Figure 4-7a,b). When treated with ang-I 
supplemented with the ACE or chymase inhibitors, the extensibility was similar to that of the 
control (Figure 4-7a). When ang-I and ang-II were supplemented with an AT-1R antagonist, 
they had a lower extensibility than the control, ang-I, and ang-II treated group. When ang-I was 
supplemented with an AT-2R antagonist, it had a lower extensibility than the control and ang-I 
treated group. Ang-II supplemented with an AT-2R antagonist had a lower extensibility than the 
control but a higher extensibility than the ang-II treated group (Figure 4-7b). In the radial 
direction, ang-II treated group had a similar extensibility than the control, but the ang-I treated 
group had a greater extensibility than the control (Figure 4-7c,d). Ang-I supplemented with an 
ACE inhibitor had a similar extensibility than the ang-I treated group. When ang-I was 
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supplemented with a chymase inhibitor, it had a similar extensibility than the control (Figure 
4-7c). When ang-I and ang-II were supplemented with an AT-1R inhibitor, they had a greater 
extensibility than the control, ang-I, and ang-II treated group. Ang-I and ang-II supplemented 
with an AT-2R inhibitor had a higher extensibility than the control, ang-I, and ang-II treated 
group (Figure 4-7d).  
 
Figure 4-7. The extensibility in the circumferential direction for (A) enzyme and (B) receptor 
inhibitors and in the radial direction for (C) enzyme and (D) receptor inhibitors. Red dotted line 
is the untreated, native leaflets. 
4.4 Discussion 
When the anisotropy index (AI) was calculated with the equibiaxial data, all treatment 
groups had an AI of less than 0.6. An AI close to 1 means that a sample is isotropic so our results 
showed that all samples were anisotropic as the AI was less than 1. The treatment groups where 
ang-I and ang-II were supplemented with an AT-1R had the lowest calculated AI. This implies 
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that when the ability for ang-II to bind to AT-1R is mitigated, the anisotropic qualities of the 
tissue increases. Ang-II supplemented with an AT-2R antagonist had a similar AI than the ang-II 
treated groups. This indicates that the effects seen in the AI of ang-II treatment is due to the 
binding of ang-II to AT-1R.  
The enzyme inhibited groups showed a similar tangent modulus in the toe and linear 
region in the circumferential and radial direction with the exception of the chymase inhibitor in 
the toe and linear region in the radial direction. This implies that by preventing ang-I to convert 
to ang-II the stiffness is similar to that of the non-treated samples. Though ang-I and ang-II 
treated groups did not seem to have a different tangent modulus in the circumferential direction 
or in the toe region in the radial direction, in the linear region in the radial direction ang-I and 
ang-II had a higher tangent modulus. This implies that in the cross-fiber direction the stiffness of 
the collagen fibers does increase. In the toe region in the circumferential and radial direction as 
well as the linear region in the radial direction, ang-I and ang-II supplemented with an AT-1R 
antagonist had the lowest tangent modulus overall. Only in the linear region in the 
circumferential direction did ang-II supplemented with AT-1R antagonist have a greater tangent 
modulus, however ang-I supplemented with AT-1R antagonist did have a lesser tangent modulus 
in that region. This implies that by inhibiting the ability for ang-II to bind to AT-1R the stiffness 
decreases. This is further verified in the AT-2R inhibited treatment groups. Ang-I and ang-II 
supplemented with the AT-2R antagonist had a higher tangent modulus in the toe and linear 
region in the circumferential and radial direction with the exception of ang-II supplemented with 
AT-2R antagonist in the linear region in the circumferential direction. By inhibiting the ability 
for ang-II to bind to AT-2R, ang-II will bind more to AT-1R increasing the stiffness of the 
sample. There was a high variation in the extensibility, and it seems to be highly unreliable 
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because small changes in the high TM fit will result in wide changes in where the line cuts the x-
axis, thereby affecting extensibility. 
Tissue being treated with ang-I and ang-II may not have shown a trend in the change of 
mechanical behaviors as this was a short term treatment. Though ang-II is more prone to bind to 
AT-1R, the amount of time may not have been sufficient to increase the binding of AT-1R over 
AT-2R. However, limiting the ability to bind to just one receptor did show a trend in mechanical 
behavior. 
In the next chapter, we will use the multiple tension loading ratios to develop three non-
linear phenomenological constitutive models to characterize the mechanical behavior of aortic 
valve tissues pretreated with RAS mediators. In this aim, all these measurements are very 
dependent on fitting to inherently non-linear data, and the constitutive models we’ll use are non-







CHAPTER 5 SPECIFIC AIM 2 
Utilize phenomenological constitutive models to characterize the biomechanical changes 
that occur due to RAS mediators on aortic valves 
5.1 Introduction 
Phenomenological constitutive models can be used to quantify the anisotropic and 
nonlinear material properties of soft tissue such as aortic valve leaflets (75). They can account 
for the regional variation and the properties of the leaflet layers, and the stress environment the 
cells undergo can be predicted with the appropriate model (76). In incompressible materials such 
as isotropic rubber materials, they undergo finite deformation in which a two-dimensional stress-
state is sufficient to develop constitutive equations such as the Mooney-Rivlin (M-R) (77, 78). 
However, biological tissue require more rigorous models due to their complex mechanical 
behavior (77).  Viscoelastic behavior of materials is discussed through mechanical models in 
terms of how a material behaves when stress or strain is applied (79). Isotropic models such as 
M-R have been modified to be used for anisotropic material by adding an additional anisotropic 
term (80). A more commonly viscoelastic anisotropic model used for valve leaflets is the Fung-
type model (75, 81). Material constants derived from constitutive models are important for 
generating computational simulations of tissue deformation. Simulations can be performed using 
specimen-specific constants, however, having material constants that represent a generic 
(average) response is favorable (75).  
This aim focuses on selecting an appropriate constitutive model that mimics the 
biomechanical changes that occur in aortic valves due to RAS mediators. In addition, material 
constants will be derived from an average response to simulate the generic mechanical behavior. 
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Mechanical properties will be assessed through the anisotropy index calculated through material 
constants and the stress-strain response graphs from the average model. 
5.2 Methods 
MATLAB codes can be found in Appendix B. Prior to running the MATLAB codes, 
excels sheets need to be created with the appropriate information. Refer to Appendix B as it is 
important to create the excel file in the correct order as MATLAB codes load the data 
accordingly.  
5.2.1 Average model 
The average stress-strain response can be calculated by using an average model based on 
identical tension states (75). The user is asked to first choose the file containing the thickness of 
each sample and then the file containing the x and y-force and E11 and E22. The MATLAB code 
will then extract the information and create an individual matrix for each. The x and y-tension is 
calculated by dividing the force by the width which is assumed to be 1 cm. The average tension 
(Tavg,ii) for x and y is calculated by averaging the individual x and y tensions. The same is done 
to calculate the average green strain (Eavg,ii) for the x (circumferential, E11) and y (radial, E22) 
directions. The average 1st P-K stress (Pavg,ii) is calculated with Eq. (5.1).  
n is the number of samples and hi is the thickness of the individual leaflets. The average 
deformation gradient (Favg,ii) is calculated using Eq. (5.2) assuming negligible shear deformation. 

















The average anisotropy index AIavg is calculated by dividing the max Eavg,11 and Eavg,22. 
The code then exports two excel files. AveragePlotData.xlsx contains the average of E, S, and P 
for each direction and ASavg. AverageEandTandStandardError.xls contains the average E and T 
and the standard errors for E and T in each direction. The code then creates two figures. Figure 1 
is Savg,ii vs Eavg,ii including the standard error bars, and figure 2 is Savg,ii vs Eavg,ii without the 
standard error bars. 
5.2.2 Mooney-Rivlin model 
Two modified Mooney-Rivlin (M-R) constitutive models were used: an isotropic and an 
anisotropic model. The strain energy equation function for the isotropic M-R model is given by 
Eq (5.4), and the strain energy (W) equation function for the anisotropic M-R model is given by 
Eq (5.5) (80).  
W is a function of the strain invariants (I) can be calculated using Eq. (5.6) (78).  
λ1, λ2, and λ3
 are the principal stretches and the left Cauchy-Green tensor (B) can be 
calculated by B=FFT. nc refers to the principle direction of the material fibers. The standard 
constitutive model for an incompressible, isotropic, elastic material can be determined with Eq. 
(5.7) (78).  
 Savg = PavgFavg
−T  (5.3) 
 W=c1 (I1-3) + c2 (I2-3) + D1 [exp (D2 (I1 - 3)) - 1] (5.4) 
 W=c1(I1-3) + D1 [exp (D2 (I1 - 3)) - 1] + (k1/2k2) [exp [k2 (I4 - 1)


























p is a hydrostatic pressure term associated with the incompressibility constraints and σ is 
Cauchy stress. For this study, the stress for the models needs to be in 2nd P-K stress (S) and 
relative to Green strain (E). The relationship between σ, P, and S are the following (82):  
J is the Jacobian and F is the deformation gradient. J is a measurement of the volume 
change produced by the deformation. We assumed that there is no change in volume so J=1 
hence σ relates to S by Eq. (5.9). 
The relationship between E and λ1, λ2, and λ3 can be calculated using F with Eq. (5.11) (82). 
Using Eq. (5.9)  the following can be said about S in the circumferential and radial direction: 
Using Eq. (5.11), the following can be said about λ in terms of E: 
Using the strain energy equation for the isotropic and anisotropic modified M-R, Eq. 
(5.4) and Eq. (5.5) respectively , S in the circumferential and radial direction were calculated in 
















 E=0.5(FTF-I) (5.11) 














Isotropic modified M-R: 
Anisotropic modified M-R: 
The constants for the M-R constitutive model were calculated using MATLAB, 
ModifiedMooneyRivlin_Isotropic.m for the modified M-R isotropic model and MATLAB code  
ModifiedMooneyRivlin_Anisotropic.m for the modified M-R anisotropic model. The MATLAB 
code uses the objective function to calculate the sum of squares of the residuals given by Eq. 
(5.18) (82). 
In the isotropic model, it used Eq. (5.14) and Eq.(5.15), and in the anisotropic model it 
used Eq. (5.16) and Eq. (5.17). The minimization of the objective function was done by using the 
function fmincon. In the anisotropic model, D2 was set to 2 without appreciably reducing the 
goodness of fit (82). The code then calculates the constants and total R2. The isotropic MATLAB 
code exports an excel sheet (Modified M-R (Isotropic) Constants.xlsx) containing the c1, c2, D1, 
and D2 constants and the R
2 combined. The anisotropic MATLAB code exports an excel sheet 
(Modified M-R (Anisotropic) Constants.xlsx) containing the c1, D1, D2, k1, and k2 constants and 
the R2 combined.  
 S11= [2c2 – 2 (c1 + D1 [D2 exp (D2 (2E11 + 2E22 + 3) - 3D2)]) + 2(2E11+1)  (c1 + 





S22= [2c2 – 2 (c1 + D1 [D2 exp (D2(2E11 + 2E22 + 3) - 3D2)]) + 2(2E22 + 1) 
(c1+D1[D2exp(D2(2E11 + 2E22 + 3) - 3D2)]) - 2c2 (2E22 + 1)
 -1] ÷ (E11+1) 
 
(5.15) 



















Using the constants, it generates values for plotting the model fit for each tension load 
ratio using the experimental values E11 and E22 in Eq. (5.21) and Eq (5.22). It plots two figures 
using the model fit. Figure 1 plots the individual ratios (5 subplots) with the circumferential and 
radial direction in one graph. Figure 2 plots all the ratios in either the circumferential or radial 
direction (2 subplots). 
5.2.3 Fung Type model 
The strain energy density (W) function of the fung-type model utilized is given by Eq. 
(5.19).  
 W=0.5c (eQ-1),  (5.19) 
where Q=c1E11
2+ c2E22
2+2 c3E11E22. The second P-K stress tensor (Sij) is evaluated by Eq. (5.20).  
 Sij=dW/dEij, (5.20) 
Eij are the components of the Green strain tensor and i and j are dummy indices (75). S11 and 




2+2 c3E11E22)*(2c1 E11+2c3E22) (5.21) 
 S22=0.5c*exp( c1E11
2+ c2E22
2+2 c3E11E22)*(2c2 E22+2c3E11) (5.22) 
The constants for the Fung-type constitutive model were calculated using MATLAB code 
FungModelFit_EnergyPlot.m. The MATLAB code uses the objective function to calculate the 
sum of squares of the residuals using Eq. (5.21) and Eq. (5.22) for each tension load ratio. The 
minimization of the objective function was done by using the function fmincon which was 





 c > 0 
c1 > |c3| 
c2 > |c3| 
 
The code calculates the optimal c, c1, c2, and c3 constants, and calculates the total R
2. 










It then exports an excel sheet (Fung-type Constants.xlsx) containing the c, c1, c2, and c3 
constants, the condition number, R2 combined, and the AI. Using the constants, it generates 
values for plotting the model fit for each tension load ratio using the experimental values E11 
and E22 in Eq. (5.21) and Eq (5.22). It plots two figures using the model fit. Figure 1 plots the 
individual ratios (5 subplots) with the circumferential and radial direction in one graph. Figure 2 
plots all the ratios in either the circumferential or radial direction (2 subplots).  
In addition to calculating the Fung-type constants, the MATLAB code also generates a strain 
energy contour plot. Contour plots are used to show that the material constants fulfill the positive 
definiteness requirement of elasticity tensor by satisfying the strain energy convexity constraints. 
Contour plots are generated by graphing E11 and E22 in a range from -1.5 to 1.5 into the strain 
energy Eq. (5.19) using the material constants. The contours are plotted at W= 0.01, 0.5, 3, 10, 
and 30 (75). 
5.2.4 Average stress-strain graph analysis 
By graphing the 2nd P-K Stress vs green strain of the various tension ratios in the 
circumferential and radial direction, there are mechanical properties that can be observed. 
(Figure 5-1). First is the mechanical anisotropy which shows if samples have a different stress-
strain behavior in the circumferential and radial direction. The native valve is typically highly 
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anisotropic and any trend towards less anisotropy suggest pathological changes. An anisotropic 
sample will show a spacing between the circumferential and radial curves. The second is the 
cross coupling of the fibers which is where the stress in one direction affects the mechanical 
behavior of the orthogonal direction. If we look at circumferential curves, the equibiaxial, black 
dots, is in the middle as it was stretched equally in both directions. The green diamonds are in 
which it was stretch 3/4 in the circumferential direction and full tension in the radial direction, 
and the blue diamond’s half the tension as the radial direction.  As it can be seen, the sample 
underwent less strain in the circumferential direction in comparison, but in the radial direction 
(grey diamond) corresponding to that stretch, it underwent the most strain. This means that the 
strain in each direction is affected by how much stress is applied in the perpendicular direction. 
This is the cross-coupling affect and can be seen by the spreading out of the stress strain curves. 
 
Figure 5-1. (A) Aortic valve leaflet (73) showing circumferential and radial direction. (B) 2nd P-
K stress vs Green strain graph for tension ratios 1:1, 1:0.75, 0.75:1, 1:0.50, 0.50:1 
5.2.5 Statistical methods 
Results are reported as mean with standard error. Data was first analyzed for normality 
using the Shapiro-Wilk normality test. For the enzyme inhibition, a one way ANOVA was run 
using multiple comparisons versus the diseased (ang-II) state using the Dunnett’s Method. For 
the receptor inhibition, a two way ANOVA was run using all pairwise multiple comparison 
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followed by the Tukey post hoc test for normally distributed data. Analyses were performed 
using Sigma Plot. A p value of less than 0.05 was used to indicate statistical significance.  
5.3 Results 
The material constants for the modified M-R isotropic and anisotropic constitutive model 
and the Fung-type model were calculated for each individual sample using the green strain 
acquired from the experimental data acquired during biaxial testing. In addition, the material 
constants were calculated for the average stress-strain response given from the average model. 
A total of 6-8 samples were tested for each treatment group. After testing, some samples were 
excluded from the analysis (Table 5-1). See Appendix C for images of samples during testing. 
Reasons to exclude samples: 
 Steel wires ripped off during testing 
 Steel wires were not placed properly causing the sample to be loaded unevenly  
 Sample believed to be mounted backwards (circumferential in y axis and radial in x axis) 
 Sample completely tore and all tension ratio tests were not completed 
Table 5-1. Number of samples tested and number of samples excluded and included in analysis 






Control 8 3 5 
Ang-I 8 3 5 
Ang-II 8 2 6 
Ang-I+Quinaprilat 7 3 4 
Ang-I+Chymostatin 6 1 5 
Ang-I+Losartan 7 2 5 
Ang-II+Losartan 8 4 4 
Ang-I+PD123,319 7 2 5 




5.3.1 Average model  
Mechanical testing in the circumferential and radial axes consisted of the following 
tension ratios with a maximum tension of 90 N/m:  Tcirc:Trad – 1:1, 1:0.75, 1:0.5, 0.75:1, 0.5:1. In 
the circumferential direction, most tension ratios and treatment groups had a low standard error. 
However, in the radial direction, some tension ratios had a higher standard error suggesting 





Figure 5-2. Average response based on identical tension states for each tension ratio with a 







5.3.2 Model Fit 
Modified M-R isotropic model 
The material constants for each individual specimen varied greatly as can be seen in 
Table 5-2 . For example, in the control, the D1 constant was 0.14 in one sample whereas it was -
1144.73 in another sample. When the D1 constant was averaged in the control treatment group, it 
had a value of 45.23 with a standard error of 398.71. This trend is seen in the majority material 
constants in treatment groups. This showed that by averaging the individual constants in each 
treatment group an accurate finite constitutive model would not be possible. Table 5-2 also 
shows that the R2 is very low in all samples and in their average implying that this model was not 
a good fit for the data. 
Table 5-2. Material constants c1, c2, D1, and D2 for the Modified Mooney-Rivlin isotropic 




No. c1 c2 D1 D2 R2 
Control 1 80.71 -81.99 0.14 -4145.97 0.25 
2 207.56 -259.20 -1144.73 -5473.06 0.64 
 3 191.83 -229.31 -0.04 -178.03 0.57 
 4 151.45 -133.34 1370.82 -4903.07 0.32 
 5 61.04 -23.75 -0.05 -677.56 0.22 
 Ave 138.52 -145.52 45.23 -3075.54 0.40 
 SEM 29.26 44.13 398.71 1104.08 0.09 
       
Ang-I 1 106.20 -122.06 -835.07 -4574.14 0.35 
2 82.65 -79.13 -1057.92 -5163.50 0.34 
 3 18.94 4.29 -649.32 -4278.89 0.11 
 4 215.97 -262.82 -0.03 -532.76 0.55 
 5 198.03 -199.26 -1384.41 -4663.88 0.45 
 Ave 124.36 -131.79 -785.35 -3842.63 0.36 
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No. c1 c2 D1 D2 R2 
Ang-II 1 36.14 -7.08 0.67 -4194.06 0.19 
2 195.13 -237.35 -0.08 -5183.26 0.50 
 3 84.99 -80.49 0.02 -357.33 0.32 
 4 34.62 17.48 110.39 -5234.66 0.17 
 5 128.70 -128.81 -1524.30 -5137.66 0.28 
 6 62.07 -16.25 -0.13 -174.45 0.16 
 Ave 90.27 -75.42 -235.57 -3380.24 0.27 
 SEM 25.38 39.12 258.37 997.59 0.05 
       
       
Ang-I+ 
Quinaprilat 
1 233.03 -269.64 -1305.74 -4869.95 0.53 
2 72.30 -65.57 -836.17 -4118.82 0.34 
 3 40.61 -3.61 -1135.49 -5420.32 0.15 
 4 87.98 -75.42 -967.25 -4806.53 0.22 
 Ave 108.48 -103.56 -1061.16 -4803.90 0.31 
 SEM 42.67 57.60 101.97 266.72 0.08 
       
Ang-I+ 
Chymostatin 
1 54.40 -20.81 -1.20 -4613.05 0.22 
2 98.27 -110.17 -936.59 -4757.37 0.35 
 3 70.80 -55.94 -1154.65 -5296.60 0.25 
 4 97.99 -76.44 -1461.78 -4934.57 0.23 
 5 268.02 -310.07 -1357.86 -5374.42 0.45 
 Ave 117.90 -114.69 -982.42 -4995.20 0.30 
 SEM 38.45 50.95 261.28 148.48 0.04 
       
Ang-I+ 
Losartan 
1 34.55 -21.38 0.00 -588.39 0.23 
2 10.69 25.09 0.00 -132.06 0.12 
 3 37.28 -16.19 0.00 -1014.24 0.21 
 4 96.43 -102.93 0.01 -470.80 0.37 
 5 64.93 -33.10 1764.85 -5845.27 0.19 
 Ave 48.78 -29.70 352.97 -1610.15 0.22 
 SEM 14.69 20.77 352.97 1068.13 0.04 
       
       
Ang-II+ 
Losartan 
1 12.72 25.44 -0.01 -406.89 0.10 
2 58.95 -41.56 -928.54 -4367.70 0.24 
 3 114.31 -94.39 -0.03 -76.93 0.28 
 4 65.13 -39.46 -1569.22 -5748.08 0.18 
 Ave 62.78 -37.49 -624.45 -2649.90 0.20 
 SEM 20.78 24.53 383.50 1420.12 0.04 
       
       
       
61 
 




No. c1 c2 D1 D2 R2 
Ang-I+ 
PD123,319 
1 91.85 -85.76 -909.63 -4431.09 0.28 
2 35.33 0.22 -616.77 -3975.13 0.15 
 3 157.00 -145.60 -0.02 -130.82 0.33 
 4 48.22 -9.93 -1421.68 -6139.60 0.18 
 5 22.74 11.06 -505.32 -4237.18 0.10 
 Ave 71.03 -46.00 -690.68 -3782.76 0.21 
 SEM 24.44 30.16 234.43 988.82 0.04 
       
Ang-II+ 
PD123,319 
1 66.49 -51.45 -825.04 -4154.06 0.25 
2 32.89 2.36 -999.52 -4733.29 0.15 
 3 153.77 -166.82 -0.04 -42.21 0.38 
 4 87.05 -81.27 0.02 -210.23 0.32 
 5 62.79 -39.29 0.31 -4146.38 0.22 
 Ave 80.60 -67.29 -364.85 -2657.23 0.26 
 SEM 20.23 28.27 225.18 1039.09 0.04 
 
In (Table 5-3), the material constants were derived from the average model. The material 
constants from the average model are very different than those from when the material constants 
of each sample were averaged. The R2 in all treatment group was less than 0.50 which indicates a 
poor fit.This is expected as valve leaflets are anisotropic material and not isotropic material. 
Table 5-3 Material constants c1, c2, D1, and D2 for the Modified Mooney-Rivlin isotropic 
constitutive model and the R2 of the fit for the average response based on identical tensions. 
Treatment c1 c2 D1 D2 R2 
Control 164.49 -182.48 -1044.68 -4696.10 0.44 
Ang-I 118.73 -127.76 -901.80 -4468.60 0.40 
Ang-II 115.69 -110.49 -1183.05 -4892.73 0.33 
Ang-I + Quinaprilat 112.46 -109.37 -941.61 -4311.37 0.34 
Ang-I + Chymostatin 135.84 -139.62 -1195.81 -5114.54 0.36 
Ang-I + Losartan 66.20 -54.61 0.03 -1721.22 0.29 
Ang-II + Losartan 88.79 -72.32 -0.01 -430.03 0.27 
Ang-I + PD123,319 90.61 -72.76 -941.24 -4661.92 0.27 
Ang-II + PD123,319 103.65 -98.93 0.03 -269.10 0.32 
 
When the model fit was plotted with the experimental data, it can be seen that it does not 
follow the shape of the stress strain curve (Figure 5-3). The 1fit for the different tension loading 
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ratios are all similar to one another meaning that there is no spreading between the loading ratios. 
The max 2nd P-K stress of the model fit in the circumferential and radial direction was half if not 
much less than that of the experimental data.   
 
Figure 5-3. The Modified Mooney-Rivlin isotropic constitutive model fit along the experimental 
data in the circumferential and radial direction for the average response of each treatment 
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Modified M-R anisotropic model 
The material constants for each individual specimen did not vary as drastically in the M-
R anisotropic model as they did in the isotropic model (Table 5-4). It was only the SEM for the 
k2 constant that was large. Table 5-4 also shows that the R2 is higher in all samples and in their 
average in comparison to the isotropic model implying that this modified M-R anisotropic model 
is a better fit than that of the modified M-R isotropic model.  
Table 5-4. Material constants c1, D1, D2, k1, and k2 for the Modified Mooney-Rivlin 





No. c1 D1 D2 k1 k2 R2 
Control 1 -60.20 11.55 2.00 6.98 2.97 0.68 
2 -73.37 18.40 2.00 31.47 -24.78 0.84 
 3 -74.13 20.94 2.00 0.07 13.95 0.84 
 4 -157.19 45.51 2.00 24.99 4.76 0.81 
 5 -94.38 26.32 2.00 24.66 10.83 0.82 
 Ave -91.86 24.55 2.00 17.64 1.54 0.80 
 SEM 17.22 5.75 0.00 5.99 6.88 0.03 
        
Ang-I 1 -67.07 13.37 2.00 5.33 2.90 0.77 
2 -51.08 12.92 2.00 0.78 15.49 0.85 
 3 -23.58 4.16 2.00 7.47 8.14 0.74 
 4 -81.49 21.33 2.00 18.55 -41.20 0.78 
 5 -133.81 43.39 2.00 1.03 30.01 0.89 
 Ave -71.41 19.04 2.00 6.63 3.07 0.81 
 SEM 18.32 6.67 0.00 3.24 11.97 0.03 
        
Ang-II 1 -45.35 9.77 2.00 13.69 7.41 0.80 
2 -82.16 21.22 2.00 30.30 -17.23 0.74 
 3 -51.80 13.99 2.00 3.03 9.58 0.78 
 4 -103.81 28.89 2.00 38.61 8.09 0.74 
 5 -161.89 46.47 2.00 34.10 -9.51 0.65 
 6 -178.02 57.31 2.00 16.26 47.97 0.78 
 Ave -103.84 29.61 2.00 22.66 7.72 0.75 
 SEM 22.71 7.66 0.00 5.63 9.21 0.02 
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No. c1 D1 D2 k1 k2 R2 
Ang-I+ 
Quinaprilat 
1 -94.70 28.94 2.00 5.90 4.54 0.84 
2 -49.62 12.30 2.00 2.48 13.34 0.88 
 3 -70.22 16.73 2.00 16.19 15.43 0.77 
 4 -63.88 15.40 2.00 5.07 9.23 0.72 
 Ave -69.61 18.34 2.00 7.41 10.63 0.80 
 SEM 9.41 3.65 0.00 3.02 2.40 0.03 
        
Ang-I+ 
Chymostatin 
1 -72.75 18.51 2.00 19.64 8.76 0.85 
2 -45.02 10.62 2.00 1.15 9.29 0.76 
 3 -54.78 15.32 2.00 9.28 9.10 0.64 
 4 -157.51 46.46 2.00 15.20 16.35 0.74 
 5 -141.42 38.71 2.00 2.25 9.55 0.81 
 Ave -94.30 25.92 2.00 9.50 10.61 0.76 
 SEM 23.10 7.02 0.00 3.59 1.44 0.03 
        
Ang-I+ 
Losartan 
1 -28.36 5.12 2.00 10.38 2.94 0.76 
2 -32.18 7.45 2.00 27.91 5.60 0.70 
 3 -44.90 10.41 2.00 3.03 23.06 0.81 
 4 -55.79 13.39 2.00 1.97 8.76 0.84 
 5 -134.37 37.63 2.00 20.38 20.26 0.74 
 Ave -59.12 14.80 2.00 12.73 12.13 0.77 
 SEM 19.43 5.87 0.00 5.02 4.03 0.02 
        
        
Ang-II+ 
Losartan 
1 -40.79 8.88 2.00 3.42 32.71 0.67 
2 -63.83 15.67 2.00 8.10 12.54 0.73 
 3 -112.86 27.81 2.00 7.33 15.83 0.85 
 4 -120.65 34.62 2.00 24.31 26.04 0.72 
 Ave -84.53 21.74 2.00 10.79 21.78 0.74 
 SEM 19.25 5.81 0.00 4.62 4.64 0.04 
        
Ang-I+ 
PD123,319 
1 -68.37 15.62 2.00 4.45 7.69 0.75 
2 -40.11 7.59 2.00 27.58 4.24 0.70 
 3 -109.57 30.11 2.00 6.23 13.63 0.82 
 4 -92.01 23.43 2.00 28.22 6.80 0.72 
 5 -62.44 13.71 2.00 32.22 14.51 0.73 
 Ave -74.50 18.09 2.00 19.74 9.37 0.74 
 SEM 12.05 3.93 0.00 5.94 2.00 0.02 
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No. c1 D1 D2 k1 k2 R2 
Ang-II+ 
PD123,319 
1 -60.96 14.09 2.00 0.93 23.89 0.81 
2 -65.41 15.78 2.00 17.98 19.90 0.77 
 3 -97.77 26.65 2.00 10.19 4.73 0.80 
 4 -44.89 12.85 2.00 5.23 7.35 0.73 
 5 -62.17 16.29 2.00 14.16 7.17 0.66 
 Ave -66.24 17.13 2.00 9.70 12.61 0.76 
 SEM 8.65 2.46 0.00 3.05 3.87 0.03 
 
In Table 5-5, the material constants were derived from the average model. The material 
constants from the average model are still quite different than those from when the material 
constants of each sample were averaged. It is very clear in the k2 constant where the average of 
the k2 constants in the control group was 1.54 (Table 5-4) and the k2 for the average model is 
7.96. The R2 in all treatment group was more than 0.75 which indicates a better fit.  
Table 5-5. Material constants c1, D1, D2, k1, and k2 for the Modified Mooney-Rivlin 
anisotropic constitutive model and the R2 of the fit for the average response based on identical 
tensions. 
Treatment c1 D1 D2 k1 k2 R2 
Control -92.38 24.09 2.00 2.70 7.96 0.83 
Ang-I -65.72 15.96 2.00 1.85 10.63 0.85 
Ang-II -101.31 27.42 2.00 6.49 10.79 0.79 
Ang-I + Quinaprilat -78.69 20.31 2.00 4.28 11.29 0.83 
Ang-I + Chymostatin -97.94 25.94 2.00 4.11 11.51 0.79 
Ang-I + Losartan -64.06 14.55 2.00 8.06 8.92 0.82 
Ang-II + Losartan -96.89 24.00 2.00 8.97 19.30 0.78 
Ang-I + PD123,319 -86.33 20.10 2.00 13.58 8.62 0.78 
Ang-II + PD123,319 -83.19 21.07 2.00 2.77 16.56 0.82 
 
When the model fit was plotted with the experimental data, it can be seen that it does not 
follow the shape of the stress strain curve (Figure 5-4). However, in this model the different 
tension loading ratios are spreading as seen in the experimental data, suggesting that the 
modified M-R is able to capture the cross-coupling between the fiber and cross-fiber directions 
in the samples. The max 2nd P-K stress of the model fit in the circumferential and radial direction 
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was also closer to that of the experimental data in comparison to the modified M-R isotropic 
model.   
 
Figure 5-4. The Modified Mooney-Rivlin anisotropic constitutive model fit along the 






The Fung-type model provided the best fit. The material constants for each individual 
samples was consistent as can be seen by the low standard error (Table 5-6). All samples had a 
much greater R2 than either of the modified M-R models.   
Table 5-6. Material constants c, c1, c2, and c3 for the Fung-type constitutive model, R2 of the fit, 




No. c(kPa) c1 c2 c3 R2 AI 
Control 1 0.519 9.273 5.750 3.427 0.789 0.723 
2 0.828 13.507 10.866 0.143 0.929 0.807 
 3 0.650 15.021 12.657 2.263 0.917 0.863 
 4 1.025 23.489 12.816 3.983 0.953 0.612 
 5 0.768 36.907 9.974 2.432 0.968 0.315 
 Ave 0.758 19.639 10.413 2.450 0.911 0.664 
 SEM 0.085 4.896 1.284 0.658 0.032 0.097 
        
Ang-I 1 1.020 13.428 6.171 0.634 0.797 0.484 
2 0.446 26.804 8.946 -0.413 0.932 0.323 
 3 1.252 22.536 3.497 -1.407 0.773 0.099 
 4 1.117 18.514 11.811 -2.554 0.878 0.580 
 5 0.834 55.868 22.981 -9.307 0.911 0.294 
 Ave 0.934 27.430 10.681 -2.609 0.858 0.356 
 SEM 0.140 7.445 3.373 1.756 0.031 0.083 
        
Ang-II 1 1.016 19.318 5.132 0.958 0.897 0.300 
2 0.613 15.122 15.580 -1.391 0.830 0.968 
 3 2.109 15.167 7.231 -0.482 0.799 0.460 
 4 1.190 26.848 9.286 4.411 0.853 0.438 
 5 0.303 19.716 17.911 11.475 0.847 0.942 
 6 0.145 124.516 31.700 -4.411 0.958 0.227 
 Ave 0.896 36.781 14.473 1.760 0.864 0.556 
 SEM 0.293 17.634 3.985 2.274 0.023 0.131 
        
        
Ang-I+ 
Quinaprilat 
1 1.295 19.452 15.117 -0.026 0.867 0.777 
2 0.410 31.756 9.752 -2.171 0.977 0.256 
 3 0.266 43.667 10.297 -0.128 0.920 0.234 
 4 1.305 19.559 7.445 -0.453 0.756 0.366 
 Ave 0.819 28.609 10.653 -0.695 0.880 0.408 
 SEM 0.279 5.791 1.611 0.501 0.047 0.126 
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No. c(kPa) c1 c2 c3 R2 AI 
Ang-I+ 
Chymostatin 
1 0.745 35.161 8.706 -0.210 0.947 0.243 
2 0.263 24.898 12.574 -3.234 0.874 0.431 
 3 2.687 15.398 6.111 0.601 0.661 0.419 
 4 0.202 47.316 19.776 8.456 0.932 0.506 
 5 0.569 19.440 13.074 5.374 0.898 0.743 
 Ave 0.893 28.443 12.048 2.197 0.863 0.469 
 SEM 0.459 5.767 2.318 2.087 0.052 0.081 
        
Ang-I+ 
Losartan 
1 1.124 11.492 3.380 0.960 0.822 0.349 
2 1.616 16.468 3.648 2.534 0.802 0.325 
 3 0.147 47.865 10.640 -2.500 0.944 0.179 
 4 0.440 29.980 13.038 -5.049 0.909 0.320 
 5 0.054 84.662 21.148 7.781 0.971 0.313 
 Ave 0.676 38.093 10.371 0.745 0.889 0.297 
 SEM 0.301 13.239 3.297 2.201 0.033 0.030 
        
        
Ang-II+ 
Losartan 
1 0.148 49.333 8.734 -0.303 0.833 0.172 
2 0.373 20.683 8.121 4.874 0.912 0.508 
 3 0.876 34.483 8.960 0.080 0.903 0.262 
 4 0.247 75.102 15.093 4.835 0.960 0.249 
 Ave 0.411 44.900 10.227 2.372 0.902 0.298 
 SEM 0.162 11.643 1.632 1.436 0.026 0.073 
        
Ang-I+ 
PD123,319 
1 0.238 25.266 10.718 0.786 0.875 0.442 
2 2.177 11.520 3.095 1.361 0.792 0.346 
 3 1.863 35.166 11.017 -4.903 0.872 0.202 
 4 0.357 29.659 9.811 5.883 0.926 0.442 
 5 0.168 53.634 8.830 2.424 0.955 0.201 
 Ave 0.961 31.049 8.694 1.110 0.884 0.326 
 SEM 0.436 6.869 1.451 1.744 0.028 0.054 
        
Ang-II+ 
PD123,319 
1 0.167 46.462 10.402 -2.232 0.906 0.185 
2 0.296 68.502 9.727 -2.616 0.943 0.108 
 3 1.163 17.597 8.951 3.697 0.823 0.594 
 4 3.373 14.523 5.380 -0.476 0.750 0.349 
 5 1.553 16.063 6.792 1.733 0.747 0.479 
 Ave 1.311 32.630 8.250 0.021 0.834 0.343 
 SEM 0.578 10.739 0.940 1.198 0.040 0.090 
 
In Table 5-7, the material constants were derived from the average model. The material 
constants from the average model are very similar than those from when the material constants 
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of each sample were averaged. The R2 in all treatment group was greater than 0.90 indicating 
that the Fung-type model was an excellent fit for our experimental data.  
Table 5-7. Material constants c, c1, c2, and c3 for the Fung-type constitutive model, R2 of the fit, 
and anisotropy index (AI) for the average response based on identical tensions. 
Treatment c(kPa) c1 c2 c3 R2 AI 
Control 0.729 18.099 10.770 1.528 0.934 0.627 
Ang-I 0.758 24.682 9.308 -2.028 0.911 0.321 
Ang-II 0.428 26.315 13.746 1.768 0.941 0.552 
Ang-I + Quinaprilat 0.496 28.738 11.999 -1.437 0.946 0.387 
Ang-I + Chymostatin 0.433 26.628 12.961 1.208 0.911 0.509 
Ang-I + Losartan 0.264 29.547 9.158 1.052 0.952 0.334 
Ang-II + Losartan 0.326 41.367 10.903 1.132 0.934 0.283 
Ang-I + PD123,319 0.599 28.018 8.701 0.146 0.922 0.314 
Ang-II + PD123,319 0.665 26.950 9.675 0.294 0.913 0.366 
 
When the model fit was plotted with the experimental data, it can be seen that it does 
follow the shape of the stress strain curve (Figure 5-5). The model fit overlaps the experimental 
data which shows that by using the material constants in the Fung-type model the responses the 





Figure 5-5. The Fung-type constitutive fit along the experimental data in the circumferential and 






The modified M-R isotropic model had a significantly lower R2 than the modified M-R 
anisotropic model and the Fung-type model. This implies that it was the worst fit for the 
experimental data. The Fung-type model had the highest R2. 
 
Figure 5-6. The R2 fit for each constitutive model in the 9 treatment groups 
5.3.3 Fung-type material constants 
The material constants of the Fung-type model were used to plot a constant strain energy 
contour over the strain field. This was done to verify the convexity of the strain energy function 
over a range of strains (75). Figure 5-7 shows that the plots for all the average treatment groups 
were all convex. This shows that the developed models are reliable. Contour plots were also 




Figure 5-7. Constant strain energy contours plotted over the Green strain field for the average 
response of each treatment 
A non-linear anisotropy index (AI) can also be calculated using the material constants 
derived from the Fung-type model which is more ideal than the linear anisotropy index from aim 
1. An isotropic response would have an AI value close to one, and the smaller the value of AI the 
more anisotropic the material is. The treatment groups had an average AI of 0.66 or lower 
implying that all treatment groups kept their anisotropic qualities. Control had the highest 
average AI at 0.664 for averaged samples and an AI of 0.637 for the average model. The AI was 
the lowest when treated with receptor antagonist with the AI being less than 0.34 for averaged 
individual samples in each treatment group. The AI was also low for the ang-I treated group and 
the ang-I supplemented with enzyme inhibitors. Ang-II had a lower AI than the control, but a 





Figure 5-8.  The anisotropy index for the (A) enzyme and (B) receptor inhibitors calculated 
using the Fung-type material constants. Red dotted line is the untreated, native leaflets. 
5.3.4 Anisotropy and cross-coupling  
The average stress-strain behavior was used to identify the anisotropy and cross-coupling 
of the fibers (Figure 5-9). The anisotropy of a sample can be identified by the spacing between 
the circumferential and radial experimental data, and the cross-coupling of the fibers can be 
identified by analyzing the stress-strain behavior at the different loading ratios (addressed in aim 
2). All treatment groups showed that the leaflets kept their anisotropic qualities as the spacing 
between the circumferential and radial loading directions is clear. However, the cross-coupling 
between the fibers was affected. In the control, a consistent spreading of the stress strain curves 
of the tension ratios can be seen in both the circumferential and radial direction. When treated 
with ang-I, the spreading decreases in the circumferential direction in comparison to the radial 
direction, and when treated with ang-II, the spreading decreases in the radial direction in 
comparison to the circumferential direction (Figure 5-9a,b). When ang-I was supplemented with 
an ACE inhibitor (quinaprilat), the spreading in the radial direction was slightly less than in the 
circumferential direction. Ang-I supplemented with a chymase inhibitor (chymostatin) had a 
consistent spreading in both the circumferential and radial direction, and had a higher spreading 
in the circumferential direction than the ang-I treated group (Figure 5-9a). When ang-I and ang-
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II was supplemented with an AT-1R antagonist, it had a greater spacing between the 
circumferential and radial direction than the ang-I and ang-II treated groups implying that they 
were more anisotropic. The spreading of the stress strain curves in the circumferential and radial 
direction was also consistent in the ang-I supplemented with AT-1R antagonist, however when 
ang-II was supplemented with an AT-2R antagonist, the spreading was less in the circumferential 
direction. When ang-I and ang-II were supplemented with an AT-2R antagonist, they showed 
similar results to those supplemented with AT-1R antagonist. 
 
Figure 5-9. 2nd P-K stress vs Green strain graph for tension ratios 1:1, 1:0.75, 0.75:1, 1:0.50, 





Aortic valve tissue is an anisotropic material, and an anisotropic constitutive model was 
used to characterize the mechanical changes that occur due to RAS activation and inhibition. The 
modified M-R isotropic constitutive model was the worst fit model for the aortic valve tissue 
since tissue since it is a model used for isotropic materials. The R2 ranged from 0.10 to 0.64 for 
individual samples and ranged from 0.27 to 0.44 in the average response model. The material 
constants were also not consistent between the samples in the same treatment group nor were 
they similar to the material constants derived from the average stress strain response model. The 
modified M-R anisotropic constitutive model was a better fit than the isotropic model with an R2 
ranging from 0.65 to 0.89 for each sample and an R2 ranging from 0.78 and 0.89 for the average 
response for each treatment. However as it was derived from the Mooney-Rivlin model, the 
stress-strain curve was linear which was not consistent with the experimental data. The Fung-
type model was the best fit model with an R2 ranging from 0.75 to 0.98 for each individual 
sample. In the average model, the R2 ranged from 0.91 to 0.95. When the model fit was graphed 
with the experimental data, it had the same stress strain response. The Fung-type model was the 
best constitutive fit to use to model the effects that RAS has on aortic valve tissue mechanics.  
The contour plots showed that the Fung-type models were all convex verifying that they do 
satisfy the strain energy convexity constraints. The AI calculated with the fung-type material 
constants showed that the samples maintained their anisotropic qualities. When samples were 
treated with receptor inhibitors, the AI was less than 0.5 implying that they were highly 
anisotropic. The stress-strain graphs for each treatment group showed a clear spacing between 
the circumferential and radial direction of loading, implying that the samples preserved their 
anisotropic qualities under all treatment groups. The treatment groups where ang-I and ang-II 
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were supplemented with an AT-1R had the greatest spacing in the stress-strain graphs and the 
lowest calculated AI. Though the control had the highest AI, it was seen that it had the greatest 
cross-coupling. This suggests that the stress in one direction affects the mechanical behavior in 
the orthogonal direction. This cross-coupling affect is important as the mechanical behaviors in 
the native valve are dependent of direction. In the next chapter, we will attempt to relate these 




CHAPTER 6 SPECIFIC AIM 3 
Investigate the biological effects of mediators of the RAS system on aortic valves 
6.1 Introduction 
There are two phases during aortic valve disease progression: (I) the early initiation 
phase, and (II) the propagation phase. The initiation phase involves valvular lipid deposition, 
injury and inflammation (14). This phase has many similarities to atherosclerosis. The 
propagation phase is where pro-calcific and pro-osteogenic factors drive the progression of the 
disease (14). It is believed that the renin-angiotensin system (RAS) plays a role in the 
progression of aortic valve disease as the angiotensin-converting enzyme (ACE) is upregulated 
in calcified valves which facilitate angiotensin I (ang-I) to convert to angiotensin II (ang-II). This 
then affects the valve via the angiotensin II type I receptor (AT-1R) by mediation of its 
profibrotic effects. Angiotensin II type 2 receptor (AT-2R) mediation the antifibrotic and anti-
inflammatory effects of ang-II, but differentiation of expression favors AT-1R (14).  
The extracellular matrix (ECM) is composed of three different layers: the fibrosa, 
spongiosa, and ventricularis. The fibrosa is located near the aorta, the ventricularis near the left 
ventricle, and the spongiosa between both those layers (13). In a healthy valve, the fibrosa is 
predominately comprised of circumferentially-aligned type 1 collagen; the spongiosa is 
composed of proteoglycans; and the ventricularis is composed of a radially-aligned 
collagen/elastin network (30). Valve endothelial cells (VECs) are located in the outer layers of 
the leaflet, and within these layers, valve interstitial cells (VICs) are arranged in subpopulations. 
VECs maintain valve homeostasis, and the VICs secret ECM proteins to maintain valve strength 
and stability (16).  
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AS can proceed to calcific aortic valve disease (CAVD) from the initial cellular changes 
seen in the stenotic valve leaflets. Differentiation of VICs to other cell types, including 
myofibroblasts and osteoblasts, can be triggered from factors such as fluid shear stress, 
inflammatory cytokines, and growth factors (28). Inflammation in the valve is triggered by 
endothelial damage which release pro-inflammatory cytokines such as transforming growth 
factor-beta-1 (TGF-β1). This inflammatory activity activates the cells within the valve, and VICs 
differentiate from fibroblast-like cells to myofibroblast cells (5). As the disease progresses, VICs 
become further activated and differentiate into osteoblast-like bone-forming cells and respond to 
osteogenic mediators such as bone morphogenetic proteins (BMPs) which are member of the 
TGF-β superfamily (16). Calcified valves have an increased presence of TGF-β1 in the ECM and 
may contribute to the progression of CAVD by initiating apoptosis (6, 39). VECs may also 
undergo differentiation into osteoblast-like bone-forming cells through endothelial-to-
mesenchymal-transformation (EndoMT) in which they lose their endothelial cell properties. 
These transformed VECs begin to acquire phenotypic characteristics of myofibroblasts and 
express myofibroblast-specific markers such as α-SMA, Type I collagen, and vimentin. Similar 
to VICs, they can be stimulated by osteogenic mediators such as TGF-β and undergo osteogenic 
differentiation and fibrosis (16).  
The increased production of collagen and the disorganization of the fibers are an 
indication of CAVD. In a diseased valve, the structure of the valve trilayer is disturbed. The 
crosslinking of the fibers is affected in the fibrosa layer while collagen production is affected in 
the other layers. In the fibrosa layer, fibers are shorter than that of those in a healthy valve, and in 
the spongiosa layer, the collagen fibers appear to become wider and denser. There are typically 
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more immature fibers in the spongiosa and are more mature fibers in the fibrosa during CAVD 
progression (30). 
As phenotypic changes and alterations in tissue collagen are integral during the valve 
disease process, this aim focuses on investigating these biological effects that RAS has on the 
leaflet tissue. The phenotypic changes that VICs undergo due to RAS were investigated via 
immunohistochemistry, and the alterations in collagen fibers were investigated via quantitative 
polarized light microscopy and Picrosirius red staining. 
6.2 Materials and Methods 
Protocols can be found in Appendix A. MATLAB codes and instructions can be found in 
Appendix B. 
6.2.1 Tissue treatment 
Fresh porcine hearts (3-6 months old) were provided by Cockrum’s Custom Meat 
Processing and Taxidermy (Rudy, AR) or Braunschweig Processing (Neosho, MO), both FDA-
approved abattoirs. Samples were transported in cold, sterile dPBS. The hearts were then 
dissected aseptically, and the left, right, and non-coronary aortic valve leaflets were pooled and 
washed in sterile dPBS. They were then supplemented with 150 U/ml penicillin/streptomycin in 
PBS for 10 mins.  
The leaflets were then incubated in DMEM, 2% FBS, 150 U/ml P/S, and HEPES, and 
treated with the following. The binding of ang-I and ang-II to the receptors was investigated by 
inhibiting the AT-1R or AT-2R receptor subtypes. The samples were treated with either AT-1R 
inhibitor losartan (1μM) or AT-2R inhibitor PD123-319 (1μM) for 24 hours before being treated 
in combination with ang-I (10 μM) or ang-II (10 μM) for an additional 48 hours (69). The local 
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conversion of ang-I to ang-II was investigated by inhibiting ACE or chymase. Samples were 
treated with ACE inhibitor quinaprilat (1 μM) or chymase inhibitor chymostatin (10 μM) (69). 
Following treatment, samples for immunohistochemistry and picrosirius red (PSR) 
staining were immediately placed in optimum cutting temperature (OCT) compound and flash 
frozen at -80˚C. Tissues for quantitative polarized light microscopy (QPLI) were obtained from 
the biaxial testing experiments (Aims 1 and 2). The tissues were placed in a cryopreservation 
agent and flash frozen at -80˚C.  
6.2.2 Immunohistochemistry 
Immunohistochemistry was performed against the primary antibodies rabbit anti- α-SMA 
(1:100, Abcam) and mouse anti-calponin (1:100, Abcam) in 2% goat serum and 1x PBS.  Either 
1:200 Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary antibodies (Life Technologies) 
was used to label primary antibodies of the proteins of interest. Secondary solution also 
contained 1:200 DAPI and 1x PBS. 
Briefly, 5 µm thick sections were cryosectioned in the transverse plane and stored in -
80˚C freezer until staining. Slides were fixed in ice-cold acetone for 5 minutes and placed on a 
paper towel for 10 minutes to allow acetone to evaporate. A square was placed around each 
section with a water/alcohol proof marker and let dry for 10 minutes. Slides were rehydrated in 
1x PBS for 5 minutes. Slides were placed in a humid chamber and 195 µL of 20% goat serum in 
1x PBS was placed on each section as a blocking agent. They were incubated at 37 ˚C for 60 
minutes. Blocking solution was removed by carefully holding the coverslip perpendicular to the 
bench and edge blotted with a kimwipe. 195 µL of desired primary antibody solution was placed 
on each section and incubated at room temperature for 2 hours in the humid chamber. Slides 
were washed by dipping three times in a staining jar containing 1x PBS and let sit for 5 minutes. 
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This was repeated three times in fresh 1x PBS. Slides were placed back in humid chamber and 
195 µL of secondary antibody was placed on each sectioned. Samples were incubated for 2 hours 
at room temperature. Slides were washed again as stated before but in the dark to not photo-
bleach the sample. Samples were mounted with pro-long gold and mounted media was allowed 
to cure for 24 hours. A thin layer of nail polish was placed around the cover slip and allowed to 
dry for 2 hours. Separate slides were stained with secondary antibody only and served as 
negative controls to assess non-specific binding of the secondary reagent. Slides were stored in 
the -20˚C freezer until imaging. Images were acquired via a regular epifluorescence microscope. 
6.2.3 Picrosirius red (PSR) staining 
5 µm thick sections were cryosectioned in the transverse plane and stored in the -80˚C 
freezer until staining. Slides were fixed in cold acetone for 5 minutes and then washed under 
running tap water for 10 minutes. Slides were then rinsed by dipping into distilled water three 
times. They were then placed on a paper towel, a few drops of phosphomolybdic acid 0.2% 
aqueous were placed on each tissue section, and treated for 5 minutes. Slides were placed in a 
glass staining jar containing 100ml of sirius red, 0.1% in saturated picric acid, for 90 minutes. 
Slides were washed for 2 minutes in 0.01N hydrochloric acid and then rinsed in 70% alcohol for 
45 seconds. Slides were dehydrated by placing in 95% ethanol for 3 minutes two times and 
100% ethanol for 3 minutes two times. They were cleared in xylene for 5 minutes two times and 
then mounted with cytoseal. Mounting medium was allowed to cure for at least 24 hours before 
imaging.  
PSR stained samples were imaged via polarized light microscopy, and were subsequently 
analyzed using a custom MATLAB (Mathworks Inc.) script based on a published algorithm to 
quantify the red, orange, yellow, and green pixel count by their respective hue and saturation 
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levels (68). The colors red, orange, yellow, and green correspond to the thickness of the collagen 
fibers present from thickest to thinnest respectively. The pixel count for each color was divided 
by the total pixel count for the four colors to acquire the percentage of each color present in the 
image.  
6.2.4 Quantitative polarized light imaging (QPLI)  
Tissue was in washed in dPBS after biaxial testing and placed in a solution of 85% 
DMEM, 5% FBS, and 10% dimethyl sulfoxide (DMSO) to prevent ice crystal from damaging 
the tissue when frozen, as a cryopreservation agent. Samples were flash frozen at -80˚C. Prior to 
imaging, samples were defrosted by placing at room temperature for 30mins.  
A custom-built trans-illumination based QPLI microscope (Olympus BX51, Olympus Corp., 
Tokyo, Japan) setup was used which utilizes a rotating polarizer and circular analyzer (83, 84). 
Images were collected using a 20x objective (UPlanFL N 20x, 0.5 NA, Olympus Corp.) and data 
was collected using a 10x objective (UPlanFL N 10x, 0.3 NA, Olympus Corp.). Full field images 
were produced via image stitching. The images were analyzed using a custom MATLAB code. 
Average light retardation was measured as proportional to the amount of collagen in the tissue. A 
rotating polarizer and circular analyzer enabled the assessment of variance in collagen fiber 
alignment as a measure of collagen fiber orientation.  
6.2.5 Statistical methods 
Results are reported as mean with standard error. Data was first analyzed for normality 
using the Shapiro-Wilk normality test. For the enzyme inhibition, a one way ANOVA was run 
using multiple comparisons versus the diseased (ang-II) state using the Dunnett’s Method. For 
the receptor inhibition, a two way ANOVA was run using all pairwise multiple comparison 
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follow by the Tukey post hoc test for normally distributed data. Analyses were performed using 
Sigma Plot. A p value of less than 0.05 was used to indicate statistical significance.  
6.3 Results  
6.3.1 Cellular phenotypic changes in tissue 
Via immunohistochemistry (IHC), we observed that activation or inhibition of the RAS 
pathway altered the valve cell phenotype in the valve tissue. α-SMA and calponin were not 
expressed in the control samples (Figure 6-1a.I,II & b.I,II), implying that when treated with only 
media, the cells in the tissue were not being activated. When the tissue was treated with ang-I or 
ang-II, α-SMA and calponin expression was upregulated, suggesting that the cells were being 
activated and becoming more contractile and myofibroblast-like (Figure 6-1a.III-VI & b.III-VI). 
Additionally, the upregulation of these markers in the ang-I treated groups suggests that ang-I is 
being converted to ang-II locally on the valve leaflet. To validate that enzymes are present 
locally to convert ang-I to ang-II, valves leaflets were treated with an ACE and chymase 
inhibitors, quinaprilat and chymostatin respectively, prior to and during treatment of ang-I. The 
upregulation of α-SMA and calponin seen when treated with ang-I alone was mitigated in the 
ACE and chymase inhibitor groups. This suggests that ang-I activates the cells due to it 
converting to ang-II locally through either ACE (Figure 6-1a.VII,VIII) or an ACE-independent 
pathway (Figure 6-1a.IX,X).  
When the tissue was treated with an AT-1R inhibitor (losartan) in conjunction with ang-I 
or ang-II, α-SMA and calponin were not expressed (Figure 6-1b.VII-X). This suggests that by 
inhibiting the ability for ang-II to bind to AT-1R the activation of the cells was being mitigated. 
When the tissue was treated with an AT-2R inhibitor (PD123,319) in conjunction with ang-I or 
ang-II, α-SMA and calponin were expressed (Figure 6-1b.XI-XIV). This suggests that by 
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inhibiting the ability for ang-II to bind to AT-2R, ang-II is binding to AT-1R causing the 
activation of the cells. It should be noted that this last observation is supported in the literature as 
the AT-1R receptor subtype is known to be pro-atherosclerotic and AT-2R antagonizes its effects 
(55).   
  
Figure 6-1. Representative micrographs of aortic valve leaflets immunohistochemically labeled 
with α-SMA (green), calponin (red) and DAPI (blue) treated with (a) enzyme inhibitors and (b) 
receptor inhibitors. Arrows indicate expressed areas. (scale bar=100µm)  
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6.3.2 Alterations of collagen structure 
Next, we wanted to relate the mechanical observations from aims 1 and 2 to possible 
alterations in the collagen structure of the leaflets. To do so we utilized two techniques that 
leverage the birefringence of collagen fibers: picrosirius red staining (PSR) and quantitative 
polarized light imaging (QPLI).  
In the enzyme inhibition treatment groups, ang-I (21.53±0.77) and ang-II (22.80±1.77) 
had a higher percentage of the thinnest fibers than the control (17.35±3.42). When ang-I was 
supplemented with the ACE (19.77±3.16) and chymase (20.32±2.57) inhibitors, they showed a 
higher percentage of thinnest fibers to the control but a lower percentage than the ang-I and ang-
II treated groups (Figure 6-2b). The control (27.62±1.45), ang-I (28.24±1.52), and ang-II 
(28.63±.097) treatment groups showed a similar percentage of thin intermediate fibers. The ang-I 
supplemented with ACE (25.76±2.55) and chymase (26.52±1.47) inhibitors showed a lower 
percentage of thin intermediate fibers (Figure 6-2c). The control (44.97±4.68) and ang-I 
supplemented with ACE (45.52±4.69) and chymase (46.84±4.02) inhibitors treatment groups had 
a similar percentage of thinnest and thin intermediate fiber percentage combined while the ang-I 
(49.77±0.91) and ang-II (51.43±2.51) treated samples showed a higher thinnest and thin 
intermediate fiber percentage combined (Figure 6-2a). The ang-I (36.43±0.60) and ang-II 
(37.18±2.01) treated group had a lower percentage of thick intermediate fibers than the control 
(40.29±1.80). The ang-I supplemented with ACE (38.18±2.02) and chymase (38.74±2.09) 
inhibitors had a lower percentage of thick intermediate fibers than the control but a higher 
percentage than the ang-I and ang-II treated groups (Figure 6-2d). The ang-I (13.81±1.47) and 
ang-II (11.39±1.15) treated group had a lower percentage of thickest fibers than the control 
(14.74±2.89). The ang-I supplemented with ACE (16.30±2.83) and chymase (15.70±2.96) 
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inhibitors had a higher percentage of thickest fibers than the control, ang-I and ang-II treated 
groups (Figure 6-2e). The control (55.03±4.68) and ang-I supplemented with ACE (54.48±4.69) 
and chymase (54.43±4.99) inhibitors treatment groups had a similar percentage of thickest and 
thick intermediate fiber percentage combined while the ang-I (50.23±0.91) and ang-II 
(48.57±2.51) treated samples showed a lower percentage of thickest and thick intermediate fiber 
percentage combined (Figure 6-2a). This indicates that when samples are treated with ang-I and 
ang-II there is more newly synthesized collagen fiber, and when the conversion of ang-I to ang-II 
is inhibited by either ACE or an ACE-independent pathway, there is more mature fiber and 
similar to what is seen when tissue is not treated with ang-I or ang-II.  
 
Figure 6-2.  (A) Quantification of picrosirius stain for enzyme inhibitors of collagen fiber 
thicknesses of (B) thinnest, (C) thin intermediate, (D) thick intermediate, and (E) thickest 
collagen fiber present. Red dotted line is the untreated, native leaflets. 
In the receptor inhibition treatment groups, ang-II (28.88±4.62) had a higher percentage 
of the thinnest fibers than the control (21.14±1.27) while ang-I (19.42±3.21) had a similar 
percentage of thinnest fibers than the control. When ang-I was supplemented with AT-1R 
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antagonist (22.46±5.77), there was a higher percentage of thinnest fibers than the ang-I treated 
group, and when ang-II was supplemented with an AT-1R antagonist (19.94±5.26), it had a 
lower percentage of thinnest fibers and a similar percentage than the control. When ang-I was 
supplemented with an AT-2R antagonist (20.75±7.66), it had a similar percentage of thinnest 
fibers than the control and ang-I, but when ang-II was supplemented with AT-2R antagonist 
(25.87±4.81), it had a higher percentage of thinnest fibers than the control but lower than the 
ang-II treated group (Figure 6-3b). The control (34.07±1.57) had the highest percentage of thin 
intermediate fibers. The ang-I (26.83±.85) and ang-II (28.28±2.81) treated group had a lower 
percentage of thin intermediate fibers than the control. When ang-I was supplemented with an 
AT-1R antagonist (27.68±3.06), it had a similar percentage of thin intermediate fibers than the 
ang-I treated group. When ang-II was supplemented with AT-1R antagonist (25.57±3.69), it had 
a lower percentage of thin intermediate fibers than the ang-II treated group. When ang-I was 
supplemented with an AT-2R antagonist (26.57±2.8), it showed a similar percentage of thin 
intermediate fibers than the ang-I treated group. When ang-II was supplemented with AT-2R 
antagonist (26.84±2.34), it had a similar percentage of thin intermediate fibers than the ang-II 
treated group (Figure 6-3c).  The ang-I (46.25±2.52) treatment group had a lower percentage of 
thinnest and thin intermediate percentage combined than the control (55.20±2.68). The ang-II 
(57.16±7.27) treatment group had a higher percentage of thinnest and thin intermediate 
percentage combined than the control and ang-I. The ang-I supplemented with AT-1R antagonist 
(50.14±8.69) treatment group had a similar percentage of thinnest and thin intermediate fiber 
percentage combined than the ang-I treatment group. The ang-II supplemented with AT-1R 
antagonist (45.51±8.94) treatment group had a lower percentage of thinnest and thin intermediate 
fiber percentage combined than the ang-II treatment group. The ang-I supplemented with AT-2R 
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antagonist (47.32±10.42) treatment group had a similar percentage of thinnest and thin 
intermediate fiber percentage combined than the ang-I treatment group and lower percentage 
than the control group. The ang-II supplemented with AT-2R antagonist (52.72±6.34) treatment 
group had a lower percentage of thinnest and thin intermediate fiber percentage combined than 
the control and ang-II treatment group (Figure 6-3a). Ang-II (33.04±3.41) had a lower 
percentage of the thick intermediate fibers than the control (38.42±2.45) while ang-I 
(40.24±2.62) had a higher percentage of thick intermediate fibers than the control. When ang-I 
was supplemented with AT-1R antagonist (39.15±4.53), there was a similar percentage of thick 
intermediate fibers than the ang-I treated group, and when ang-II was supplemented with an AT-
1R antagonist (40.72±4.92), it showed a higher percentage of thick intermediate fibers as the 
ang-II treated group. When ang-I was supplemented with an AT-2R antagonist (39.38±5.37), it 
had a similar percentage of thick intermediate fibers than the ang-I treated group, and when ang-
II was supplemented with AT-2R antagonist (35.79±3.15), it had a higher percentage of thick 
intermediate fibers than the ang-II treated group but lower percentage than the control (Figure 
6-3d). The control (6.38 ±0.76) had the lowest percentage of thick fibers. The ang-I (13.52±0.19) 
and ang-II (9.80±3.98) treated groups had a higher percentage of thick fibers than the control. 
When ang-I was supplemented with an AT-1R antagonist (10.71±4.29), it had a lower 
percentage of thick fibers than the ang-I treated group. When ang-II was supplemented with AT-
1R antagonist (13.77±4.07), it had a higher percentage of thickest fibers than the ang-II treated 
group. When ang-I was supplemented with an AT-2R antagonist (13.29±5.06), it had a similar 
percentage of thickest fibers than the ang-I treated group and higher percentage than the control. 
When ang-II was supplemented with AT-2R antagonist (11.49±3.38), it had a higher percentage 
of thickest fiber percentage than the control and ang-II treated group (Figure 6-3d). The control 
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(44.80±2.68) and ang-II (42.84±7.27) treatment group had a similar percentage of thickest and 
thick intermediate percentage combined, and ang-I (53.75±2.52) and a higher percentage of 
thickest and thick intermediate than the control and ang-II treated group. When ang-I was 
supplemented with an AT-1R antagonist (49.86±8.69), it had higher thickest and thick 
intermediate percentage combined than the control and lower percentage to the ang-I treated 
group. When ang-II was supplemented with an AT-1R antagonist (54.49±8.94), it had a higher 
thickest and thick intermediate percentage combined than the ang-II and control. When ang-I 
was supplemented with an AT-2R antagonist (52.68±10.42), it had a similar thickest and thick 
intermediate percentage combined than the ang-I treated group and higher percentage than the 
control. When ang-II was supplemented with an AT-2R antagonist (47.28±6.34), it had higher 
thickest and thick intermediate percentage combined than the control and lower percentage than 
the ang-II treated group (Figure 6-3a). 
 
Figure 6-3. (A) Quantification of picrosirius stain for receptor inhibitors of collagen fiber 
thicknesses of (B) thinnest, (C) thin intermediate, (D) thick intermediate, and (E) thickest 
collagen fiber present. Red dotted line is the untreated, native leaflets.    
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The QPLI set up uses a rotating polarizer and a circular analyzer allowing for the 
quantification of fiber amount and orientation via the measurement of average retardation 
(collagen amount) and the local directional variance (variance of the collagen orientation). The 
ang-I (35.83±4.26) treated group had a lower average retardation than the control (43.68±5.53) 
while the ang-II (47.55±3.17) treated group had a higher average retardation than the control. 
The ang-II treated group had the overall greatest average retardation (Figure 6-4a,b). When ang-
I was supplemented with the ACE (40.98±4.95) and chymase (37.27±4.08) inhibitors, they 
showed a lower average retardation than the control and ang-II treated group but a higher 
average retardation than the ang-I treated group (Figure 6-4a). When ang-I was supplemented 
with an AT-1R antagonist (44.35±3.02), it had a higher average retardation than the ang-I treated 
group but similar average retardation than the control. When ang-II was supplemented with an 
AT-1R antagonist (41.72±3.06), it had a lower average retardation than the control and ang-II 
treated group. Ang-I supplemented with an AT-2R antagonist (28.20±4.43) had a lower average 
retardation than the control and ang-I treated group. Ang-I supplemented with an AT-2R 
antagonist (38.05±2.86) had a lower average retardation than the control and ang-II treated group 
(Figure 6-4b).  
The ang-I (0.064+0.025) treated group had a lower higher local directional variance than 
the control (0.032±0.14) while the ang-II (0.022±0.007) treated group had a lower local 
directional variance than the control (Figure 6-4c,d). When ang-I was supplemented with an 
ACE (0.037±0.015) and chymase (0.052±0.017) inhibitors, it had a lower local directional 
variance than the ang-I treated group but higher local directional variance than the control and 
ang-II treated group (Figure 6-4c). When ang-I was supplemented with an AT-1R antagonist 
(0.035±0.020), it had a higher local directional variance than the control but lower variance than 
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the ang-I treated group. When ang-II was supplemented with an AT-1R antagonist 
(0.044±0.013), it had a higher local directional variance than the control and ang-II treated 
group. When ang-I was supplemented with an AT-2R antagonist (0.157±0.035), it had the 
highest local directional variance. Ang-II supplemented with an AT-2R antagonist (0.053±0.020) 
had a higher local directional variance than the control and ang-II treated group (Figure 6-4d).  
 
 
Figure 6-4.  Quantification of the average retardation (collagen amount) in the (A) enzyme and 
(B) receptor inhibitors and local directional variance (variance of collagen orientation) in the 
(C) enzyme and (D) receptor inhibitors using quantitative polarized light imaging. Red dotted 
line is the untreated, native leaflets.  




Immunohistochemistry (IHC) showed that RAS affects the phenotypic properties of the 
cells in the aortic valve tissues. Tissue treated with ang-I and ang-II showed an upregulation in 
expression of α-SMA and calponin implying that cells were becoming activated. When ang-I 
was supplemented with an ACE and chymase inhibitor, these effects were mitigated implying 
that by inhibiting the ability for ang-I to convert to ang-II cells maintain their quiescent state. 
This also strongly suggests that the effects seen by treating samples with ang-I is due to its 
ability to convert locally into ang-II. Ang-I and ang-II supplemented with an AT-1R receptor 
inhibitor also mitigated the effects of ang-I and ang-II mediated pathological signaling. This 
result indicates that the quiescent state can be maintained by inhibiting the binding of ang-II to 
AT-1R. When ang-I and ang-II were supplemented with an AT-2R antagonist, there was an 
upregulation of α-SMA and calponin. This indicates that when the ability for ang-II to bind to 
AT-2R is inhibited, ang-II will bind to AT-1R causing the cells to become activated.  
The sample size for picrosirius red (PSR) staining was small (n=3) and so it was 
underpowered and did not show significant difference. However, PSR showed various trends, 
and the sample size will be increased to verify its significance. Tissue treated with ang-I and ang-
II had a higher percentage of thin collagen fibers suggesting more newly synthesized fibers. This 
suggests that there is an increase in production of collagen which is a hallmark for early 
progression of valve fibrosis. When ang-I was supplemented with an ACE and chymase 
inhibitor, there was a similar percentage of thin fibers than that of the control suggesting that by 
inhibiting the ability of ang-I to convert to ang-II, the pathological increased production of 
collagen fiber is mitigated.  
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When ang-II was supplemented with an AT-1R antagonist, there was a lower percentage 
of thin fibers than the ang-II treated group, and when supplemented with an AT-2R antagonist, it 
had a similar percentage of thin fibers as the ang-II group. Overall, this suggested that by 
inhibiting that the binding of ang-II to AT-2R increases pathologic-like collagen production as 
seen in the ang-II groups alone.  
In contrast to PSR, QPLI was conducted on tissue after biaxial mechanical testing. QPLI 
showed the maximum collagen amount in Ang-II, which matches PSR. Perhaps ang-II treatment 
increased collagen synthesis while reducing collagen degradation. AT-2R inhibitor seemed to 
reduce collagen amount significantly. QPLI showed that there was an increase in the variance of 
the collagen orientation in ang-I treated samples. When ang-I was supplemented with an ACE 
and chymase inhibitor, the collagen orientation was similar to that of the untreated leaflet. Ang-I 
and ang-II supplemented with an AT-2R antagonist also showed an increase in variance of 
collagen orientation while ang-I and ang-II supplemented with AT-1R had a similar directional 
variance than the control. This suggests that the binding of ang-II to AT-1R increases the 
disorganization of the fibers. By inhibiting the ability for ang-I to convert to ang-II and inhibiting 
the ability for ang-II to bind to AT-1R these effects are mitigated. There may be increased 
collagen degradation in the AT-2R inhibitor groups caused by elevated signaling at the AT-1R. 
The activation of VICs, an increase production of collagen fibers, and disorganization of 
collagen fibers are hallmarks of early disease progression. Two days of treatment were enough to 
alter phenotype, but not long enough to observe significant changes at the collagen fiber level. In 




CHAPTER 7 LIMITATIONS AND FUTURE DIRECTIONS 
One of the limitations in the study was the amount of time the samples were treated. 
More time in culture was needed as there were very little changes in collagen observed. Though 
the effects could be seen when limiting ang-II to bind to just one receptor, the time given for 
ang-II to bind to either receptor when given the option to bind to both AT-1R and AT-2R was 
not enough. Though ang-II is prone to bind to AT-1R, a longer time period is needed to increase 
the potential binding to AT-1R over AT-2R. The study had to be limited to a 48 hour treatment 
of ang-I and ang-II as samples are more prone to become contaminated if treated for longer 
periods of time.  
Another limitation was the mechanical testing in the current biaxial system. Our current 
loading cells are not capable of detecting very low tensions properly. The load cells in the 
upgraded biaxial system will allow for detection of the lower tensions seen in the toe region. 
This would allow for more sensitive reading of the stiffness in the toe region and also help in 
obtaining better constitutive model fits. In addition, our system was displacement based. This 
means that to stretch the samples to the desired tension multiple tests had to be run to determine 
the correct displacement needed for it. In addition, the samples were stretched close to their 
desired tension such as 90 N/m, but the tension could vary approximately from ± 7N/m on 
certain samples. This could affect the calculations using the max green strain such as anisotropy 
index and areal strain. 
The alterations of the collagen measured using QPLI was done on samples after the 
biaxial testing. Using QPLI while running the mechanical tests would be ideal as it would 
provide information on the instantaneous alterations of the collagen fibers in real time. In 
addition, QPLI was done on a portion of the sample tested and not on the sample as a whole. The 
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current biaxial system did not have the ability to do this, but the biaxial system which we are 
currently upgrading will have the ability to do QPLI during the mechanical testing and image the 
sample as a whole and not just a small portion. In the future, the new biaxial system will 
eliminate these limitations seen during the mechanical testing and QPLI performed during this 
thesis. 
In this study, we sought to investigate the affects that RAS has on aortic valve tissue 
mechanical and phenotypic properties. In the future, we will investigate how RAS affects the 
aortic valve at the cellular level. We conducted some preliminary studies on the effects that RAS 
has on valvular interstitial cells (VICs), but there were a few limitations in the study. 
Traditionally, VICs were grown in media containing basal Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS). However, studies have shown that 
by growing VICs in this “classical DMEM” VICs become activated and exhibit myofibroblast 
qualities instead of the fibroblast-like qualities which quiescent VICs have (85). To overcome 
this, a study conducted by Latif, et al showed that growing VICs in DMEM supplemented with 
2% FBS, 50 ng/ml insulin, and 10 ng/ml fibroblast growth factor-2 (FGF2) allow the cells to 
maintain their fibroblast phenotype (85). In our preliminary studies, we cultured VICs in this 
“fibroblast media” and treated them with ang-I, ang-II, ang-I supplemented with an AT-1R or 
AT-2R antagonist, and ang-II supplemented with an AT-1R or AT-2R antagonist in the same 
manner as we treated the tissue in our study. However, culturing cells in fibroblast media 
presented us with some limitations in the thin-film experiment and western blots. Thin-film 
experiments allow us to measure the contraction and relaxation of cells when stimulated with 
endothelin-1 (ET-1) and relaxed with HA-1077. In a previous study conducted by our lab, we 
were able to measure the contraction and relaxation of VICs treated with ang-II (68). In that 
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study, VICs had been cultured in classical DMEM. When we tried to conduct thin film 
experiments in VICs cultured in fibroblast media, the VICs were not strong enough to lift the 
thin film when they were stimulated. It the lifting and curling of the thin film that allows the 
measurement of the VICs contractility and relaxation. To overcome this limitation, we will be 
conducting traction force microscopy (TFM) to measure the mechanical properties of VICs 
instead of the thin film experiment. In TFM, VICs are cultured on an acrylamide membrane 
containing fluorescent beads. Using a multi-photon microscope, the beads can be tracked when 
the VICs are stimulated instead. The VICs in our preliminary study were also treated in a static 
state which means that the VICs were not undergoing strain as they are within their native 
environment in the body. When western blotting was done to determine the expression of 
vimentin and calponin, there was no significant difference between the expression of calponin or 
vimentin in the treatment groups (Figure 7-1). To overcome this limitation, VICs will be 
exposed to mechanical strain in all future studies.  
 
 
Figure 7-1. (A) Western blot analysis of VICs treated with receptor inhibitors for vimentin and 
calponin. Expression of (B) vimentin and (C) calponin normalized with β-actin.  
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CHAPTER 8 SUMMARY AND CONCLUSIONS 
The objective of this study was to investigate how renin-angiotensin signaling (RAS) 
pathway mediators affect the biological and mechanical function of the aortic valve tissue by 
further understanding the ACE or ACE independent pathway in which angiotensin I (ang-I) 
converts to angiotensin II and also the binding of ang-II to type 1 ang-II receptor (AT-1R) and 
type 2 ang-II receptor (AT-2R). This was done so by treating porcine aortic valve tissues with 
ang-I, ang-II, ang-I+ACE inhibitor (quinaprilat), ang-I+chymase inhibitor (chymostatin), ang-
I+AT-1R antagonist (losartan), ang-II+AT-1R antagonist, ang-I+AT-2R antagonist (PD123,319), 
ang-II +AT-2R antagonist, or vehicle (DMEM).  
In the first aim, aortic valve tissue was exposed to biaxial mechanical testing after being 
pre-treated. The samples were tested at five different tension load ratio protocols at a maximum 
tension of 90 N/m: Tcirc:Trad – 1:1, 1:0.75, 1:0.5, 0.75:1, 0.5:1. Key findings from this study are 
outlined below: 
 The cross-coupling of the fibers was affected as can be seen by the spreading of the 
stress-strain curves in the 2nd P-K stress vs Green strain graph 
 The anisotropic properties were not affected as can be seen by the clear spacing between 
the circumferential and radial curves in the 2nd P-K stress vs Green strain graph and a 
strain anisotropy index of less than 0.6.  
In most cases, the mechanical properties exhibited by enzyme inhibitors were similar to 
the control which could suggest that when ang-I is not able to convert to ang-II it can sustain its 
native properties. However the mechanical properties exhibited by ang-I and ang-II were similar 
to the control as well. Though ang-II is more prone to bind to AT-1R, the amount of treatment 
time may not have been sufficient to increase the binding of AT-1R over AT-2R. However, 
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limiting the ability to bind to just one receptor did show a trend in mechanical behavior. In most 
cases, the tangent modulus was lower in samples treated with an AT-1R antagonist than those 
with an AT-2R antagonist implying that the binding of ang-II to AT-1R increases the stiffness of 
the sample. There was a high variation in the extensibility, and it seems to be highly unreliable 
because small changes in the high TM fit will result in wide changes in where the line cuts the x-
axis, thereby affecting extensibility. 
In specific aim 2, three phenomenological constitutive models were utilized to 
characterize the biomechanical changes that occur due to RAS mediators on aortic valves: (1) 
modified Mooney-Rivlin (M-R) isotropic model, (2) modified M-R anisotropic model, and (3) 
Fung-type model. Typically M-R constitutive models are used to characterize the behavior of 
isotropic materials, but the modified anisotropic model adds an anisotropic term to the modified 
M-R isotropic model. The Fung-type constitutive model is typically used to characterize the 
behavior of a non-linear anisotropic material. Material constants for each model was derived for 
each individual sample and averaged, and material constants were also calculated using data 
from an average stress strain response model.  Key findings from this study are outlined below: 
(1) The modified Mooney-Rivlin (M-R) isotropic model fit the experimental data the least 
having an R2 ranging from 0.27 to 0.44 in the average response model for the treatment 
groups. It was the least adequate for the experimental data. 
(2) The modified M-R anisotropic model fit the experimental data better than the isotropic 
model having an R2 ranging from 0.78 and 0.89 for the average response for each 
treatment. However, it still had a linear-like stress-strain response for our strain range, 
making it inadequate for the experimental data.  
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(3) The Fung-type model had the best fit model with an R2 ranging from 0.91 to 0.95 in the 
average response model for the treatment groups. The curve was also non-linear as seen 
in the experimental data.  
The material constants derived from the Fung-type model can give us some insight on the 
convexity of the model and the anisotropy of the samples. The contour plots showed that the 
Fung-type models were all convex verifying that they do satisfy the strain energy convexity 
constraints. The treatment groups had an average AI of 0.66 or lower implying that all treatment 
groups kept their anisotropic qualities. Limiting the ability to bind to just one receptor did show a 
trend in the AI derived from the Fung-type model in which the AI was the lowest when treated 
with receptor antagonist implying that they are highly anisotropic. Samples treated with receptor 
inhibitors had the greatest spacing between curves and lowest AI implying that the samples 
became highly anisotropic. 
It was clear that an anisotropic model would provide a better model fit to characterize the 
biomechanical changes that occur due to RAS mediators on aortic valves. Though the modified 
M-R anisotropic model was a good fit, a non-linear model such as the Fung-type model was the 
best phenomenological constitutive model. 
In specific aim 3, we sought to understand the biological effects that mediators of the 
RAS system had on aortic valve tissues. The phenotypic changes the cells undergo on the tissue 
due to RAS were investigated via immunohistochemistry (IHC), and the changes that collagen 
fibers undergo were investigated with quantitative polarized light microscopy (QPLI) and 
picrosirius red staining (PSR).  
VICs were becoming activated when aortic valve tissue was treated with ang-I, ang-II, 
and ang-I or ang-II supplemented with an AT-2R as an upregulation of α-SMA and calponin was 
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seen. The upregulation in expression of α-SMA and calponin was mitigated in ang-I or ang-II 
supplemented with an AT-2R antagonist and ang-I supplemented with an ACE or chymase 
inhibitor implying that cells are maintaining their quiescent form.  
PSR showed an increase in production of collagen fibers in tissue treated with ang-I and 
ang-II. When the binding of AT-1R was impeded, there was lower production of collagen fibers, 
and when the binding of AT-2R was impeded, there was higher production of collagen fibers. 
This suggests that the binding of ang-II to AT-1R increased the collagen production. 
QPLI showed an increase in disorganization of collagen fibers. Ang-I and ang-II 
supplemented with an AT-2R antagonist also showed an increase in variance of collagen 
orientation while ang-I and ang-II supplemented with AT-1R had a similar directional variance 
than the control. This suggests that the binding of ang-II to AT-1R increases the disorganization 
of the fibers. QPLI showed the maximum collagen amount in Ang-II, which matches PSR. 
Perhaps ang-II treatment increased collagen synthesis while reducing collagen degradation. 
This study showed that ang-I and ang-II activated VICs, increased production of collagen 
fibers, and increased disorganization of collagen fibers. By inhibiting the binding of ang-II to 
AT-2R and only to AT-1R, these same effects were shown. When ability for ang-I to convert to 
ang-II and inhibiting the ability for ang-II to bind to AT-1R was inhibited, these effects are 
mitigated. 
In this study, we were able to see that ang-I had an effect on the aortic valve which leads 
to believe that it can be converted locally. Ang-II may increase in the plasma during illnesses 
such as hypertension (66), but ang-II production could also increase in the heart via ACE or 
chymase locally. We observed the activation valvular interstitial cells both in ang-I and ang-II 
treated tissue. The upregulation of α-SMA and calponin has been seen in calcified aortic valves 
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(86), and we can infer that the activation we observed by RAS mediators can potentially lead to 
the progression of valve disease. Ang-II has also shown to increase the thickness and endothelial 
derangements in aortic valves which have been linked to early progression of aortic stenosis 
(87). Thickening and calcification in the aortic valve can lead to reduced opening of the valve 
and increased stiffness (13). In our study, we observed that RAS mediators altered the stiffness 
of the aortic valve in addition to other biomechanical behaviors observed in stenotic aortic 
valves. Quinaprilat and losartan showed to mitigate these effects at the whole-tissue level, and 
more studies need to be conducted to further understand if common ACE inhibitors and ARBs 
used to treat other diseases such as hypertension can also be used as therapeutic treatments for 
the prevention of the progression of aortic stenosis that could lead to more severe conditions 
such as calcific aortic valve disease (CAVD).  
In conclusion, through this thesis we were able to see that RAS mediators affected the 
biological and mechanical functions of the aortic valve leaflet. The activation of VICS and 
increased production and disorganization of collagen fibers correlated to the stiffness of the 
tissue which is linked to aortic stenosis. The finite Fung-type constitutive model was the best fit 
model to characterize the changes in the mechanical properties of the tissue due to RAS 
mediators. Further understanding of the role of the local RAS pathway in potentiating early 
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APPENDIX A PROTOCOLS 
Protocols listed here are for methods mentioned. Additional protocols for cell work not included 
in Chapter 4 but in preliminary studied are also included. MATLAB codes for analysis of 
methods are in Appendix B.
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Preparing for Slaughterhouse trip to Collect Large Animal Samples 
 
Reagents and Materials: 
 
Reagent Notes 
10x PBS VWR #101076-194 
70% EtOH In spray-bottle 
Penicillin-Streptomycin (10,000 U/mL)  ThermoFisher #15140122 
(15 mL aliquots; -20°C freezer) 
Distilled water 40 mL in 50 mL conical  
  
Materials Notes 
30 mL syringe Sterile 
Filter  
6L container  
Aluminum foil  
Surgical tools  Large scissors, small scissors, scalpel 
handle, larger straight and smaller curved 
tweezers 
Stainless steel tray  
Absorbent pads (2)  




Calling slaughterhouses and schedules 
MSML works with two slaughterhouses. As of November 2018, the following is the contact 
information and schedules for them: 
 Cockrum’s Meat Processing (Rudy, AR) 
o Phone number: (479) 474-3012 
o Receive pigs on Sundays and Thursdays. Slaughter on Mondays and Fridays. 
o Open Mon-Fri 8am-5pm; Saturday 8am-noon; Sunday 2pm-5pm 
o Call two days before as sometimes they slaughter a day early if they have to many 
 Braunschweig Processing (Neosho, MO) 
o Phone number: (417) 451-3150 
o Receive pigs on Sundays, Tuesdays, and Wednesdays. Slaughter on Mondays, 
Wednesdays, and Thursdays. 
o Open Mon-Fri 8am-5pm; Saturday 9am-12pm 
 
Always call day before close to closing time to see how many pigs they will have. Call the 
morning of to remind them to save the hearts and make sure what time the hearts will be ready. 







Preparing diluted pen/strep (can be days before dissecting)  
1. Thaw pen/strep in water bath 
2. In hood, mix 1 mL pen-strep with 40 mL ddH2O 
3. Sterilize with 30 mL syringe and filter 
4. Aliquot in ~12 mL of reagent into three 15 mL conicals 
5. Place in -20°C freezer 
 
Preparing PBS (day before dissecting) 
1. Prepare required amount of 1x PBS from 10x PBS stock. (Call slaughterhouse day before to 
know how many hearts will be available) 
a. 300 ml 10x PBS + 2700 ml ddH2O if picking up less than 3 hearts 
b. 200 ml 10x PBS + 1800 ml ddH2O if picking up more than 4 hearts. Max that can fill 
is 8 
2. Fill appropriate sized polycarbonate containers with 1x PBS.  
3. Cover top of container with aluminum foil. 
4. Autoclave in liquid setting. Do not remove foil at any point when container is outside 
5. Return autoclaved containers to biosafety hood in lab using sterile technique.  
a. Container is very hot after autoclaving. Either wait for it to cool down or use gloves 
to carry. 
b. Sterile technique: spray container with 70% alcohol before placing in hood 
6. Remove foil, switch on UV light and expose overnight. 
 
Preparing tools (day before dissecting) 
1. Autoclave the following surgical tools in wrapped setting 
a. Small pack: Large scissors, small scissors, scalpel handle, larger straight and smaller curved 
tweezers 
b. Large pack: Stainless steel tray and absorbent pads (2 sheets) 
c. 250 ml beaker with top covered in aluminum foil 





Biaxial stretching of soft tissues 
 
Important things to remember: 
 
 If using tissue samples, make sure it doesn’t dry out by constantly adding a few drops of 
deionized water. 
 When you turn on the actuators sometimes one of the axis might make a noise trying to pull 
itself inside. Make sure to switch off the controller on the software and follow these steps for 
trouble shooting; 
o In the cycle menu, change the settings to regular mode. 
o Check all the actuators are being operated in position mode and not in load mode. 





















Reagents and Materials: 
 
Reagents Notes 
0.9% Saline Dissolve 54 grams of NaCl in 6 L of DI water 
PDMS  For mold to fix sample 
 
Materials Notes 
Water Sprayer Keep sample moist at all times 
Small and large petri dish For PDMS mold and to cut samples 
1cm x 1cm metal stamp Used as stencil to cut sample 
Cardboard frame Sample is fixed to cardboard frame and is 
gripped onto grips 
Staples To fix sample to cardboard frame 
Super glue To administer tracking nodes 
Black beads To administer tracking nodes 
Scissors To cut cardboard frame 
Razor blade and forceps To excise sample and mount on frame 




Preparing material prior to day of testing 
 
Prior to testing on day of 
1. Place 6L of saline solution into water bath and turn on heating unit. Wait for at least 1 
hour for solution to reach 37ºC. 
 
Setting up system 
1. Turn on all the actuators using the power knob under the desk. 
2. Start the application named “MTL32” and once it loads, open “Testbuilder.” 
3. In Testbuilder application, click on Proceed. 
4. On the tab choose Test > Function generator. 
5. On the right screen, open the tracking software named “Video Gauge.” 
6. Transfer the 6 L of prepared saline into the bath and turn on the heater  
7. Start the application Pylon Viewer 
8. On the tab choose View>Devices and choose the Basler camera 
9. On the tab choose View>Features and enable the acquisition frame rate and type 100 Hz 
for the frame rate 
10. Mount the sample onto the cardboard frame and clamp them using grips. 
11. Mark four points forming a square on the tissue sample using India ink and let it dry for a 
couple of minutes. (Will use 16 or 32 points later) 





13. Now move the actuators one by one using the Jog function on the testbuilder screen and 
mount the other sides of the cardboard frame to the other actuators.  




15. Use the DAQ settings to create a new file for each test and set the frame rate at 50 Hz. 
16. Using the jog function bring all the actuators closer so that the sample is not expressing 
any load from any side. 
17. Offset all the loads of the actuators. Setup > Offset readout. 
18. Move each of the actuators until they all reach a tear load of 0.05N. 
19. Offset all the positions of the actuators. Setup > Offset readout 
20. Choose the Cycle function and choose General > Biaxial > input the dimensions of the 
samples. The Biaxial tab is where you can control if you want your actuators to work 




21. Set waveform to “Ramp” with a mean strain of 0.75 and amp of 0.75. Ensure you select 
the “start point min” option to ensure the test begins at the relaxed state and proceeds to 




22. Run 20 cycles of preconditioning. Wait for 5 minutes. 
23. Click Start on Pylon Viewer. Run and record three cycles of stretch. Click Stop on Pylon 
Viewer when cycles have been completed 
24. Once the test is done, click on “Report” and in the following screen choose single and 
click on “Single File”. This brings up another dialog box where you choose the file name 





25. In the following screen, choose the file type as “CSV”; select all the loads for each 
actuator and export it. Save this CSV file to your desired location. 
 
26. The saved file is ready to be analyzed using MATLAB. 
27. Optional: For a quick view at the results, in the above shown screen you can choose 







Reagents and Materials: 
 
Reagent Note 
1x PBS 100 ml 10x PBS 
900 ml ddH2O 
Acetone  
Goat serum -20ºC freezer 
Primary antibodies Look at primary antibody table 
Secondary antibody GAM 488 (green) (4 ºC fridge) 
GAR 594 (red) (4 ºC fridge) 
DAPI (blue) (-20ºC freezer) 




Plastic slide jar and carrier  
Water/Alcohol proof marker  
Humid chamber  
Coverslip  
Slide box  




Preparing serum and antibodies 
For each section, make 200µL i.e. multiply number of sections by 200 and do calculations 
Note: Following are with blocking serum as goat serum. Donkey serum can also be used, just 
replace goat serum with donkey serum and secondary as DAM 488 and DAR 594. 
 
Example of calculations for 1 section: 
1. 20% blocking serum 
a. 4 µL goat serum (20%) 
b. 196 µL PBS 
2. Primary 
a. See table 
3. Secondary  
Note: Keep in dark because it is fluorescent. 
a. 1 µL GAM 488 (green) (1/200) 
b. 1 µL GAR 594 (red) (1/200) 
c. 2 µL DAPI (blue) (1/100) 






1. Remove slides and allow to reach room temperature 
2. Soak for 5 minutes in ice-cold acetone 
3. Leave out for 5-10 mins till acetone evaporates 
4. Put square sharpie mark around each section & wait 5-10 mins to dry 
5. Put in a slide jar filled with 1x PBS to rehydrate section for 5 mins or more  
a. DO NOT TAKE OUT until ready to start block 
 
Block 
6. Place slides in humid chamber 
a. Place 1 slide at a time. Put blocking serum immediately as to not dry out the sample 
7. Place 195 µl of 20% goat serum on each section 
8. Incubate at 37ºC for 30-60 mins 
 
Primary Stain 
9. Remove the slide from the blocker solution.  
a. DO NOT WASH! 
10. Blot the slide. This is done by carefully holding the coverslip perpendicular to the lab bench. 
Once a bead of liquid builds up at the bottom of the coverslip, press the edge of the coverslip 
again a Kim Wipe to wick away the excess moisture 
a. Goal is NOT to completely dry the slide-simply remove excess PBS from glass 
surface. 
11. For each section, place 195 µl of the primary.  
12. Cover and incubate at room temperature for 1-2 hours in humid chamber 
 
Wash 2 
13. In plastic slide container, dip 3 x in 1x PBS and then let sit for 5 min 
14. Repeat step 1 3x in new solution of PBS 
 
Secondary 
15. With a pipette place 195 µl of secondary antibody solution on each sections 
16. Incubate for 1-2 hours in room temperature 
 
Wash 3 
17. Repeat wash 2 in dark area 
 
Mount (in dark) 
18. Place drop of Pro-long Gold ant fade reagent (brown bottle) 
19. Cover slip and wait 12-24 hours 
20. Then thin layer of nail polish around the cover slip 
21. Let set for 2 hours 
22. Once dry, they are ready for microscopy. When not imaging them, store in a slide box or a 




Primary & Secondary Antibodies 
 
Primary  Species Block Concen. Primary for 1 slide Secondary 
TGF-β1 
(-20 freezer) 
Rb Goat 1/25 8 µl TGF-β1 
4 µl (2%) Goat 






Ms Goat 1/50 4 µl RUNX2 
4 µl (2%) Goat 






Rb Goat 1/250 0.8 µl TGF-β1 
4 µl (2%) Goat 






Ms Goat 1/300 0.67 µl vimentin 
4 µl (2%) Goat 






Rb Goat 1/100 2 µl AT-1 
4 µl (2%) Goat 






Ms Goat 1/200 1 µl α-SMA 
4 µl (2%) Goat 






Rb Goat 1/100 2 µl Calponin 
4 µl (2%) Goat 




Secondary Antibodies that we have 
GAR 594 (red)  
(Goat-anti rabbit)  
GAM 488 (green) 










Phosphomolybdic Acid 0.2% Aqueous  
Sirius Red, 0.1% in Sat/d Picric Acid  
0.01 N Hydrochloric Acid  
70% Alcohol  
Xylene  
95% Ethanol, 100% Ethanol  
Ultrapure water (ddH2O)  
Cytoseal mounting medium Electron Microscopy Sciences #18006 




1. Let slides come close to room temperature 
2. Fix in cold acetone for 5 min. 
3. Wash in running tap water, 10 minutes. 
4. Rinse in distilled water. 
5. Treat in Phosphomolybdic Acid 0.2% Aqueous (1-5 minutes). Place the slides on a paper 
towel and put a few drops of the acid on each tissue section. 
6. Stain in Sirius Red, 0.1% in Sat'd Picric Acid , for 90 minutes. Note: You can filter and re-
use sirius red stain. 
7. Wash for 2 minutes in 0.01 N Hydrochloric Acid . 
8. Rinse in 70% Alcohol for 45 seconds. 
9. Dehydrate: 
a. EtOH 95% (3 min, 2x) 
b. EtOH 100% (3 min, 2x) 
10. Clear in xylene (5 min, 2x). 
11. Mount with cytoseal in fume hood and coverslip. 




Order of colors from least mature to most mature (thinnest fibers to thickest fibers):  






Reagents and Materials: 
 
Reagent/Material Notes 
RIPA Lysis Buffer System Santa Cruz # sc-24948 
1x lysis buffer (pH 7.4) 
PMSF in DMSO (200mM) 
Protease inhibitor cocktail (PIC) in DMSO 
Sodium orthovanadate (NaVO) in water (100mM) 
1xPBS  




1. Culture cells or tissues under the appropriate conditions (if relevant). Proteins are 
typically extracted using lysis buffers. We use a strongly denaturing urea lysis buffer as 
outlined below. You may wish to use other lysis buffer formulations if you don’t want the 
protein to be as denatured or if you are running the gel in native conditions. 
2. For every 1mL of lysis buffer, add 10μL of PMSF, PIC, and NaVO. 
3. For cells:  
a. Wash cells 3x with sterile dPBS.  
b. Aspirate all PBS 
c. Add ~ 30-60μL of cold lysis buffer per coverslip and scrape using cell scraper.  
d. Using a 100μL pipet, suction up and down until the solution becomes less viscous 
(~10 times).  
e. Transfer to a clean 0.5mL microcentrifuge tube. 
4. For tissues:  
a. Wash tissue 3x with sterile dPBS. 
b. Pulverize tissue in a mortar and pestle under liquid nitrogen.  
c. Transfer pulverized tissue to a clean microcentrifuge tube. 
d. Add cold lysis buffer. In general, we use 3mL of lysis buffer per gram of tissue. 
(I.e. for a 5x5 mm valve leaflet sample, we would use 200μL lysis buffer). 
5. Centrifuge at max speed, 4°C, for 5 mins to pellet cell/tissue debris. 0.5mL tubes too 
small for the centrifuge so put inside capless, empty 1.5 mL tube or tube will break. 
6. Carefully withdraw supernatant into a separate clean 1.5 mL microcentrifuge tube labeled 
with sample information. 





BCA Protein Assay 
Reagents and Materials: 
 
Reagent Notes 
RIPA Lysis Buffer System Santa Cruz # sc-24948 
1x lysis buffer (pH 7.4) 
PMSF in DMSO (200mM) 
Protease inhibitor cocktail (PIC) in DMSO 
Sodium orthovanadate (NaVO) in water 
(100mM) 
Micro BCA Protein Assay Kit ThermoFisher # 23235 
Micro BCA Reagent A, B, & C 






1. Label microcentrifuge tubes with BCA, lysis, and the names of each of your samples.  
You need one tube per sample. 
2. Add the appropriate amount of ddH2O water to each microcentrifuge tube, depending on 
what dilution you want to use: 
a. For 1:100:  Add 45 L of ddH2O 
b. For 1:200:  Add 47.5 L of ddH2O 
3. Add 5 L (for 1:100) or 2.5 L (for 1:200) of each sample to appropriate microcentrifuge 
tube.  Mix by vortexing. 
4. Make up the dilute BSA solution ( final -  0.4mg/ml) 
a. 320 L ddH2O 
b. 80  L 2 mg/mL BSA (vial in the kit) 
5. Make up the dilute lysis buffer solution (or whatever solvent your proteins are in): 
a. Stock: For every 1mL of lysis buffer, add 10μL of PMSF, PIC, and NaVO. 















Adding in 96 well plate 
 1 2 3 4 5 6 7 8 9 10 11 12 
A C0 C0 S1 S1         
B C4 C4 S2 S2         
C C8 C8 S3 S3         
D C16 C16 S4 S4         
E C24 C24 etc. etc.         
F C32 C32           
G C40 C40           
H             
Do duplicates for each control and sample well 
6. For each control well,  add the following amount of ddH2O: 
a. C0  90 L 
b. C4   89 µL 
c. C8  88L 
d. C16 86L 
e. C24  84 L 
f. C32  82 L 
g. C40  80 L 
7. Add 90 L of MilliQ water to each Sample well.   
8. Add 10 µL of the dilute lysis buffer to each control well. 
9. Add the following dilute BSA to each control well: 
a. C0  0 L 
b. C4  1 µL 
c. C8  2 µL 
d. C16 4 µL 
e. C24  6 L 
f. C32  8 L 
g. C40  10 L 
10. Add 10 L the dilute sample to the appropriate well in the 96-well plate. 
11. Calculate the amount of BCA reagent that you need:  100 L / well   
12. Make up the BCA Assay reagent (Pierce kit) 
a. Add 50% Solution A 
b. Add 48% Solution B 
c. Add 2% Solution C 
d. Mix 
13. Add 100 L of the reagent to each well 
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14. Incubate at 37°C for 30-60 min (you need to optimize this) 
15. Read the absorbance at 562 nm on the plate reader. 
 
Calculating protein concentration 
16. Average the absorbance reading for the duplicates 
17. Subtract the absorbance of CO from the absorbance of all samples to normalize 
18. Graph the normalized absorbance of the control wells vs known concentration of control 
wells and calculate the equation of the best fit line 
a. y=absorbance and x=known concentration (0,4,16, etc.) 
19. Using the equation, calculate the concentrations of sample with their absorbance 
20. Samples were diluted by 100 so multiply the calculated concentration with 100 to 






Sample Preparation  
 
To get a good signal in the gel scanner, approximately 5-20μg of protein is recommended per 
well of an electrophoresis gel. Prepare your gel samples in a 0.5 mL microcentrifuge. Sample for 
SDS-Page consists of the protein sample + 4x sample buffer + reducing agent (β MeEth) + 
ddH2O. Amount of total sample depends on gel and the volume each well can take.  
 
1. Divide amount of protein (i.e. 10 μg) by the concentration of the specimen sample and 
multiply by 1000 to calculate the amount of sample volume (μL) needed. 
2. ¼ of volume is the sample buffer with or without the reducing agent.  
a. Sample buffer with reducing reagent is 90% 4x sample buffer and 10% β MeEth. 
b. Sample without reducing reagent is used only for the standard. 
3. Add the volume of the protein sample, 2x sample buffer, and reducing agent and subtract 
by the total volume needed to calculate the volume of ddH2O. 
4. Mix sample 
a. Tip: It’s easiest to put the water first into the 0.5 mL microcentrifuge tube, then 
the reducing agent, and last the specimen volume. Can label the 0.5 mL 
microcentrifuge tube as well as pipetting in the amount of water days before 
running the gel. For best results, wait till the morning to pipette in the reducing 
agent and specimen sample.   
5. Boil sample at 95°C for 5 min using heating block. This ensures complete denaturation 
and breakage of any disulfide links in the protein. 
6. Condensation will happen so spin the samples down and the water will go back to the 




The standard is what shows the molecular weight bands on the membrane. You can have more 
than 1 lane of standard depending on how many samples you have as long as there is at least one 
lane in front of your set of samples. i.e. if you have 16 samples and an 18 well gel, you can put 
one in the 1st and 18th well, if you have 14 samples, you can put one in the 2nd and 17th well, or if 
you have 17 samples, you can only put in the 1st well. Standard consists of the protein standard + 
4x sample buffer + ddH2O. 
 
1. Multiply the number of lanes by the volume per well to get total volume. 
2. Multiply 5 by the number of lanes for amount of protein standard. 
3. Divide total volume by 4 for amount of 4x sample buffer. 
4. Subtract amount of protein standard and 4x sample buffer from the total volume for 
amount of ddH2O. 
5. Mix sample. DO NOT BOIL! 
a. Tip: It’s easiest to put the water first into the 0.5 mL microcentrifuge tube, then 




Running the Gel Electrophoresis 
 
1. Prepare the appropriate amount of buffer for the electrophoresis depending on the type of 
gel you are running: 
a. Tris-HCl/TGX gel:  Tris/glycine/SDS running buffer 
i. 100 ml buffer + 900 ml ddH2O  
b. Tris-acetate gel:  Tricine buffer 
c. Bis-tris gel:   MES or MOPS buffer 
2. Each precast gel is packaged individually in a plastic storage tray, which can also be used 
as its own staining dish. 
3. Remove tape from bottom of the cassette. 
4. Insert precast gels in electrophoresis tank making sure that the integral buffer chamber 
faces the center of the tank. 
5. Fill the integrated upper buffer chamber with running buffer (~60mL). 
6. Carefully remove the comb and top up any spilt running buffer. DO NOT THROW THE 
COMB AWAY AT THIS POINT! 
7. Fill each half of the lower buffer tank with ~400mL running buffer to the marked fill line. 
8. Load samples using a pipet with gel loading tips. Using the sample loading guide will 
ensure that there are no “parallax” errors. 
9. Load protein standard to appropriate lane (s).  
10. Place lid on the tank, aligning the color coded banana plugs with the corresponding jacks 
on the lid. Run gels as follows. Run time is approximately 45 – 65 min. 
a. Tris-HCl: 200V constant 
b. TGX:  200V constant 
c. Tris-acetate: 150V constant 
d. Bis-tris: 200V constant 
11. After electrophoresis is complete, turn off power supply and disconnect the electrical 
leads. 
12. Remove the lid from tank and remove gel and discard running buffer. 
13. Insert comb into the slits on either side of the cassette and gently crack open the cassette. 
14. Pull the two halves of the cassette apart to completely expose the gel. BE CAREFUL! 
THE GEL IS EXTREMELY FRAGILE! 
15. If you are going to do a western blot, proceed to that protocol. For staining the gel go to 









 Make sure you know what antibodies you will be doing as the molecular weight of the 
primaries dictates where the membranes will be cut. Can do 2 antibodies on the same 
membrane with similar MW if different species (rabbit and mouse). Otherwise, cut the 
membrane so as to have thinner strips. 
 Have at least 1.5L cold transfer buffer already made. 
 
Preparation for Transfer/Western blot 
 
1. When the electrophoresis is halfway done, cut a section of PVDF membrane of 
approximately the same size as the gel. DO NOT TOUCH THE MEMBRANE EVEN 
WITH GLOVED HANDS AS THAT WILL CAUSE TRANSFER OF “SELF” 
PROTEINS WHICH WILL CONFOUND YOUR RESULTS! 
2. The PVDF membrane is extremely hydrophobic so we need to “prewet” it. Dip it in 
methanol, and then soak it in cold Transfer buffer on the belly button shaker in the 4°C 
fridge for the remainder of the duration of the electrophoresis. You can use the tray that 
came with the gel for this purpose. 
3. Recipe for 10L 1x transfer buffer is (scale for your needs accordingly) as follows. Store 
buffer in the 4°C fridge. 
i. 2L methanol 
ii. 1L 10x TG buffer 
iii. 7L ddH2O 
4. Prepare sponges by adding transfer buffer on the plate and soak them. Roll out all 
bubbles. Leave in transfer buffer and re-roll right before assembly incase bubbles were 
formed. 
5. After electrophoresis is complete, turn off power supply and disconnect the electrical 
leads. 
6. Remove the lid from tank and remove gel  
a. Save the running buffer as it can be reused at most 3 times. 
7. Insert comb into the slits on either side of the cassette and gently crack open the cassette. 
8. Pull the two halves of the cassette apart to completely expose the gel. BE CAREFUL! 




1. In the provided plastic tray, assemble the Bio-rad transfer cassette as follows, starting 
from black side (negative) to red (positive): 
a. Sponge 
b. Filter paper 
c. Gel 
d. PVDF membrane 




2. When assembling the above, make sure you don’t rub or smudge the gel with the PVDF 
membrane. The PVDF membrane is extremely protein-philic, so any smudge of the gel 
(which is full of your protein samples) will appear when you are scanning the membrane. 
3. It is absolutely crucial that the PVDF membrane is on the red (positive) terminal. If you 
reverse the gel and PVDF membrane, the proteins will travel the opposite way and will 
go out of the cassette into solution. That is, you have lost everything! 
4. Once the assembly has been made, use the roller to roll out any air bubbles as presence of 
bubbles will appear as empty circles on your PVDF membrane scan. 
5. Close and lock cassette and assemble in Bio-Rad transfer tank. Don’t forget to insert 
cooling block as tank gets very hot when running. 
6. Run western/transfer blots in the 4°C fridge under the following conditions: 
a. Standard (1 hour): 100V constant voltage  
b. Overnight (16 hours): 10V constant voltage 
7. At the end of the transfer step, disassemble cassette and place PVDF membrane protein 
side up on gel cassette and using the molecular weight markers as a guide, cut PVDF 
membrane horizontally into regions of interest. Can use the comb as a guide but make 
sure to clean it first with distilled water. YOU MUST USE A CLEAN RAZOR BLADE 
AND COMB! 
8. Immediately place membrane strips in full strength Li-cor blocking buffer. Use the black 




This procedure is similar to immunostaining, in the sense that it involves blocking, primary and 
secondary antibody incubations. 
 
Blocking 
1. Blocking is done in full strength Li-cor blocking buffer for 1.5 hours at room temperature 
on belly dancer (speed 0.5).  
a. 10 ml for long membrane and 5 ml for small membrane (can vary as long as 
covered) 
2. When done, store blocking buffer in a 100-250ml container and store in 4°C. Can be 
reused at most 3 times.  
Primary antibody incubation 
3. Prepare appropriate dilution of primary antibody in full strength Li-cor buffer. 
4. Place a 300-500μL drop of antibody on petri dish (can have multiple membranes but have 
to be same primaries) and invert membrane onto the drop. Amount depends on length of 
membrane. This is similar in technique to immunostaining of coverslips. 
5. Incubate the membranes in primary antibody for 16 hours (overnight) at 4°C. 
Washing 
6. Make washing buffer. One quarter strength Li-cor blocking buffer diluted in PBS (1:3). 
7. Return the membranes face up, and wash in washing buffer 3 times, 5 min each on the 
belly dancer (speed 4). 
8. During this time, pipette the primary from the petri dish into a 1.5ml Eppendorf and store 
in -20°C. Can be reused at most 3 times.  
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Secondary antibody incubation (LIGHT-SENSITIVE) 
9. Prepare appropriate dilution of secondary antibody during washing (cover conicals with 
aluminum). 
a. 1/15,000 DAM 700 or DAR 800  
b. 1:1 dilution of Licor buffer in PBS 
c. 15 ml for long membranes and 10 ml for small membranes. Can vary as long a 
covered but more than washing as it is highly important that it is completely 
immersed since speed is slower on belly dancer and incubation is longer.  
10. Incubate membranes in secondary antibody for 1 hours at room temperature on belly 
dancer (speed 1). 
a. If done in black Licor box, it can just be placed on belly dancer, but if done in a 
box that allows light to go through, cover them with a cardboard box that won’t 
allow light in (i.e. careful with holes on box).  
Washing  
11. Discard the secondary and wash the membranes in washing buffer 3 times, 5 min each on 
the belly dancer. 




1. Clean odyssey scanner using ddH2O and Kim wipes only. 
2. Place membranes face down on the glass and orient them appropriately. 
3. Cover the membranes with the thick rubber mat and use the roller to roll out air bubbles. 
This roller is larger and different from the one you used for the western/transfer blot step. 
4. Close the odyssey scanner lid. 
5. Open the Odyssey program and do: File  New 
6. Select your folder and click open. 
a. Password: Admin 
7. On toolbar click blue icon with blue arrow 
8. Another window will open.  With mouse double click on grid that is shown, and drag the 
box to match where your membranes were. Click flip image 
a. The greater the area, the longer the scan  
b. The greater the resolution, the slower the scan  
9. Select the channel in which you want to scan your membrane. For antibodies labeled with 
IR680, select channel 700. For antibodies labeled with IR800, select channel 800. Both 
channels can be selected at once, but the scan will be slower. 
10. Select intensity. The starting point is usually “5”. 
11. Select appropriate resolution, and thickness setting. 
12. Click scan. Once scan runs, you can save your image and use the Odyssey software to 
analyze your bands. 
 
Tips: 
If you want stronger signal, you can place the membranes on the scanner, and let them 




 APPENDIX B MATLAB CODE 
MATLAB codes listed here are to analyze methods mentioned in methods sections of each 




Biaxial Testing MATLAB Instructions 
Use: 
Manual to analyze data acquired from biaxial mechanical testing.  
 
Images: 
Collected during biaxial testing from Basler AC640 camera. 100 images of desired stretch. 
 
Tension: 
Collected during biaxial testing from biaxial mechanical tester (Test resources) and software 
provided by test resources. 
 
Measurements: 
Thickness of sample measured by placing sample in OCT compound after biaxial testing, 
sectioning the samples with the cryotome, imaging with darkfield microscope, and measuring 










In earlier testing, tensions were being read accurately in all directions. However at a later time 
point, x1 is not able to read the tension being applied in the x1 direction properly. The code must 
be changed accordingly to average or not average the tensions in the x direction. There may be 
times where there can also be an issue in the y direction. Check and change the following lines in 




For average x, x_tension(j)=(x1x2(row(j)))-(x1x2(row(j)-49)); 
For only x1, x_tension(j)=(x1(row(j)))-(x1(row(j)-49)); 
For only x2, x_tension(j)=(x2(row(j)))-(x2(row(j)-49)); 
 
Line 103: 
For average y, y_tension(j)=(y1y2(row(j)))-(y1y2(row(j)-49)); 
For only y1, tension(j)=(y1(row(j)))-(y1(row(j)-49)); 










For average x, plot ([1:50],x1x2s); 
For only x1, plot ([1:50],x1s); 
For only x2, plot ([1:50],x2s); 
 
Line 119: 
For average y, plot ([1:50],y1y2s); 
For only y1, plot ([1:50],y1s); 




For average x, x_ten=data([1:50],5); 
For only x1, x_ten=data([1:50],1); 
For only x2, x_ten=data([1:50],2); 
 
Line 30: 
For average y, y_ten=data([1:50],6); 
For only y1, y_ten=data([1:50],3): 








This code creates a matrix containing the max x and y tension to allow the user to choose the 
stretch that was stretched to the most accurate tension. This is due to the fact that our biaxial 
machine is not load bearing but by displacement so the tension can vary through test. In addition, 
our biaxial machine does not detect low tensions well so even though it may look like the tension 
reached the desired tension, once substracted by the starting tension, it may be different. When 
testing user does choose a stretch that looks good, but this code allows the user to make sure that 
it is the best. 
  
Input: 
Biaxial Machine csv file: x1,x2,y1,y2 
  
Output:     
Matrix: x_tension and y_tension on command window (in order of stretches) 
  
Instructions on how to use this in following biaxial codes: 
 
This code will allow the user to determine which stretch has most appropriate tension. Make sure 
to write down the stretch for further use. User analyzes the deformation of that stretch in 
biaxial_2.m and calculates the needed tensions in biaxial_3.m. 
 
Notes: 
File must be .csv, have no text, and at least the following columns: 
Column B (2nd) is Rel. LOAD - X1 (N) 
Column C (3rd) is Rel. LOAD - Y1 (N) 
Column D (4th) is Rel. LOAD - X2 (N) 




1. Delete all words in .csv file.  
2. Drag file to MATLAB folder 
3. Run code 
4. Input how many stretches were done 
5. Choose stretch that best fits ratio 
6. In excel sheet, put how many stretches were done, what stretch will be analyzed, and 









This code is used to analyze the deformation the sample undergoes during testing. Samples must 
have 4 marks on the surface (2x2 square array) to trace and must be consecutive. Code will trace 
the movement of the markers during testing from the 100 images provided.  
 
Input: 
 Images collected from Basler AC640 camera 
 MATLAB functions: automarkertrack.m and leastsq.m 
 
Output: 
 Two figures will pop up: figure (1) plot of Exx and (2) plot of Eyy. This is to insure that 
the code tracked the points correctly and did not scew. If they are not a peak, repeat 




 Excel file: deformresults.xlsx.  
o File contains Exx, Eyy, Exy, Ezz, E1, E2, dir1, dir1, dir2, and dir2. This file will 
be used in Biaxial_3.m. 
o Will be saved in output folder 
 Two MATLAB data files: defg.mat and lamz.mat.  
o These will be used in Biaxial_4.mat.  
o Will be saved in output folder 
Note: 
 The function leastsq.m is used in the function automarkertrack.m. 
 If there is noise when tracking the dots, change the pixel and num in the function 
automarkertrack.m 
o Make sure to write down the ideal pixel and num on excel sheet for future use. 
 
Instructions: 
1. Change path to folder containing the images. (Will always change ) 
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a. Click the drop down menu and copy and paste the path name that appears onto 
line 27 of the code (path1= “pathname”).  
                              Ex. path1='J:\Biaxial\20171230\ AngII \test 
18_1_0.5\stretch 2+'; 
2. Change file name to retrieve images (Will always change ) 
a. Click on first image of the set of images you will be analyzing and copy and paste 
name onto line 28 of code (name1= “filename” ). 
b. Erase the last three numbers of file name 
                               Ex. File name: “Basler acA640-750um 
(21856823)_20171230_185607817_0389” to   
                         “Basler acA640-750um (21856823)_20171230_185607817_0” 
                                       name1='Basler acA640-750um 
(21856823)_20171230_185607817_0'; 
 
3. Change output file path (Will be same as long as in same computer path) 
a. Click the drop down menu and copy and paste the path name that appears onto 
line 29 of the code (path1= “outputpathname”).  
b. Make sure to add \point at the end 
    Ex. out1='C:\Users\jxp040\Desktop\test\point'; 
  Note: Make output folder same folder that contains the MATLAB codes 
 
4. Run program 
5. User will be asked to input the number of the first image on command window 
Ex. 389 
6. Click on 4 points to track in the following order: 
     3---------4 
    /         / 
   /         / 
  2---------1 










This code creates an excel sheet containing x1,x2,y1,y2 and average of x1&x2 and y1&y2 from 
the csv file provided by the biaxial machine containing the forces from different axis for the first 
50 points as well as the Exx and Eyy for the first 50 points. 
 
Input: 
Excel file: deformresults.xlsx 
 
Output: 





 Excel file will be saved in output folder: rawdata.xlsx. File contains x1, x2, y1, y2, x1x2, 
y1y2, Exx, and Eyy. These will be used in Biaxial_3.mat. 
 
Instructions: 
1. Run program 
2. Choose csv file provided by the biaxial testing machine  
a. Words should have been deleted prior to running biaxial_1.m and placed in folder 
b. The columns must contain the following information: 
  A: Time 
  B: Rel. LOAD - X1 N 
  C: Rel. LOAD - Y1 N 
  D: Rel. LOAD – X2 N 
  E: Rel. LOAD – Y2 N 
3. Input how many stretches were done 






This code creates an excel sheet E11, E22, S11, S22, P11, and P22 by using the excel sheet 
rawdata.xlsx from biaxial_3.m and mat files defg and lamz from biaxial_2.m. The excel file 
plotdata.xlsx can then be used to graph stress and strain data on sigma plot. 
 
Input:  
 Excel file: rawdata.xlsx  
o x1,x2,y1,y2,x1x2, y1y2, Exx, and Eyy 
 Mat files: defg.mat and lamz.mat 
o defg.mat: deformation gradient 
o lamz.mat: lambda 
 Measurement: sample thickness 
 
Output: 
 Excel file: plotdata.xlsx.  
o Will be saved in output folder. 
o File contains E11, E22, S11, S22, P11, and P22.  
o These will be used in sigma plot to create graphs and MATLAB to make 
constitutive models.  
 
Instructions: 
1. Run program 
2. Input the thickness of the samples in mm 








Cut and paste all output files into sample folder. 
 Csv file from biaxial machine 
 Excel files: deformresults.xlxs, rawdata.xlsx, and plotdata.xlsx 
 MATLAB files: defg.m and lamz.m 
 Txt files: point1.txt, point2.txt, point3.txt, and point4.txt 
 
Graphing and statistical analysis 
 Use the information on plotdata.xlsx  





Biaxial Testing MATLAB Codes 
To calculate the stress and strain for each tested sample, four MATLAB codes and two 
MATLAB functions were used. Biaxial_1 allows the user to choose which stretch had the most 
adequate force applied as our biaxial machine is displacement based. Biaxial_2 tracks the four-
dot array to calculate the deformation gradient and strain. Biaxial_3 extracts the force and 
displacement data for the chosen stretch (50 data points as it was at 100 Hz). Biaxial_4 calculates 
the stress and output the stress and strain. The automarkertrack function automatically tracks the 
4-dot array and the pixel size can be altered depending on the size of the dot being tracked. If the 
camera was move to where the x axis was in the y axis, the images need to be rotated and 




Biaxial_1.m MATLAB Code 






%Written by Jessica Perez 
%Version June 2018 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%This code creates a matrix containing the max x and y tension to allow the 
%user to choose the stretch that was stretched to the most accurate 
%tension. This is due to the fact that our biaxial machine is not load 
%bearing but by displacement so the tension can vary through test. In 
%addition, our biaxial machine does not detect low tensions well so even 
%though it may look like the tension reached the desired tension, once 
%substracted by the starting tension, it may be different. When testing 
%user does choose a stretch that looks good, but this code allows the user 
%to make sure that it is the best. 
  
%Input: 
% Csv file: x1,x2,y1,y2 
  
%Output:     
% Matrix: x_tension and y_tension on command window (in order of stretches) 
  
%Instructions on how to use this in following biaxial codes: 
% See which stretch has most appropriate load and use images of that  
% stretch in biaxial part 2 and input the stretch number in biaxial part 3. 
  
%Notes: 
% File must be .csv, have no text, and at least the following columns: 
% Column B (2nd) is Rel. LOAD - X1 (N) 
% Column C (3rd) is Rel. LOAD - Y1 (N) 
% Column D (4th) is Rel. LOAD - X2 (N) 
% Column E (5th) is Rel. LOAD - Y2 (N) 
  
%choosing file 




%Note:currently x1 doesn't read properly so we only look at x2. See 
%instructions on what lines to change if all tensions are reading properly. 
  











%plot tension. This allows user to see how many stretches were done and 
%what tensions may not be reading properly 
figure(1) 
subplot(2,3,1); 
plot ([1:index],x1 ); 
title ('x1 load'); 
subplot(2,3,2); 
plot ([1:index],x2 ); 
title ('x2 load'); 
subplot(2,3,3); 
plot ([1:index],x1x2 ); 
title ('x1x2 load'); 
subplot(2,3,4); 
plot ([1:index],y1 ); 
title ('y1 load'); 
subplot(2,3,5); 
plot ([1:index],y2 ); 
title ('y2 load'); 
subplot(2,3,6); 
plot ([1:index],y1y2 ); 
title ('y1y2 load'); 
  
%prompt user to how many stretches there were. 
prompt='How many stretches were done? '; 
st=input(prompt); 
  
%Each stretch has a peak when graphed. This find the peaks that correspond 
%to each stretch 
pks = findpeaks(x2); 
max = sort( pks, 'descend' ); 
n = max(1:st); 
  
%index the row for the max of each stretch 
for j=1:st; 
    q=n(j); 
    r(j)=find(x2==q); 
end 
  
%row where max is for desired stretch 
row=(sort(r, 'ascend')); 
  
%difference between forces of peaks at DAQ of 100 Hz and frequency of 1 Hz. 
%i.e 100 data points, peak at 50 data points, subtract 49 to zero out 
for j=1:st; 
x_load(j)=(x2(row(j)))-(x2(row(j)-49)); %only use x2 and not x1  







Biaxial_2.m MATLAB Code 




Biaxial_3.m MATLAB Code 






%Written by Jessica Perez 
%Version June 2018 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%This code creates an excel sheet containing x1,x2,y1,y2 and average of 
%x1&x2 and y1&y2 from the csv file provided by the biaxial machine  
%containing the forces from different axis. 
  
%Input: 
% CSV file: Forces from biaxial Machine  
% Excel file: derform deformresults.xlsx 
  
%Output:     
% Excel files: rawdata.xlsx 
% Four plots: x axis load, y axis load, Exx and Eyy.   
  
%Notes: 
% File must be .csv, have no text, and at least the following columns: 
% Column B is Rel. LOAD - X1 (N) 
% Column C is Rel. LOAD - Y1 (N) 
% Column D is Rel. LOAD - X2 (N) 
% Column E is Rel. LOAD - Y2 (N) 
  
%Instructions: 
% 1. Run program 
% 2. Choose csv. file 
% 3. Input how many stretches were done 
% 4. Input what stretch will be analyzed 
  
%choosing file 















%Prompt how many stretches were done 
prompt='How many stretches were done? '; 
st=input(prompt); 
  
%Prompt what stretch will be analyzed 
prompt= 'Which stretch will be analyzed? '; 
sn=input(prompt); 
  
%Each stretch has a peak when graphed. This find the peaks that correspond 
%to each stretch 
pks = findpeaks(x2); 
max = sort( pks, 'descend' ); 
n = max(1:st); 
  
%index the row for the max of each stretch 
for j=1:st; 
    q=n(j); 
    r(j)=find(x2==q); 
end 
  





























%Output figure of first 50 E11, E22, and average x and y load 
figure(1) 
subplot (2,2,1) 





plot ([1:50], E22); 
title ('E22'); 
subplot (2,2,3) 
plot ([1:50],x2s); %x1 load is not reading properly so x value is just x2s 
title ('x load'); 
subplot (2,2,4) 
plot ([1:50],y1y2s); 







Biaxial_4.m MATLAB Code 
 






%Edited by Jessica Perez 
%Version June 2018 
%Written by Prashanth Ravishankar, 2016 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%This code creates an excel sheet E11,E22,S11,S22,P11,and P22 by using 
%the excel sheet rawdata.xlsx from biaxial_3.m and mat files defg and lamz  
%from biaxial_2.m. The excel file plotdata.xlsx can then be used to graph  
%stress and strain data on sigma plot. 
  
%Input: 
% Excel file:rawdata.xlsx 
% mat files: defg.mat and lamz.mat  
  
%Output:     
% Excel file: plotdata.xlsx 
  
data=xlsread('rawdata.xlsx'); 
x=data([1:50],2); %x value is just x2 because x1 load was not reading 




%Assume width is 1cm and thickness 1mm so area equals 10^-5 
prompt= 'What is the thickness of the sample (mm)? '; 
t=input(prompt)*10^-3; %in mm 
w= 1*10^-2; %assumed 1 cm 
A=t*w; 
  
%1st P-K (P) equals tension/area 
P11=x./A./1000; % (Unit kPa) 
P22=y./A./1000; % (Unit kPa) 
  
%2nd P-K (S) equals F^-1 x P 
  
load('defg.mat'); %gives you F [ lam1 0; 0 lam2] 





F11_i=F11.^(-1); %inverse of F 
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F22_i=F22.^(-1); %inverse of F 
  
S11=F11_i.*P11; % (Unit kPa) 
S22=F22_i.*P22; % (Unit kPa) 
  
%Cauchy stress (sigma) equals (1/J)x(F x P) 
  
J=1 % J is the measure of volume change, assume no volume change so J=1 
sigma11=(1./J).*F11.*P11; % (Unit kPa) 
sigma22=(1./J).*F22.*P22; % (Unit kPa) 
  
%Areal strain and anisotropy index 
AS=E11.*E22; %areal strain is Ecirc*Erad 
ASmax=max(AS) 
AI=max(E11)./max(E22) %anisotropy index is Ecirc/Erad 
  
output=[E11, E22, S11, S22, P11, P22,AS]; 









output=[lam1, lam2, lam3, sigma11, sigma22]; 









Automarkertrack.m MATLAB Function Code 
 
%Automarker function used in Biaxial_2.m 
  
%Written by Kartik Balachandran 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%Instructions: 











    p=[distance*cos(angle)+N(1), distance*sin(angle)+N(2)]; 
    p=round(p); 
    [s1 s2]=size(p); 
    int=[]; 
    for i=1:s1 
        int(i)=M(p(i,2),p(i,1)); 
    end 
  
    fitpol=leastsq(distance,int',8); 
    int2=fitpol{1}; 
     
    beta=fitpol{2}; 
    beta=flipud(beta); 
    s1=length(beta); 
    index=[1:s1-1]'; 
    p=beta(1:s1-1).*index; 
    r=roots(p); 
  
%this portion has been changed due to difficulty in tracking 
    a=find(abs(r)==min(abs(r))); 
    if length(a)>1 
        a=a(1); 
    end 
    centroid(count)=real(r(a)); 

















Leastsq.m MATLAB Function Code 
 
%Leastsq function used in function automarkertrack to be used in Biaxial.m 
  
%Written by Kartik Balachandran 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%least square fit to find Gfit. 
%z is unvaried x-axis parameter 
%ord is the order of the polynomial used for the fit 
  
%Basic principles: 
% fitted values {Gfit}=[X]*{beta} 
% {beta} is vector of coefficients 
% For least square, [X]*{beta}-{G} is orthogonal to [X] 








    zz=z.*zz; 


















%Paths and file names 
path1='I:\Biaxial\Biaxials Fresh\analyzed images\Ang-II+Los_FB4b\test 
19_0.5_1\stretch 3';%where orignal images are 
path2='I:\Biaxial\Biaxials Fresh\analyzed images\Ang-II+Los_FB4b_rotate\test 
19_0.5_1\stretch 3'; %where rotated images go 
name1='Basler acA640-750um (21856823)_20180830_191536482_0'; %image name 
without last three numbers 
  
%Frame number 




























Average Model MATLAB Instructions 
Prior to running the MATLAB code for the average model, an excel sheet containing the average 
x and y force provided by the system the E11 and E22 calculated by MATLAB code. The 
information can be found in the rawdata.xls file exported from MATLAB code Biaxial_3. Note: 
the x1 load cell was not functional so the x2 force was used as the average x force.  
For example: If the treatment group is control, all control tests for ratio 1:1 must be in one excel 
sheet. The columns would be as followed. First sample: column A: x average force; column B: y 
average force; column C: E11; column D: E22; column E: empty. Repeat for every sample into 
next column i.e. second sample: column F: x average force; etc.  
In addition, another excel file containing the thickness of each sample in column A must be 
made. For example: If there were 3 samples for the control at 1:1 force, A1 would be the 
thickness of the first sample, A2 the second sample, and A3 the third sample.. The thicknesses 
must correspond to the information on the previous excel sheet. For example: the thickness in A1 
must correspond to the information for that sample in the in columns A-D of the previous excel 
sheet. The thickness in A2 must correspond to the information for that sample in the in columns 
F-I of the previous excel sheet. The thickness in A3 must correspond to the information for that 












%%Written by Jessica Perez 
%Version January 2019 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  









% Excel files: 
%    (1)File containing tension and strain data for n# samples for one  
%       tension ratio (see notes (1) for order of information) 
%    (2)File containing thicknesses (mm) of each sample being averaged in  
%       column A in order  
  
%Output: 
% Command window: 
%   (1) max areal strain and (2) anisotropy index 
% Excel files:  
%   (1) AveragePlotData.xlsx 
%       Contains: Average Green Strain, 2nd P-K stress, 1st P-K stress and 
%       areal strain for circumferential and radial direction 
%   (2) AverageEandTandStandardError.xlsx 
%       Contains: Average Green strain and tension in circumferential and 
%       radial direction and the standard error 
% Graphs that need to be saved as jpeg or other filetype: 
%   (1) Average 2nd P-K stress vs average Green strain of circumferential 
%       and radial direction with error bars 
%   (2) Average 2nd P-K stress vs average Green strain of circumferential 
%       and radial direction without error bars 
%           Legend: 
%               Circumferential=Black  
%               Radial=Red  
  
%Notes:  
% (1) To extract the files the data should be as follows for however many 
%     sample numbers there are being averaged of one tension ratio: 
%         n1: Column A=x2; Column B=y1y2; Column C:Exx; Column D:Eyy 
%         n2: Column F=x2; Column G=y1y2; Column H:Exx; Column I:Eyy 
%         n3: Column K=x2; Column L=y1y2; Column M:Exx; Column N:Eyy 
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%         etc ...... 
% (2) Figures have no titles, x and y labels, or legends. I put those when 
%     I'm compiling figures in a powerpoint. However, the code to do so is 
%     commented so you can just uncomment them for whatever you want on 
%     the graph. 
  
%Extracting all control thickness from excel file and indexing 
disp('Select thickness file ') 




%Extracting all control data from excel file and indexing 
disp('Select data file ') 




%Creating matrices for the average x and y force and green strain (Exx and 
%Eyy) according to number of samples (n) 
for j=1:n 
    col_x(j)=1+(5.*(j-1)); 
    x(j)={data([1:50],col_x)}; 
    col_y(j)=2+(5.*(j-1)); 
    y(j)={data([1:50],col_y)}; 
    col_Exx(j)=3+(5.*(j-1)); 
    E11(j)={data([1:50],col_Exx)}; 
    col_Eyy(j)=4+(5.*(j-1)); 







% x and y tension 
w=10.^-2; % (m) assume width 1 cm 
Txx=x./w; %(N/m) force/width 
Tyy=y./w; %(N/m) force/width 
  

















% Pavg,ii=Tavg,ii/n * Sum(1/h) 
  
t=t.*(10.^-3); %(m) h in mm and need in m 
P11_avg=Txx_avg./n.*(sum(1./t)); 
P11_avg=P11_avg./1000; %kPa   
P22_avg=Tyy_avg./n.*(sum(1./t)); 

















%Average areal strain and anisotropy index 
  
ASavg=E11_avg.*E22_avg; %areal strain is Ecirc*Erad 
ASavg_max=max(ASavg) 
AIavg=max(E11_avg./E22_avg) %anisotropy index is Ecirc/Erad 
  
output=[E11_avg, E22_avg, S11_avg, S22_avg, P11_avg, P22_avg,ASavg]; 






output=[E11_avg,E11_sem, E22_avg, E22_sem, Txx_avg, Txx_sem, Tyy_avg, 
Tyy_sem]; 
h={'E11 avg','E11 std', 'E22 avg', 'E22 std', 'Txx avg', 'Txx std', 'Tyy 































E22_std_negmidpos=transpose([E22_std_neg, E22_std_spot, E22_std_pos]); 
E22_std_pos_neg=E22_std_pos-E22_std_neg; 
  




plot(E11_avg,S11_avg,'k',E22_avg,S22_avg,'r','LineWidth',2); hold on 
scatter (E11_std_spot, S11_std_spot,sz,'k');hold on 
plot(E11_std_negmidpos,S11_std_spot_th,'k');hold on 




% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
  
Savg_max=max(max(max(S11_avg)),(max(max(S22_avg)))); %max S for axis limits 
(y limit) 
Estd_max=max(max(max(E11_std_negmidpos)),(max(max(E22_std_negmidpos)))); 


















scatter(E11_avg,S11_avg,sz,'k'); hold on; 





% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
  
Emax=max(max(max(E11_avg)),(max(max(E22_avg)))); %max E for axis limits (x 
limit) 
Smax=max(max(max(S11_avg)),(max(max(S22_avg)))); %max S for axis limits (y 
limit) 

















Plotting_Figures.m MATLAB Code 
 






%Written by Jessica Perez 
%Version April 2019 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%This code graphs all tension ratios in both circumferential and radial 
%direction with S vs E in one graph, E vs S and AS vs S in one direction, 
%and S11 vs S22 
  
%Input: 
% File containing ratio data 
  
%Output: 
% Graphs that need to be saved as jpeg or other filetype: 
%   (1) One graph with all ratios in both the circumferential and radial 
%       direction for Green Strain (E) vs 2nd P-K stress (S) 
%   (2) One figure with 2 subplots. E vs 2nd P-K stress. Left graph is  
%       the circumferential direction and the right one is the radial 
%       direction 
%   (3) One figure with 2 subplots. Areal strain (AS) vs 2nd P-K stress.  
%       Left graph is the circumferential direction and the right one is  
%       the radial direction 
%   (4) One graph with S11 vs S22 for all 5 ratios 
  
% All legends and axis can be uncommented to see appropriate symbols for 
% each item graphed. 
  
%Note:  
% To extract the files the data should be as follows on the file with 
% all the ratio data: 
%   1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22  
%   1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22  
%   0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22  
%   1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22  
%   0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22  
  
%Extracting all ratio data from excel file 





































E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1]; 
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1]; 
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1]; 
S22=[S22_1_1, S22_1_75, S22_75_1, S22_1_50, S22_50_1]; 






scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E11_1_75,S11_1_75,sz,'r'); hold on; 
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
  
sz=20; 
scatter(E22_1_1,S22_1_1,sz,'k','x'); hold on; 








0],'LineWidth',0.6); hold on; 
scatter(E22_50_1,S22_50_1,sz,'b','h','filled','MarkerEdgeColor',[0 0 




% legend('Circumferential 1:1','Circumferential 1:0.75','Circumferential 
0.75:1','Circumferential 1:0.5','Radial 0.5:1','Radial 1:1','Radial 
1:0.75','Radial 0.75:1','Radial 1:0.5','Radial 0.5:1') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
  
Emax=max(max(max(E11)),(max(max(E22)))); %max E for axis limits (x limit) 
Smax=max(max(max(S11)),(max(max(S22)))); %max S for axis limits (y limit) 



















scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E11_1_75,S11_1_75,sz,'r'); hold on; 
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
  
title ('Green Strain vs.'); %title only so easier to save/distinguish 
% legend('Circumferential 1:1','Circumferential 1:0.75','Circumferential 
0.75:1','Circumferential 1:0.5') 
% title('Circumferential') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
  
Emax=max(max(E11)); %max E for axis limits (x limit) 
Smax=max(max(S11)); %max S for axis limits (y limit) 













scatter(E22_1_1,S22_1_1,sz,'k','x'); hold on; 




0],'LineWidth',0.6); hold on; 
scatter(E22_1_50,S22_1_50,sz,'y','d','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E22_50_1,S22_50_1,sz,'b','h','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
  
title ('2nd P-K stress'); %title only so easier to save/distinguish 
% legend('Radial 1:1','Radial 1:0.75','Radial 0.75:1','Radial 1:0.5') 
% title('Radial') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
  
Emax=max(max(E22)); %max E for axis limits (x limit) 
Smax=max(max(S22)); %max S for axis limits (y limit) 

















scatter(AS_1_1,S11_1_1,sz,'k'); hold on; 
scatter(AS_1_75,S11_1_75,sz,'r'); hold on; 
scatter(AS_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(AS_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(AS_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
  
title ('Areal Strain vs.'); %title only so easier to save/distinguish 
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% legend('Circumferential 1:1','Circumferential 1:0.75','Circumferential 
0.75:1','Circumferential 1:0.5') 
% title('Circumferential') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
  
ASmax=max(max(AS)); %max E for axis limits (x limit) 
Smax=max(max(S11)); %max S for axis limits (y limit) 











scatter(AS_1_1,S22_1_1,sz,'k','x'); hold on; 




0],'LineWidth',0.6); hold on; 
scatter(AS_1_50,S22_1_50,sz,'y','d','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(AS_50_1,S22_50_1,sz,'b','h','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
  
title ('2nd P-K stress'); %title only so easier to save/distinguish 
% legend('Radial 1:1','Radial 1:0.75','Radial 0.75:1','Radial 1:0.5') 
% title('Radial') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
  
ASmax=max(max(AS)); %max E for axis limits (x limit) 
Smax=max(max(S22)); %max S for axis limits (y limit) 














scatter(S11_1_1,S22_1_1,sz,'k'); hold on; 




0],'LineWidth',0.6); hold on; 
scatter(S11_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(S11_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
  




% xlabel('S22 (kPa)') 
% ylabel('S22 (kPa)') 
  
S11max=max(max(S11)); %max S11 for axis limits (x limit) 
S22max=max(max(S22)); %max S22 for axis limits (y limit) 
















Constitutive Models MATLAB Instructions and Codes 
For the constitutive models, excel sheets containing the Green strain (E), 1st P-K (P) stress, and 
2nd P-K (S) stress in the circumferential and radial direction of all tension loading ratios must be 
made. MATLAB code Biaxial_4.m exports an excel sheet (plotdata.xlsx) containing E, S, and P 
in both the circumferential and radial direction and the areal strain for each tension loading 
ratios. One excel sheet needs to be made containing all 5 ratios (1:1, 1:0.75, 0.75:1, 1:0.50, and 
0.50:1).  
The columns would be as followed. For the first tension ratio of 1:1: column A: E11; column B: 
E22; column C: S11; column D: S22; column E: P11; column F: P22, column G: AS, and 
column H: empty. Repeat in the preceding columns for the remaining ratios in the order of 1:1, 
1:0.75, 0.75:1, 1:0.50, and 0.50:1 i.e. Tension ratio 1:0.75: column I: E11; column J: E22, etc. 
Tension ratio 0.75:1: column Q: E11; column R: E22, etc. Tension ratio 1:0.50: column Y: E11; 
column Z: E22, etc. Tension ratio 0.50:1: column AG: E11; column AH: E22, etc. It is important 
to create the excel file in this order as MATLAB codes load the data accordingly. 
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ModifiedMooneyRivlin_Isotropic.m MATLAB Code 







%Written by Jessica Perez 
%Version January 2019 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%This code calculates the constants for the Mooney Rivlin computational   
%model and graphs the experimental data and model data. 
  
%%Yang Modified Mooney Rivlin-Isotropic Equation 
  
%Strain Energy (W) 
%W=c1*(I1-3)+c2*(I2-3)+D1*[exp(D2*(I1-3))-1] 
  
%Cauchy Stress (sigma) 
%sigma=-pI+2.*dW/dI1.*B-2.*dW/dI2.*B.^-1  
%p=hydrostatic pressure term associated with the incompressibility 
%constraint 
  




%E vs S 
%S11=(2E11+1)^(-1)*[2c2-2(c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])+2(2E11+1) 
%    (c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])-2c2(2E11+1)^(-1)] 
%S22=(2E22+1)^(-1)*[2c2-2(c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])+2(2E22+1) 
%    (c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])-2c2(2E22+1)^(-1)] 
  
%Note:  
% To extract the files the data should be as follows on the file with 
% all the ratio data. 
%  1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22  
%  1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22  
%  0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22  
%  1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22  
%  0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22  
  
%Input: 
% File containing ratio data 
  
%Output: 
% Excel file:Mooney-Rivlin Constants.xlsx 
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%   Contains: c1,c2,D1,D2,condition data, r square combined 
% Graphs that need to be saved as jpeg or other filetype: 
%   (1) Individual ratios of the circumferential and radial together (5 
%       figures in subplot) 
%           Legend: 
%               Experimental Circumferential=black circles 
%               Experimental Radial=red circles 
%               Model Fit=Red Line 
%           Order: 
%               left to right= 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1 
%   (2) All ratios with circumferential and radial seperate (2 figures in  
%       subplot) 
%           Legend: 
%               Experimental 1:1=black circles 
%               Experimental 1:0.75=red circles 
%               Experimental 0.75:1=upside down green triangle 
%               Experimental 1:0.50=yello triangle 
%               Experimental 0.5:1=blue square 
%               Model Fit=Red Line 
%           Order: 
%               left to right= Circumferential, Radial 
  
%  Note:  
%   (1)Figures are the size that allows the subplots to be saved  
%      properly and not be stretched out. 
%   (2)Figures have no titles, x and y labels, or legends. I put those when 
%      I'm compiling figures in a powerpoint. However, the code to do so is 
%      commented so you can just uncomment them for whatever you want on 
%      the graph. 
  
%Extracting all ratio data from excel file 







































































% Model formulation 
  




clear E11 E22 
  
% Objective function. This is the sum of squares of the residuals. I had to 
% write out the complete equations because I'm not sure yet how to 
% incorporate function handles fun_11 and fun_22 into this. 
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obj_fun = @(x)... 








































     
% obj_fun=matlabFunction(sum((sym(fun_11)-S11).^2+(sym(fun_22)-S22).^2)); 
  
% Minimization of objective function using fmincon 
x0=[1,2,3,4]; % initial guesses 
lb=[-inf,-inf,-inf,-inf]; % lower bound for parameters 
ub=[inf,inf,inf,inf]; % upper bound for parameters 
A=[0,0,0,0;0,0,0,0;0,0,0,0;0,0,0,0]; % Variables to enforce inequality 
constraint  
b=[0,0,0,0]; % Variables to enforce inequality constraint  
options = optimoptions('fmincon','Display','iter','Algorithm','sqp'); 
%Options to control execution of fmincon 





x = fmincon(obj_fun,x0,A,b,[],[],lb,ub,[],options); 
  






% Matrix form of coeffecients 
D=[c1,c2,D1,D2];  
  
% Total R_square 
SSres= ... 























































    + sum(((S11_1_1-c_bar1).^2)+((S22_1_1-r_bar1).^2))... 
    + sum(((S11_1_75-c_bar2).^2)+((S22_1_75-r_bar2).^2))... 
    + sum(((S11_75_1-c_bar3).^2)+((S22_75_1-r_bar3).^2))... 
    + sum(((S11_1_50-c_bar4).^2)+((S22_1_50-r_bar4).^2))... 
    + sum(((S11_50_1-c_bar5).^2)+((S22_50_1-r_bar5).^2)); 
     
R_square_combine=1-(SSres/SStot) 
  
%Export constants into excel sheet 
output=[c1,c2,D1,D2, R_square_combine]; 
h={'c1', 'c2','D1','D2', 'R_square_combine'}; 
m=[h;num2cell(output)]; 
filename='Modified M-R (Isotropic) Constants.xlsx'; 
xlswrite(filename,m); 
  






































































% Large matrix containg all values 
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1]; 
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1]; 
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1]; 






%Figure (1) plots Individual ratios of the circumgerential and radial  
%together (5 figures in subplot)Figure is very wide to insure that plots  
%are displayed properly. Save figure as jpeg or desired file type. 
  







scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E22_1_1,S22_1_1,sz,'r'); hold on; 
plot(E11_1_1_m,model11_1_1_m,'r',E22_1_1_m,model22_1_1_m,'r'); hold off; 
Emax_1_1=max(max(max(E11_1_1)),(max(max(E22_1_1)))); %max E for axis limits 
(x limit) 
Smax_1_1=max(max(max(S11_1_1)),(max(max(S22_1_1)))); %max S for axis limits 
(y limit) 




% xlabel('Green Strain') 









scatter(E11_1_75,S11_1_75,sz,'k'); hold on; 
scatter(E22_1_75,S22_1_75,sz,'r'); hold on; 
plot(E11_1_75_m,model11_1_75_m,'r',E22_1_75_m,model22_1_75_m,'r'); hold off; 
  
Emax_1_75=max(max(max(E11_1_75)),(max(max(E22_1_75)))); %max E for axis 
limits (x limit) 
Smax_1_75=max(max(max(S11_1_75)),(max(max(S22_1_75)))); %max S for axis 
limits (y limit) 




% xlabel('Green Strain') 










scatter(E11_75_1,S11_75_1,sz,'k'); hold on; 
scatter(E22_75_1,S22_75_1,sz,'r'); hold on; 
plot(E11_75_1_m,model11_75_1_m,'r',E22_75_1_m,model22_75_1_m,'r'); hold off; 
  
Emax_75_1=max(max(max(E11_75_1)),(max(max(E22_75_1)))); %max E for axis 
limits (x limit) 
Smax_75_1=max(max(max(S11_75_1)),(max(max(S22_75_1)))); %max S for axis 
limits (y limit) 






% xlabel('Green Strain') 









scatter(E11_1_50,S11_1_50,sz,'k'); hold on; 
scatter(E22_1_50,S22_1_50,sz,'r'); hold on; 
plot(E11_1_50_m,model11_1_50_m,'r',E22_1_50_m,model22_1_50_m,'r'); hold off; 
  
Emax_1_50=max(max(max(E11_1_50)),(max(max(E22_1_50)))); %max E for axis 
limits (x limit) 
Smax_1_50=max(max(max(S11_1_50)),(max(max(S22_1_50)))); %max S for axis 
limits (y limit) 




% xlabel('Green Strain') 









scatter(E11_50_1,S11_50_1,sz,'k'); hold on; 
scatter(E22_50_1,S22_50_1,sz,'r'); hold on; 
plot(E11_50_1_m,model11_50_1_m,'r',E22_50_1_m,model22_50_1_m,'r'); hold off; 
  
Emax_50_1=max(max(max(E11_50_1)),(max(max(E22_50_1)))); %max E for axis 
limits (x limit) 
Smax_50_1=max(max(max(S11_50_1)),(max(max(S22_50_1)))); %max S for axis 
limits (y limit) 




% xlabel('Green Strain') 















%Figure (2) plots all ratios with circumferential and radial seperate  
%(2 figures in subplot). Save figure as jpeg or desired file type. 
  
%Note: label of each ratio-1:1=circle; 1:0.75=astrix 
figure (2) 
subplot (1,2,1) 
scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E11_1_75,S11_1_75,sz,'r'); hold on; 
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 





Emax=max(max(E11)); %max E for axis limits (x limit) 
Smax=(max(max(max(S11)),(max(model11)))); %max S for axis limits (x limit) 
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S 
%legend('Experimental 1:1','Experimental 1:0.75','Experimental 
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit 
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1') 
% title('Circumferential') 
% xlabel('Green Strain') 









scatter(E22_1_1,S22_1_1,sz,'k'); hold on; 
scatter(E22_1_75,S22_1_75,sz,'r'); hold on; 
scatter(E22_75_1,S22_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E22_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E22_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 




Emax=max(max(E22)); %max E for axis limits (x limit) 
Smax=(max(max(max(S22)),(max(model22)))); %max S for axis limits (y limit) 





%legend('Experimental 1:1','Experimental 1:0.75','Experimental 
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit 
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1') 
% title('Radial') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',12,'FontWeight',















ModifiedMooneyRivlin_Anisotropic.m MATLAB Code 
 







%Written by Jessica Perez 
%Version January 2019 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%This code calculates the constants for the Mooney Rivlin computational   
%model and graphs the experimental data and model data. 
  
%%Rassouli Mooney Rivlin Modified Anisotropic Equation 
  
%Strain Energy (W) 
%W=c1(I1-3)+D1[exp(D2(I1-3))-1]+(k1/2k2)[exp[k2(I4-1)^2-1] 
  
%Cauchy Stress (sigma) 
%sigma=-pI+2.*dW/dI1.*B-2.*dW/dI2.*B.^-1  
%p=hydrostatic pressure term associated with the incompressibility 
%constraint 
  










% To extract the files the data should be as follows on the file with 
% all the ratio data. 
%  1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22  
%  1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22  
%  0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22  
%  1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22  
%  0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22  
  
%Input: 
% File containing ratio data 
  
%Output: 
% Excel file:Mooney-Rivlin Constants.xlsx 
%       Contains: c1,c2,D1,D2,condition data, r square combined 
181 
 
% Graphs that need to be saved as jpeg or other filetype: 
%   (1) Individual ratios of the circumferential and radial together (5 
%       figures in subplot) 
%         Legend: 
%           Experimental Circumferential=black circles 
%           Experimental Radial=red circles 
%           Model Fit=Red Line 
%         Order: 
%           left to right= 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1 
%   (2) All ratios with circumferential and radial seperate (2 figures in  
%       subplot) 
%         Legend: 
%           Experimental 1:1=black circles 
%           Experimental 1:0.75=red circles 
%           Experimental 0.75:1=upside down green triangle 
%           Experimental 1:0.50=yello triangle 
%           Experimental 0.5:1=blue square 
%           Model Fit=Red Line 
%         Order: 
%           left to right= Circumferential, Radial 
  
%  Note:  
%   (1)Figures are the size that allows the subplots to be saved  
%      properly and not be stretched out. 
%   (2)Figures have no titles, x and y labels, or legends. I put those when 
%      I'm compiling figures in a powerpoint. However, the code to do so is 
%      commented so you can just uncomment them for whatever you want on 
%      the graph. 
  
%Extracting all ratio data from excel file 
































% Objective function. This is the sum of squares of the residuals.  
obj_fun = @(x)... 
























./(2.*E22_50_1+1))-S22_50_1).^2);    
   
% obj_fun=matlabFunction(sum((sym(fun_11)-S11).^2+(sym(fun_22)-S22).^2)); 
  
% Minimization of objective function using fmincon 
x0=[1,1,1,1,1]; % initial guesses 
lb=[-inf,-inf,2,-inf,-inf]; % lower bound for parameters 
ub=[inf,inf,2,inf,inf]; % upper bound for parameters 
A=[0,0,0,0,0;0,0,0,0,0;0,0,0,0,0;0,0,0,0,0;0,0,0,0,0]; % Variables to enforce 
inequality constraint  
b=[0,0,0,0,0]; % Variables to enforce inequality constraint  
options = optimoptions('fmincon','Display','iter','Algorithm','sqp'); 
%Options to control execution of fmincon 
% options = 
optimoptions('fmincon','Display','iter','Algorithm','sqp','MaxIterations',100
00,'MaxFunEval',100000,'StepTolerance',1e-20); 
x = fmincon(obj_fun,x0,A,b,[],[],lb,ub,[],options); 
  









% Matrix form of coeffecients 
D=[c1,D1,D2,k1,k2];  
  
% Total R_square 
SSres= ... 






































    + sum(((S11_1_1-c_bar1).^2)+((S22_1_1-r_bar1).^2))... 
    + sum(((S11_1_75-c_bar2).^2)+((S22_1_75-r_bar2).^2))... 
    + sum(((S11_75_1-c_bar3).^2)+((S22_75_1-r_bar3).^2))... 
    + sum(((S11_1_50-c_bar4).^2)+((S22_1_50-r_bar4).^2))... 
    + sum(((S11_50_1-c_bar5).^2)+((S22_50_1-r_bar5).^2)); 
     
R_square_combine=1-(SSres/SStot) 
  
































































% Large matrix containg all values 
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1]; 
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1]; 
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1]; 






%Figure (1) plots Individual ratios of the circumgerential and radial  
%together (5 figures in subplot)Figure is very wide to insure that plots  
%are displayed properly. Save figure as jpeg or desired file type. 
  





scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E22_1_1,S22_1_1,sz,'r'); hold on; 
plot(E11_1_1_m,model11_1_1_m,'r',E22_1_1_m,model22_1_1_m,'r'); hold off; 
Emax_1_1=max(max(max(E11_1_1)),(max(max(E22_1_1)))); %max E for axis limits 
(x limit) 
Smax_1_1=max(max(max(S11_1_1)),(max(max(S22_1_1)))); %max S for axis limits 
(y limit) 




% xlabel('Green Strain') 









scatter(E11_1_75,S11_1_75,sz,'k'); hold on; 
scatter(E22_1_75,S22_1_75,sz,'r'); hold on; 
plot(E11_1_75_m,model11_1_75_m,'r',E22_1_75_m,model22_1_75_m,'r'); hold off; 
  
Emax_1_75=max(max(max(E11_1_75)),(max(max(E22_1_75)))); %max E for axis 
limits (x limit) 
Smax_1_75=max(max(max(S11_1_75)),(max(max(S22_1_75)))); %max S for axis 
limits (y limit) 




% xlabel('Green Strain') 












scatter(E11_75_1,S11_75_1,sz,'k'); hold on; 
scatter(E22_75_1,S22_75_1,sz,'r'); hold on; 
plot(E11_75_1_m,model11_75_1_m,'r',E22_75_1_m,model22_75_1_m,'r'); hold off; 
  
Emax_75_1=max(max(max(E11_75_1)),(max(max(E22_75_1)))); %max E for axis 
limits (x limit) 
Smax_75_1=max(max(max(S11_75_1)),(max(max(S22_75_1)))); %max S for axis 
limits (y limit) 




% xlabel('Green Strain') 









scatter(E11_1_50,S11_1_50,sz,'k'); hold on; 
scatter(E22_1_50,S22_1_50,sz,'r'); hold on; 
plot(E11_1_50_m,model11_1_50_m,'r',E22_1_50_m,model22_1_50_m,'r'); hold off; 
  
Emax_1_50=max(max(max(E11_1_50)),(max(max(E22_1_50)))); %max E for axis 
limits (x limit) 
Smax_1_50=max(max(max(S11_1_50)),(max(max(S22_1_50)))); %max S for axis 
limits (y limit) 




% xlabel('Green Strain') 









scatter(E11_50_1,S11_50_1,sz,'k'); hold on; 
scatter(E22_50_1,S22_50_1,sz,'r'); hold on; 




Emax_50_1=max(max(max(E11_50_1)),(max(max(E22_50_1)))); %max E for axis 
limits (x limit) 
Smax_50_1=max(max(max(S11_50_1)),(max(max(S22_50_1)))); %max S for axis 
limits (y limit) 




% xlabel('Green Strain') 













%Figure (2) plots all ratios with circumferential and radial seperate  
%(2 figures in subplot). Save figure as jpeg or desired file type. 
  
%Note: label of each ratio-1:1=circle; 1:0.75=astrix 
figure (2) 
subplot (1,2,1) 
scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E11_1_75,S11_1_75,sz,'r'); hold on; 
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 





Emax=max(max(max(E11)),(max(max(E22)))); %max E for axis limits (x limit) 
Smax=max(max(max(S11)),(max(max(S22)))); %max S for axis limits (y limit) 
Emax=max(max(E11)); %max E for axis limits (x limit) 
Smax=(max(max(max(S11)),(max(model11)))); %max S for axis limits (x limit) 
axis([0 Emax+0.05 0 Smax+10]); % add 0.05 for max E and 10 for mas S 
% legend('Experimental 1:1','Experimental 1:0.75','Experimental 
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit 
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1') 
% title('Circumferential') 
% xlabel('Green Strain') 











scatter(E22_1_1,S22_1_1,sz,'k'); hold on; 
scatter(E22_1_75,S22_1_75,sz,'r'); hold on; 
scatter(E22_75_1,S22_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E22_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E22_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 




Emax=max(max(E22)); %max E for axis limits (x limit) 
Smax=(max(max(max(S22)),(max(model22)))); %max S for axis limits (y limit) 
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S 
% legend('Experimental 1:1','Experimental 1:0.75','Experimental 
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit 
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1') 
% title('Radial') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',12,'FontWeight',



















%%Edited by Jessica Perez 
%Version November 26, 2018 
%Written by Alex Khang, October 31, 2018 
  
%University of Arkansas 
%Department of Biomedical Engineering 
%Mechanobiology and Soft Materials Laboratory (MSML) 
%PI: Dr. Kartik Balachandran 
  
%This code calculates the constants for the fung-type computational model  
%and graphs the experimental data and model data. 
  
%Fung-type Model: 





% To extract the files the data should be as follows on the file with 
% all the ratio data. 
%  1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22  
%  1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22  
%  0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22  
%  1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22  
%  0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22  
  
%Input: 
% File containing ratio data 
  
%Output: 
% Excel file:Fung-type Constants.xlsx 
%       Contains: c,c1,c2,c3,condition data, r square combined, anisotropy 
%                 index 
% Graphs that need to be saved as jpeg or other filetype: 
%   (1) Individual ratios of the circumferential and radial together (5 
%       figures in subplot) 
%           Legend: 
%               Experimental Circumferential=black circles 
%               Experimental Radial=red circles 
%               Model Fit=Red Line 
%           Order: 
%               left to right= 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1 
%   (2) All ratios with circumferential and radial seperate (2 figures in  
%       subplot) 
%           Legend: 
%               Experimental 1:1=black circles 
%               Experimental 1:0.75=red circles 
%               Experimental 0.75:1=upside down green triangle 
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%               Experimental 1:0.50=yello triangle 
%               Experimental 0.5:1=blue square 
%               Model Fit=Red Line 
%           Order: 
%               left to right= Circumferential, Radial 
%   (3) Contour plots of the Fung-type model 
  
%  Note:  
%   (1)Figures are the size that allows the subplots to be saved  
%      properly and not be stretched out. 
%   (2)Figures have no titles, x and y labels, or legends. I put those when 
%      I'm compiling figures in a powerpoint. However, the code to do so is 
%      commented so you can just uncomment them for whatever you want on 
%      the graph. 
  
%Extracting all ratio data from excel file 






























% Large matrix containg all values 
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1]; 
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1]; 
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1]; 
S22=[S22_1_1, S22_1_75, S22_75_1, S22_1_50, S22_50_1]; 
  
% % Model formulation 





% fun_11=matlabFunction(diff(W,Exx)); %symbolic 
% fun_22=matlabFunction(diff(W,Eyy)); %symbolic 
% clear Exx Eyy 
  
% Objective function. This is the sum of squares of the residuals. I had to 
% write out the complete equations because I'm not sure yet how to 
% incorporate function handles fun_11 and fun_22 into this. 
obj_fun = @(x)... 






























     
% obj_fun=matlabFunction(sum((sym(fun_11)-S11).^2+(sym(fun_22)-S22).^2)); 
  
% Minimization of objective function using fmincon 
x0=[1,4,1,1]; % initial guesses 
lb=[0,-inf,-inf,-inf]; % lower bound for parameters 
ub=[inf,inf,inf,inf]; % upper bound for parameters 
A=[0,-1,0,1;0,0,-1,1]; % Variables to enforce inequality constraint A1>A3 
b=[0;0]; % Variables to enforce inequality constraint A2>A3 
options = optimoptions('fmincon','Display','iter','Algorithm','sqp'); 
%Options to control execution of fmincon 
% options = 
optimoptions('fmincon','Display','iter','Algorithm','sqp','MaxIterations',100
00,'MaxFunEval',100000,'StepTolerance',1e-20); 
x = fmincon(obj_fun,x0,A,b,[],[],lb,ub,[],options); 
  








% Matrix form of coeffecients 
D=[c,c1;c2,c3];  
  
% Condition number. This must be less than or equal to 200 for acceptable 
% numerical convergence.  
Condition_number=norm(D,1)*norm(inv(D),1) 
  
% Total R_square 
SSres= ... 













































    + sum(((S11_1_1-c_bar1).^2)+((S22_1_1-r_bar1).^2))... 
    + sum(((S11_1_75-c_bar2).^2)+((S22_1_75-r_bar2).^2))... 
    + sum(((S11_75_1-c_bar3).^2)+((S22_75_1-r_bar3).^2))... 
    + sum(((S11_1_50-c_bar4).^2)+((S22_1_50-r_bar4).^2))... 
    + sum(((S11_50_1-c_bar5).^2)+((S22_50_1-r_bar5).^2)); 






%Export constants into excel sheet 
output=[c, c1, c2, c3, Condition_number, R_square_combine, AI]; 



















































%Plot fit lines: 
  
%Figure (1) plots Individual ratios of the circumgerential and radial  
%together (5 figures in subplot)Figure is very wide to insure that plots  
%are displayed properly. Save figure as jpeg or desired file type. 
  





scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E22_1_1,S22_1_1,sz,'r'); hold on; 




% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
Emax=max(max(max(E11_1_1)),(max(max(E22_1_1)))); %max E for axis limits (x 
limit) 
Smax=max(max(max(S11_1_1)),(max(max(S22_1_1),max(max(model11_1_1_m),max(max(m
odel22_1_1_m)))))); %max S for axis limits (y limit) 









scatter(E11_1_75,S11_1_75,sz,'k'); hold on; 
scatter(E22_1_75,S22_1_75,sz,'r'); hold on; 




% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
Emax=max(max(max(E11_1_75)),(max(max(E22_1_75)))); %max E for axis limits (x 
limit) 
Smax=max(max(max(S11_1_75)),(max(max(S22_1_75),max(max(model11_1_75_m),max(ma
x(model22_1_75_m)))))); %max S for axis limits (y limit) 











scatter(E11_75_1,S11_75_1,sz,'k'); hold on; 
scatter(E22_75_1,S22_75_1,sz,'r'); hold on; 




% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
Emax=max(max(max(E11_75_1)),(max(max(E22_75_1)))); %max E for axis limits (x 
limit) 
Smax=max(max(max(S11_75_1)),(max(max(S22_75_1),max(max(model11_75_1_m),max(ma
x(model22_75_1_m)))))); %max S for axis limits (y limit) 









scatter(E11_1_50,S11_1_50,sz,'k'); hold on; 
scatter(E22_1_50,S22_1_50,sz,'r'); hold on; 




% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
Emax=max(max(max(E11_1_50)),(max(max(E22_1_50)))); %max E for axis limits (x 
limit) 
Smax=max(max(max(S11_1_50)),(max(max(S22_1_50),max(max(model11_1_50_m),max(ma
x(model22_1_50_m)))))); %max S for axis limits (y limit) 









scatter(E11_50_1,S11_50_1,sz,'k'); hold on; 
scatter(E22_50_1,S22_50_1,sz,'r'); hold on; 




% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
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Emax=max(max(max(E11_50_1)),(max(max(E22_50_1)))); %max E for axis limits (x 
limit) 
Smax=max(max(max(S11_50_1)),(max(max(S22_50_1),max(max(model11_50_1_m),max(ma
x(model22_50_1_m)))))); %max S for axis limits (y limit) 













%Figure (2) plots all ratios with circumferential and radial seperate  
%(2 figures in subplot). Save figure as jpeg or desired file type. 
  
% Large matrix containg all values 
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1]; 
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1]; 
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1]; 






%Note: label of each ratio-1:1=circle; 1:0.75=astrix 
figure (2) 
subplot (1,2,1) 
scatter(E11_1_1,S11_1_1,sz,'k'); hold on; 
scatter(E11_1_75,S11_1_75,sz,'r'); hold on; 
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 




% legend('Experimental 1:1','Experimental 1:0.75','Experimental 
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit 
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1') 
% title('Circumferential') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
Emax=max(max(E11)); %max E for axis limits (x limit) 
Smax=(max(max(max(S11)),(max(modelxx)))); %max S for axis limits (y limit) 











scatter(E22_1_1,S22_1_1,sz,'k'); hold on; 
scatter(E22_1_75,S22_1_75,sz,'r'); hold on; 
scatter(E22_75_1,S22_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E22_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0 
0],'LineWidth',0.6); hold on; 
scatter(E22_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0 




% legend('Experimental 1:1','Experimental 1:0.75','Experimental 
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit 
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1') 
% title('Radial') 
% xlabel('Green Strain') 
% ylabel('2nd P-K Stress (kPa)') 
Emax=max(max(E22)); %max E for axis limits (x limit) 
Smax=(max(max(max(S22)),(max(modelyy)))); %max S for axis limits (y limit) 













%Strain Energy Contour Plot: 
  
%E for circ and rad. Note: There aren't the experimental E but a range to 
%see how the constants fit 
E11cp=[-1.5:0.02:1.5]; 
E22cp=[-1.5:0.02:1.5]; 
    



















PicrosiriusRedAnlaysis.m MATLAB Code 
% Picrosirius Red Analysis 
% 
% This program reads in picrosirius red image files and calculates 
% percentage of red, orange, yellow and green fibers in the 
% image.  
% 
% INSTRUCTIONS: Select PSR image to analyze. Create a polygon surrounding. 
% the region of interest then right click and choose create mask. Copy the 
% matrix percentage_royg to excel sheet. Matrix numbers correspond to the 
% red, orange, yellow, and green percentages respectivley.  
% 
% INPUT: PSR image 
% 
% RETURNS: Matrix with red, orange, yellow, and green percentages. 
% 
% Created by Dr. Kartik Balchandran  
%   Mechanobiology and Soft Materials Laboratory 
%   University of Arkansas, Fayetteville, AR 72701 
% 
% Edited by Jessica Perez January 2017 
%   Mechanobiology and Soft Materials Laboratory 
%   University of Arkansas, Fayetteville, AR 72701 
% 
% Edited by Ishita tandon November 2018 
%   Mechanobiology and Soft Materials Laboratory 
%   University of Arkansas, Fayetteville, AR 72701 
%   Ranges of hue bins updated. 









[filename pathname]=uigetfile('*.*','Select File...'); 
stain=imread(filename); %Image file name 
  
% select region of interest by tracing polygon and then mask by right 
% clicking and selecting creat mask 
display('Select region of interest then double click to create mask'); 
Mask=roipoly(stain); 
  
% RGB channels of image 
red = double(stain(:,:,1)); % Red channel 
green = double(stain(:,:,2)); % Green channel 
blue = double(stain(:,:,3)); % Blue channel 
  







% Recombining RGB channels and changing it from double to uint8 











% Magnifies image to simplify the selection of area of intest 
stain_cropped=double(stain_cropped); 
stain_cropped_norm = stain_cropped./255; 




hue_mat=stain_hsv(:,:,1); %h=(:,:,1); s=(:,:,2); v=(:,:,3) 
  
hue_mat1= hue_mat .* 360; % hsv is a 360 degree circle 
[height, width]=size(hue_mat1); 
  
% Defines the hue values for a particular color 
H1= double(hue_mat1 > 0 & hue_mat1 < 15) + double(hue_mat1 > 345 & hue_mat1 < 
360); %red 
H2= double(hue_mat1 > 16 & hue_mat1 < 38); %orange 
H3= double(hue_mat1 > 39 & hue_mat1 < 63); %yellow 
H4= double(hue_mat1 > 64 & hue_mat1 < 150); %green 
  

























num_total_pixels = height .* width; 
for i=1:height 
for j=1:width 
if(hue_mat1(i,j) > 0) && (hue_mat1(i,j) < 15) %red pixels 
    num_red = num_red + 1; 
elseif(hue_mat1(i,j) > 345) && (hue_mat1(i,j) <360) %red pixels 
num_red = num_red + 1; 
elseif(hue_mat1(i,j) > 16) && (hue_mat1(i,j) < 38) %orange pixels 
num_orange = num_orange + 1; 
elseif(hue_mat1(i,j) > 39) && (hue_mat1(i,j) < 63) %yellow pixels 
num_yellow = num_yellow + 1; 
elseif(hue_mat1(i,j) > 64) && (hue_mat1(i,j) < 150) %green pixels 

















% h={'total pixels', 'red pixels', 'orange pixels','yello pixels', 'green 




   
202 
 
 APPENDIX C SUMPLEMENTAL INFORMATION 
Reasons why samples were not used in overall analysis: 
*Sample ripped in one staple 
**Staples were not placed properly causing the load to be placed unevenly  
***Sample believed to be mounted backwards (circumferential in y axis and radial in x axis) 
****Sample completely tore and all tension ratios were not completed 
 

















Table 0-1. Max areal strain (ASmax), anisotropy index (AI), low (TML) and high (TMH) tangent 
modulus for the circumferential and radial direction, and extensibility for the circumferential and 
radial direction for each individual specimens.    












Control FB 1 0.138 0.477 49.9 3375.7 9.4 1048.1 0.216 0.435 
FB 2 0.122 0.822 32.4 1252.5 21.5 999.1 0.237 0.293 
 FB 3** 0.061 0.747 19.2 2324.5 23.0 1566.1 0.179 0.239 
 FB 4 0.087 0.575 38.2 2940.3 16.7 946.1 0.190 0.299 
 FB 5* 0.162 0.766 24.3 3799.7 13.8 1539.5 0.329 0.408 
 FB 6** 0.088 0.407 74.5 2187.5 21.5 1589.1 0.131 0.395 
 FB 7 0.067 0.417 88.1 3532.6 44.3 1180.0 0.120 0.288 
 FB 8 0.069 0.334 65.6 4434.1 20.5 1340.8 0.118 0.376 
          
Ang-I FB 1 0.142 0.590 35.6 2367.2 11.9 1229.4 0.237 0.407 
FB 2 0.114 0.515 27.4 2868.7 23.9 860.7 0.207 0.367 
 FB 3 0.150 0.342 25.2 2982.2 7.5 962.5 0.188 0.577 
 FB 4 0.118 0.861 53.9 1503.8 20.6 1693.2 0.236 0.309 
 FB 5*** 0.038 0.951 57.8 2238.4 69.6 2916.4 0.144 0.168 
 FB 6** 0.090 0.386 58.7 2471.8 25.5 1041.0 0.134 0.378 
 FB 7** 0.116 0.677 22.3 1502.6 16.3 1007.5 0.207 0.322 
 FB 8 0.053 0.595 66.9 2888.3 39.2 1632.0 0.139 0.234 
          
Ang-II FB 1 0.123 0.360 46.8 3382.1 8.9 815.7 0.172 0.472 
FB 2*** 0.085 0.663 42.1 1850.3 26.7 1047.1 0.190 0.268 
 FB 3 0.120 0.844 32.7 1343.9 15.6 1823.0 0.234 0.321 
 FB 4* 0.148 0.396 77.8 2330.5 28.0 683.8 0.180 0.457 
 FB 5 0.125 0.551 27.6 2278.2 17.2 1252.3 0.225 0.410 
 FB 6 0.051 0.321 77.5 3279.9 29.7 928.5 0.009 0.292 
 FB 7 0.043 0.369 21.5 4860.2 16.6 1026.3 0.104 0.257 
 FB 8 0.034 0.336 131.9 6480.7 26.6 2222.2 0.085 0.270 
          
Ang-I+ 
Quinaprilat 
FB 1 0.072 0.849 62.1 1231.1 34.2 999.1 0.174 0.215 
FB 2 0.114 0.416 36.8 2482.0 15.3 678.9 0.179 0.417 
 FB 3** 0.223 0.524 34.5 2232.7 12.0 1151.9 0.146 0.561 
 FB 4 0.088 0.297 51.9 4946.9 17.5 1371.6 0.130 0.459 
 FB 5 0.115 0.489 73.4 3285.5 19.0 1535.3 0.190 0.407 
 FB 6** 0.071 0.836 52.4 1474.8 20.2 1684.7 0.165 0.224 
 FB 7* 0.065 0.385 73.4 4154.9 23.5 1285.4 0.130 0.320 
          
Ang-I+ 
Chymostatin 
FB 1 0.086 0.356 96.5 2776.6 33.7 1011.4 0.132 0.394 
FB 2 0.127 0.573 43.8 3321.9 22.6 1185.6 0.240 0.400 
 FB 3 0.072 0.419 45.6 3341.6 40.8 852.3 0.139 0.301 
 FB 4** 0.111 0.403 74.9 2394.1 18.2 740.4 0.164 0.411 
 FB 5 0.049 0.378 43.6 4232.6 26.1 1947.3 0.104 0.301 
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Table 0-2. (Cont.) 














FB 1** 0.239 0.187 18.7 4232.1 1.9 303.6 0.193 0.964 
FB 2 0.198 0.367 22.6 1311.6 8.1 512.2 0.208 0.591 
 FB 3 0.083 0.309 60.9 2776.5 10.3 800.3 0.126 0.424 
 FB 4**** 0.125 0.615 29.8 2028.0 23.6 1001.4 0.220 0.342 
 FB 5 0.100 0.315 40.0 3075.7 15.8 765.3 0.146 0.463 
 FB 6 0.122 0.599 29.8 1439.8 10.4 1325.0 0.208 0.393 
 FB 7 0.048 0.334 34.9 4850.0 18.3 2102.4 0.102 0.330 
          
Ang-II+ 
Losartan 
FB 1** 0.096 0.416 25.5 4750.8 19.5 770.8 0.173 0.356 
FB 2* 0.067 0.568 46.4 4739.9 23.1 1241.3 0.173 0.265 
 FB 3 0.086 0.260 51.4 8038.4 4.8 1135.6 0.139 0.504 
 FB 4*** 0.052 0.732 54.4 2122.9 26.4 2449.3 0.138 0.220 
 FB 5 0.082 0.308 30.7 3854.4 17.9 1040.4 0.131 0.430 
 FB 6 0.094 0.477 25.6 2857.8 29.2 1254.9 0.155 0.328 
 FB 7** 0.042 0.691 65.3 3688.9 30.9 1827.1 0.145 0.199 
 FB 8 0.044 0.238 60.8 5840.3 14.9 885.8 0.080 0.320 
          
Ang-I+ 
PD123,319 
FB 1 0.108 0.509 30.1 4827.1 13.4 1416.3 0.212 0.386 
FB 2 0.133 0.271 78.8 7081.3 17.5 1070.4 0.166 0.588 
 FB 3 0.087 0.501 87.1 4251.3 38.5 1456.8 0.168 0.315 
 FB 4**** 0.056 0.436 73.6 3263.3 9.3 1832.1 0.114 0.299 
 FB 5* 0.056 0.386 77.8 3693.5 31.6 1127.0 0.103 0.464 
 FB 6 0.072 0.324 79.4 4612.5 17.6 1226.7 0.124 0.385 
 FB 7 0.071 0.200 47.5 5301.3 11.4 821.8 0.100 0.490 
          
Ang-II+ 
PD123,319 
FB 1**** 0.087 0.840 37.1 1935.7 34.1 1190.4 0.213 0.230 
FB 2** 0.080 0.435 23.7 4952.3 19.3 1140.6 0.165 0.354 
 FB 3* 0.193 0.216 70.9 5423.2 8.2 689.3 0.174 0.777 
 FB 4 0.107 0.397 59.8 4543.9 24.0 2009.4 0.174 0.462 
 FB 5 0.077 0.251 79.0 3911.0 14.6 1028.8 0.108 0.455 
 FB 6 0.073 0.661 41.2 2637.4 14.5 2344.4 0.182 0.292 
 FB 7 0.137 0.571 55.1 2001.9 13.7 718.0 0.180 0.443 












Table 0-3. Material constants along with the conditional number, R2 of the fit, and anisotropy 




No. c(kPa) c1 c2 c3 R2 AI 
Control FB 1 0.519 9.273 5.750 3.427 0.789 0.723 
FB 2 0.828 13.507 10.866 0.143 0.929 0.807 
 FB 3** 1.568 19.149 11.782 -2.619 0.732 0.554 
 FB 4 0.650 15.021 12.657 2.263 0.917 0.863 
 FB 5* 0.650 15.021 12.657 2.263 0.917 0.863 
 FB 6** 0.318 25.621 10.832 4.088 0.949 0.502 
 FB 7 1.025 23.489 12.816 3.983 0.953 0.612 
 FB 8 0.768 36.907 9.974 2.432 0.968 0.315 
        
Ang-I FB 1 1.020 13.428 6.171 0.634 0.797 0.484 
FB 2 0.446 26.804 8.946 -0.413 0.932 0.323 
 FB 3 1.252 22.536 3.497 -1.407 0.773 0.099 
 FB 4 1.117 18.514 11.811 -2.554 0.878 0.580 
 FB 5*** N/A           
 FB 6** 1.422 22.966 7.326 1.534 0.884 0.362 
 FB 7** 0.376 15.552 12.556 1.909 0.920 0.828 
 FB 8 0.834 55.868 22.981 -9.307 0.911 0.294 
        
Ang-II FB 1 1.016 19.318 5.132 0.958 0.897 0.300 
FB 2*** 1.313 26.269 14.274 -6.163 0.724 0.403 
 FB 3 0.613 15.122 15.580 -1.391 0.830 0.968 
 FB 4* 8.594 9.250 1.928 0.700 0.797 0.264 
 FB 5 2.109 15.167 7.231 -0.482 0.799 0.460 
 FB 6 1.190 26.848 9.286 4.411 0.853 0.438 
 FB 7 0.303 19.716 17.911 11.475 0.847 0.942 
 FB 8 0.145 124.516 31.700 -4.411 0.958 0.227 
        
Ang-I+ 
Quinaprilat 
FB 1 1.295 19.452 15.117 -0.026 0.867 0.777 
FB 2 0.410 31.756 9.752 -2.171 0.977 0.256 
 FB 3** 3.047 6.880 2.947 -0.140 0.740 0.417 
 FB 4 0.266 43.667 10.297 -0.128 0.920 0.234 
 FB 5 1.305 19.559 7.445 -0.453 0.756 0.366 
 FB 6** 0.859 20.159 18.707 1.492 0.901 0.933 
 FB 7* 0.906 23.437 11.055 2.971 0.837 0.531 
        
Ang-I+ 
Chymostatin 
FB 1 0.745 35.161 8.706 -0.210 0.947 0.243 
FB 2 0.263 24.898 12.574 -3.234 0.874 0.431 
 FB 3 2.687 15.398 6.111 0.601 0.661 0.419 
 FB 4** 1.033 26.297 6.035 -1.303 0.805 0.189 
 FB 5 0.202 47.316 19.776 8.456 0.932 0.506 
 FB 6 0.569 19.440 13.074 5.374 0.898 0.743 










No. c(kPa) c1 c2 c3 R2 AI 
Ang-I+ 
Losartan 
FB 1** 0.303 19.716 17.911 11.475 0.847 0.942 
FB 2 1.124 11.492 3.380 0.960 0.822 0.349 
 FB 3 1.616 16.468 3.648 2.534 0.802 0.325 
 FB 4****             
 FB 5 0.147 47.865 10.640 -2.500 0.944 0.179 
 FB 6 0.440 29.980 13.038 -5.049 0.909 0.320 
 FB 7 0.054 84.662 21.148 7.781 0.971 0.313 
        
Ang-II+ 
Losartan 
FB 1** 0.265 36.002 8.906 0.715 0.839 0.262 
FB 2* 0.707 23.508 12.543 1.736 0.765 0.566 
 FB 3 0.148 49.333 8.734 -0.303 0.833 0.172 
 FB 4***             
 FB 5 0.373 20.683 8.121 4.874 0.912 0.508 
 FB 6 0.876 34.483 8.960 0.080 0.903 0.262 
 FB 7** 0.131 83.916 40.398 -10.652 0.920 0.406 
 FB 8 0.247 75.102 15.093 4.835 0.960 0.249 
        
Ang-I+ 
PD123,319 
FB 1 0.238 25.266 10.718 0.786 0.875 0.442 
FB 2 2.177 11.520 3.095 1.361 0.792 0.346 
 FB 3 1.863 35.166 11.017 -4.903 0.872 0.202 
 FB 4****             
 FB 5* 2.286 27.291 10.018 1.653 0.864 0.403 
 FB 6 0.357 29.659 9.811 5.883 0.926 0.442 
 FB 7 0.168 53.634 8.830 2.424 0.955 0.201 
        
Ang-II+ 
PD123,319 
FB 1**** N/A           
FB 2** 0.721 14.299 11.003 2.393 0.809 0.803 
 FB 3* 1.797 6.176 2.570 2.024 0.820 0.560 
 FB 4 0.167 46.462 10.402 -2.232 0.906 0.185 
 FB 5 0.296 68.502 9.727 -2.616 0.943 0.108 
 FB 6 1.163 17.597 8.951 3.697 0.823 0.594 
 FB 7 3.373 14.523 5.380 -0.476 0.750 0.349 





Figure 0-3. 2nd P-K stress vs Green strain for each sample in the control group with fit to Fung-




Figure 0-4. 2nd P-K stress vs Green strain for each sample in the ang-I treated group with fit to 




Figure 0-5. 2nd P-K stress vs Green strain for each sample in the ang-II treated group with fit to 




Figure 0-6. 2nd P-K stress vs Green strain for each sample in the ang-I + quinaprilat treated 




Figure 0-7. 2nd P-K stress vs Green strain for each sample in the ang-I + chymostatin treated 





Figure 0-8. 2nd P-K stress vs Green strain for each sample in the ang-I + losartan treated group 





Figure 0-9. 2nd P-K stress vs Green strain for each sample in the ang-II + losartan treated group 





Figure 0-10. 2nd P-K stress vs Green strain for each sample in the ang-I + PD123,319 treated 





Figure 0-11. 2nd P-K stress vs Green strain for each sample in the ang-II + PD123,319 treated 












Figure 0-12. Constant strain energy contour plot over Green strain field for each individual 
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All living organisms experience or produce some type of movement in their system. The 
study of biomechanics allows scientists and engineers to analyze the biomechanical function of 
biomaterials, biological systems, organs, tissue, cells, and cell organelles. Understanding the 
mechanics of the body is important to improve the movements of the body and to understand the 
alterations in mechanical function the body may suffer after injury or during a disease. By doing 
so, the research community can develop treatments to improve movement, prosthetics for those 
that suffered limp loss, medical devices to assist loss of mechanical functions, therapeutic 
treatments, and biomaterials to replace injured tissue.  
AD.1.1 Mechanical properties 
The mechanical properties include material and structural properties. Material properties 
are what make up the material, and structural properties characterize the behavior of the material 
such as size, shape, or form it undergoes (88). Material properties can be characterized by the 
relationship between stress and strain. In a linear material, stress and strain are proportional and 
when graphed are a straight line. A non-linear relationship are when the mathematical relation 
between stress and strain cannot be characterized by a straight line. A material can be elastic or 
plastic. When stress is applied and released, and the material reverts to its undeformed state, it is 
considered an elastic material. In a plastic material, there is a permanent change in strain or 
deformation when the stress is applied and then released (Figure 0-1) (89).  These properties can 
be tested through mechanical testing methods using various standard laboratory equipment. The 
stiffness or Young’s Modulus of a linear elastic material can be calculated by measuring the 
slope of the linear region (Figure 0-1a). The area under the curve is the strain energy, the energy 




Figure 0-1. Load-displacement curve, adapted from Saunders (88) 
The key material properties studied are stress and strain. Stress is the force applied to the 
material per area, and strain is the deformation of the material in respect to a line or square. 
Stress is calculated by dividing the force by the cross-sectional surface area (A) (Figure 0-2a), 
and strain is a ratio of the change in length divided by the initial length. The load-displacement 
curve and the stress-strain curve will have an identical in shape, but the x and y scales will be 
different (Figure 0-2b,c) (88). 
 
Figure 0-2. (A) A diagram of a material experiencing load (F) and the cross-sectional area of 
the material (A). Graphs of a linear (B) load-displacement curve and a (C) stress-strain curve, 
adapted from Saunders (88) 
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AD.1.2 Stress and strain 
Stress can be determined by normalizing the force that is being applied to a cross-
sectional area. There are three forms of stress: normal stress, shear stress, and bending stresses. 
Normal stress is when a material is subject to force under axial loading. Shear stress is when 
force is being applied in equal and opposite transverse fields. (90). 
Normal stress is when force is being applied perpendicular to the surface area (Figure 0-3a). 
There are two kinds of normal stresses, tensile and compressive stress. Tensile stress is when the 
material is stretched or lengthened (Figure 0-3b), and compression stress is when the material is 
compressed or shortened (Figure 0-3c). Shear stress is force acting parallel to the surface area 
(Figure 0-3d).  
Strain is the deformation the material undergoes during stress. Normal strain is the 
deformation the material undergoes by forces acting perpendicular to the surface in respect to a 
line, normal stress. The material is either elongated by the tensile stress or contracted by the 
compression stress which act by force being applied to the surface perpendicular to it. Shear 
strain is the deformation the material experiences by forces acting parallel to the surface with 
respect to a shear stress. Shear strain changes the angle between the corners of the square which 
were originally right angles.  
 
Figure 0-3. Diagrams of (A) normal and (D) shear stress and the two types of normal stress, 




Stress-strain plots allow one to measure various bulk mechanical properties of materials. 
The strength of the material correlates with the stress required to deform material. The yield 
strength is the amount of stress that a material can undergo before it transitions to plastic 
deformation. The largest stress is the ultimate strength that a material can withstand, and the 
breaking strength, also known as failure strength, is the strength that the mateiral can endure 
before breaking (Figure 0-4a). The toughness can be measured by calculating the area under a 




Figure 0-4. Strain-strain curve depicting the (A) yield, ultimate, and breaking stress and (B) the 
toughness of the material, adapted from Saunders (88) 
Stiffness can be calculated by acquiring the slope of the linear region of a material’s 
stress-strain curve, and it allows one to measure the compliance of the material. Materials will 
deform less if its stiffness is greater. In linear material, the stiffness is called Young’s modulus 
(E). In a non-linear biological material, there are typically two pseudo-linear regimes, the toe 
region and the linear region. The stiffness of the material can be assessed via the high and low 




Figure 0-5. Stress-strain curve with Young’s Modulus for a linear material and Tangent 
Modulus for a non-linear material 
In an elastic material, the material will revert to its original state when loaded and 
unloaded. In viscous materials, the material will not revert to its original state but instead stay at 
the state in which it was when the load was released. Viscoelastic materials are materials that 
exhibit both viscous-like and elastic-like properties. The relationship between stress and strain in 
viscoelastic material depends on time (91).  
AD.1.3 Biaxial testing 
There are various forms to test material depending on its properties. For incompressible 
materials such as biological tissues, biaxial testing is ideal as it allows for the characterization of 
a three-dimensional stress-strain relationship. Biaxial testing is where a material is subjected to 
load in both the x and y directions in contrast to uniaxial testing which only subject the material 
to load in one direction.  
When running biaxial testing in viscoelastic material, such as biological tissues, 
hysteresis is present. Hysteresis is the energy lost within the material between successuve 
loading and unloading cycles. It is necessary to precondition the material prior to testing so it 
reaches an equilibrium state before running biaxial testing (Figure 0-6a), with the loading and 
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unloading curve taking the same path as it is being displaced. In other words, the material will 
exhibit more “pseudo” elastic-like properties (Figure 0-6b) (88).  
 
 
Figure 0-6. Preconditioning of material during biaxial testing (A) load vs time and (B) load vs 
displacement 
There are many modes of biaxial deformation. A material can experience tensile stress in 
both axis (Figure 0-7a), tensile stress in one axis and compression stress in the other (Figure 
0-7b), and compression stress in both axis (Figure 0-7c) (92). A material can be stretched to 
either a particular load or deformation and then allowed to return to 0 load or deformation. The 
type of biaxial model used is dependent on the load the material experiences in the body. 
 
Figure 0-7. Models of biaxial testing, (A) tensile load in both axis, (B) tensile load in one axis 




In biaxial testing, strain and stress is measured taking into account deformation. The 
deformation gradient (F) is the fundamental measurement of deformation of a material that 
mathematically explains the changes in length, angles, and area of volume. Figure 0-8 
demonstrates a simple illustration of the deformations of a square. β0 is the original position of 
the object, or the reference configuration, and βt is the position of the object after deformation, or 
its current configuration. x1 and x2 are the axis of  β0, and x1’ and x2’ are the axis of  βt. A, B, C, 
and D are the initial x1 and x2 coordinates, and A’, B’, C’, and D’ are the x1’ and x2’ coordinates 
after deformation. u is the displacement vector (x’-x).  To calculate deformation, F needs to 






Figure 0-8. Simple diagram of material deformation/motion  
Engineering strain can be calculated by dividing the experimental length by the original 




As stated previously, stress is the force being applied to a specific area. However, there 
are three stresses that consider the orientations, force and area, that give rise by the natural 
tensorial nature of stress: Cauchy stress, 1st Piola-Kirchoff (P-K) stress, and 2nd P-K stress. 
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Cauchy stress (σ) is the true stress experienced by the material. The 1st P-K stress (P) is a 
measurement of stress that is Lagrangian in nature. 1st P-K stress is the most commonly 
measured stress with mechanical testing equipment. It measures the force being applied at each 
time point divided by the area of the square in the original configuration, β0 and is calculated 
with Eq. (0.3). Cauchy stress is calculated with Eq. (0.4) where J is the Jacobian. The Jacobian is 
a measure that quantifies the change in volume that is produced during the deformation. If 
material is incompressible such as tissue, J=1. The 2nd P-K stress (S) is calculated using Eq.(0.5). 
The 2nd P-K stress is not a direct physical measure of stress, but it is useful in many ways. The 
2nd P-K stress is the energy conjugate of Green strain (E) and can thus be used to determine 
constitutive models (82).  
The maximum Green strain is used to calculate the areal strain and the strain anisotropy 
(Figure 0-9a). Areal strain is calculated by multiplying the maximum Green strain in the 
circumferential and radial directions (ECIRC * ERAD). The higher the areal strain, the more strain 
the material can undergo. Strain anisotropy index is calculated by dividing the maximum Green 
strain in the circumferential and radial direction (ECIRC ÷ ERAD). A strain anisotropy index close 
to 1 indicates a more isotropic material, while less or greater than 1 indicates a more anisotropic 
material. As mentioned previously, the stiffness of a non-linear material can be measured by the 
low and high tangent moduli, the stiffness of the toe region and the elastic region respectively 
(Figure 0-9b). The low tangent modulus (TML) is the stiffness in the toe region (pre-transitional) 
where the fibers are “un-crimping”. The high tangent modulus (TMH) is the stiffness in the 
elastic region (post-transitional) where the fibers have been “uncrimpled” and are now being 
 P=f/Ao (0.3) 
 σ=J-1PFT (0.4) 
 S= F-1P (0.5) 
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stretched (74). Extensibility is calculated by the x-intercept of the high tangent modulus (Figure 
0-9c). The higher the extensibility, the more the material can stretch. The TML, TMH, and 
extensibility are measured in both the circumferential and radial directions. The material is stiffer 
and hence less extensible in the circumferential direction than in the radial direction (74).  
 
Figure 0-9. 2nd P-K stress vs Green strain graph indicating (A) maximum Green strain used to 
calculate areal strain and strain anisotropy, (B) high and low tangent modulus, and (C) 
extensibility. 
AD.1.4 Constitutive models 
As shown previously, strain energy can be calculated by measuring the area under the 
curve. Strain energy can also be related to provide phenomenological constitutive models for 
materials. Constitutive models can also provide additional information on the mechanical 
responses of materials. One important property to note when deciding an appropriate constitutive 
model is if the material is anisotropic or isotropic. An anisotropic material has different material 
properties with respect to the direction the load is applied. An isotropic material has the same 
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material properties regardless of the direction the load is applied. Another property is if the 
sample is homogenous or non-homogenous. In a homogenous sample, it is made up of the same 
material throughout its body. In a non-homogenous sample, it is made up of different materials 
throughout its body (89). In addition, one chooses a model specific to either elastic or 
viscoelastic materials. In this thesis, we have focused on the development of constitutive models 
to characterize homogeneous pseudo-elastic materials. 
In an isotropic elastic material, there are two common models: Neo-Hookean and 
Mooney Rivlin. In these models, strain energy (W) is a function of strain variants (I) which can 
be calculated using Eq. (0.6). 
λ1, λ2, and λ3
 are the principal stretches and the left Cauchy-Green tensor (B) can be 
calculated by B=FFT. nc refers to the principle direction of the material fibers. The standard 
constitutive model for an incompressible, isotropic, elastic material can be determined with Eq 
(0.7). 
 
p is a hydrostatic pressure term associated with the incompressibility constraints and σ is 
Cauchy stress. The Neo-Hookean strain energy can be obtained with Eq. (0.8), and the Mooney-




























 W=0.5µ (I1-3) (0.8) 
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µ is the shear modulus constant for infinitesimal deformations, and α is a dimensionless 
constant. µ must be greater than 0, and α must be greater than 0 or less than 1 (78). 
In addition to the M-R strain energy seen in Eq. (0.9), there are various modified forms. 
Two modified Mooney-Rivlin strain energy equations are the isotropic and anisotropic M-R 
models. The isotropic modified M-R strain energy can be given by Eq. (0.10). The anisotropic 
M-R model has an additional anisotropic term and can be given by Eq. (0.11) (80). 
There are various models used for viscoelastic anisotropic material including the Fung-
type model and the Choi-Vito model. The strain energy for the Fung-type model can be obtain 
with Eq. (0.12), and the strain energy from the Choi-Vito model is given by Eq. (0.13).   
where Q=c1E11
2+ c2E22
2+2 c3E11E22.  
where Q1=c1E11
2, Q2=c2E22
2, Q3=c3E11E22. c*c1 and c*c2 are metrics for nonlinear stiffness in 
the circumferential and radial direction respectively, and c3 is the interaction between the 
circumferential and radial direction (82).  
 
 W= 0.5µ[ (I1-3) + (1-α) (I2-3)] (0.9) 
 W=c1 (I1-3) + c2 (I2-3) + D1 [exp (D2 (I1 - 3)) - 1] (0.10) 
 W=c1(I1-3) + D1 [exp (D2 (I1 - 3)) - 1] + (k1/2k2) [exp [k2 (I4 - 1)
2 - 1] (0.11) 
 W=0.5c (eQ-1), (0.12) 




3 - 3), (0.13) 
